<NAME id="8201_1" start="4" all_names="FEDERALFOOD" local_name_id="1" end="16" >Federal Food</NAME>

<NAME id="8201_2" start="28" all_names="COSMETICACT" local_name_id="2" end="40" >Cosmetic Act</NAME>

<ORGANIZATION start="93" end="107" id="8201_3" >Administration</ORGANIZATION>

<PROFESSION start="286" end="291" id="8201_4" >major</PROFESSION>

<DATE start="629" end="633" id="8201_9" >2004</DATE>

<LEGAL_ROLE start="635" end="645" id="8201_11" >respondent</LEGAL_ROLE>

<NAME id="8201_12" start="661" all_names="CLINORIL" local_name_id="3" end="669" >Clinoril</NAME>

<LEGAL_ROLE start="842" local_name_id="4" name="Mutual Pharmaceutical" end="852" id="8201_13" >petitioner</LEGAL_ROLE>

<NAME id="8201_14" start="853" all_names="MUTUALPHARMACEUTICAL" local_name_id="4" end="874" >Mutual Pharmaceutical</NAME>

<LEGAL_ROLE start="876" local_name_id="5" name="Mutual Pharmaceutical" end="886" id="8201_15" >Respondent</LEGAL_ROLE>

<DATE start="1138" end="1142" id="8201_10" >2005</DATE>

<LEGAL_ROLE start="1268" end="1278" id="8201_16" >Respondent</LEGAL_ROLE>

<GPE start="1294" end="1307" id="8201_17" >New Hampshire</GPE>

<LEGAL_ROLE start="1397" end="1407" id="8201_18" >respondent</LEGAL_ROLE>

<NAME id="8201_19" start="1468" all_names="FIRSTCIRCUIT" local_name_id="6" end="1481" >First Circuit</NAME>

<LEGAL_ROLE start="1573" end="1583" id="8201_20" >respondent</LEGAL_ROLE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361047" start="1624" alternative_keys="['u.s._564____']" line="2" party2_short="Mensing" end="1646" citation_local_level_id="0" party1="PLIVA, Inc." party2="Mensing" id="8201_6" citation_global_level_id="361046.037" party1_short="PLIVA" >PLIVA, Inc. v. Mensing</CITATION>

<ORGANIZATION start="1624" party1_of="8201_6" end="1635" id="8201_7" >PLIVA, Inc.</ORGANIZATION>

<ORGANIZATION start="1624" end="1634" id="8201_21" >PLIVA, Inc</ORGANIZATION>

<PERSON start="1639" party2_of="8201_6" end="1646" id="8201_8" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="2" id1="Dummy_File_361047" start="1648" lookup_key="u.s._564____" standard_reporter="U.S." end="1661" page_number="___" reporter="U. S." citation_local_level_id="1" citation_global_level_id="361046.001" id="8201_5" volume="564" no_current_file="True" >564 U. S. ___</CITATION>

<ORGANIZATION start="1677" end="1682" id="8201_22" >Court</ORGANIZATION>

<NAME id="8201_28" start="2102" all_names="PLIVA" local_name_id="7" end="2107" >PLIVA</NAME>

<NAME id="8201_29" start="2109" all_names="PP" local_name_id="8" end="2111" >Pp</NAME>

<NAME id="8201_38" start="2134" all_names="SUPREMACYCLAUSE" local_name_id="9" end="2150" >Supremacy Clause</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_332696" start="2216" alternative_keys="['u.s._451_725']" line="4" party2_short="Louisiana" end="2237" citation_local_level_id="2" party1="Maryland" party2="Louisiana" id="8201_32" citation_global_level_id="332695.006" party1_short="Maryland" >Maryland v. Louisiana</CITATION>

<GPE start="2216" party1_of="8201_32" end="2224" id="8201_34" >Maryland</GPE>

<GPE start="2228" party2_of="8201_32" end="2237" id="8201_35" >Louisiana</GPE>

<CITATION entry_type="standard_key" line="4" id1="Dummy_File_332696" start="2239" lookup_key="u.s._451_725" standard_reporter="U.S." end="2257" page_number="725" reporter="U. S." citation_local_level_id="3" paragraph_number="746" id="8201_30" volume="451" no_current_file="True" citation_global_level_id="332695.003" >451 U. S. 725, 746</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329350" start="2453" alternative_keys="['u.s._496_72']" line="4" party2_short="Elec" end="2480" citation_local_level_id="4" party1="English" party2="General Elec. Co" id="8201_33" citation_global_level_id="329349.007" party1_short="English" >English v. General Elec. Co</CITATION>

<NAME id="8201_36" start="2453" all_names="ENGLISH" local_name_id="10" end="2460" party1_of="8201_33" >English</NAME>

<ORGANIZATION start="2464" party2_of="8201_33" end="2480" id="8201_37" >General Elec. Co</ORGANIZATION>

<PROFESSION start="2464" end="2471" id="8201_39" >General</PROFESSION>

<CITATION entry_type="standard_key" line="4" id1="Dummy_File_329350" start="2483" lookup_key="u.s._496_72" standard_reporter="U.S." end="2499" page_number="72" reporter="U. S." citation_local_level_id="5" paragraph_number="79" id="8201_31" volume="496" no_current_file="True" citation_global_level_id="329349.001" >496 U. S. 72, 79</CITATION>

<NAME id="8201_40" start="2727" all_names="PP" local_name_id="8" end="2729" >Pp</NAME>

<GPE start="2742" end="2755" id="8201_52" >New Hampshire</GPE>

<CITATION entry_type="party_key" line="5" id1="Dummy_File_364766" start="2936" alternative_keys="['a.2d_395_843', 'n.h._118_802']" lookup_key="thibaultroebuck#1" party2_short="Roebuck" end="2967" standard_reporter="N.H." citation_local_level_id="6" volume="118" party1="Thibault" party2="Sears, Roebuck &amp; Co" id="8201_49" no_current_file="True" page_number="802" citation_global_level_id="364765.004" party1_short="Thibault" >Thibault v. Sears, Roebuck &amp; Co</CITATION>

<PERSON start="2936" party1_of="8201_49" end="2944" id="8201_50" >Thibault</PERSON>

<ORGANIZATION start="2948" party2_of="8201_49" end="2967" id="8201_51" >Sears, Roebuck &amp; Co</ORGANIZATION>

<ORGANIZATION start="2955" end="2967" id="8201_53" >Roebuck &amp; Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="5" id1="Dummy_File_364766" start="2970" alternative_keys="['thibaultroebuck#1', 'a.2d_395_843']" lookup_key="n.h._118_802" standard_reporter="N.H." end="2988" page_number="802" reporter="N. H." citation_local_level_id="7" paragraph_number="809" id="8201_47" volume="118" no_current_file="True" citation_global_level_id="364765.004" >118 N. H. 802, 809</CITATION>

<CITATION entry_type="standard_key" line="5" id1="Dummy_File_364766" start="2990" alternative_keys="['thibaultroebuck#1', 'n.h._118_802']" lookup_key="a.2d_395_843" standard_reporter="A.2D" end="3008" page_number="843" reporter="A. 2d" citation_local_level_id="8" paragraph_number="847" id="8201_48" volume="395" no_current_file="True" citation_global_level_id="364765.004" >395 A. 2d 843, 847</CITATION>

<NAME id="8201_54" start="3010" all_names="PP" local_name_id="8" end="3012" >Pp</NAME>

<CITATION entry_type="party_key" line="6" id1="Dummy_File_364767" start="3102" alternative_keys="['a.2d_784_1178', 'n.h._147_150']" lookup_key="vautourindustries#1" party2_short="Industries" end="3148" standard_reporter="N.H." citation_local_level_id="9" volume="147" party1="Vautour" party2="Body Masters Sports Industries, Inc" id="8201_62" no_current_file="True" page_number="150" citation_global_level_id="364766.004" party1_short="Vautour" >Vautour v. Body Masters Sports Industries, Inc</CITATION>

<PERSON start="3102" party1_of="8201_62" end="3109" id="8201_63" >Vautour</PERSON>

<ORGANIZATION start="3113" party2_of="8201_62" end="3148" id="8201_64" >Body Masters Sports Industries, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="6" id1="Dummy_File_364767" start="3151" alternative_keys="['vautourindustries#1', 'a.2d_784_1178']" lookup_key="n.h._147_150" standard_reporter="N.H." end="3169" page_number="150" reporter="N. H." citation_local_level_id="10" paragraph_number="153" id="8201_59" volume="147" no_current_file="True" citation_global_level_id="364766.004" >147 N. H. 150, 153</CITATION>

<CITATION entry_type="standard_key" line="6" id1="Dummy_File_364767" start="3171" alternative_keys="['vautourindustries#1', 'n.h._147_150']" lookup_key="a.2d_784_1178" standard_reporter="A.2D" end="3191" page_number="1178" reporter="A. 2d" citation_local_level_id="11" paragraph_number="1181" id="8201_60" volume="784" no_current_file="True" citation_global_level_id="364766.004" >784 A. 2d 1178, 1181</CITATION>

<ORGANIZATION start="3197" end="3224" id="8201_65" >New Hampshire Supreme Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="6" id1="Dummy_File_364768" start="3348" lookup_key="a.2d_784_1182" standard_reporter="A.2D" end="3366" page_number="1182" reporter="A. 2d" citation_local_level_id="12" citation_global_level_id="364767.001" id="8201_61" volume="784" no_current_file="True" >784 A. 2d, at 1182</CITATION>

<GPE start="4469" end="4482" id="8201_66" >New Hampshire</GPE>

<NAME id="8201_67" start="4547" all_names="PP" local_name_id="8" end="4549" >Pp</NAME>

<CITATION entry_type="standard_key" line="7" id1="Dummy_File_361047" start="4669" lookup_key="u.s._564____" standard_reporter="U.S." end="4686" page_number="___" reporter="U. S." citation_local_level_id="13" citation_global_level_id="361046.001" id="8201_72" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<NAME id="8201_73" start="4789" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="4806" >New Hampshire law</NAME>

<GPE start="4913" end="4921" id="8201_74" >Maryland</GPE>

<GPE start="5018" end="5031" id="8201_75" >New Hampshire</GPE>

<NAME id="8201_76" start="5156" all_names="PP" local_name_id="8" end="5158" >Pp</NAME>

<NAME id="8201_77" start="5176" all_names="FIRSTCIRCUIT" local_name_id="6" end="5189" >First Circuit</NAME>

<ORGANIZATION start="5369" end="5374" id="8201_78" >Court</ORGANIZATION>

<NAME id="8201_79" start="5533" all_names="PP" local_name_id="8" end="5535" >Pp</NAME>

<CITATION entry_type="standard_key" line="10" id1="Dummy_File_364769" start="5544" lookup_key="f.3d_678_30" standard_reporter="F.3D" end="5556" page_number="30" reporter="F. 3d" citation_local_level_id="14" citation_global_level_id="364768.001" id="8201_80" volume="678" no_current_file="True" >678 F. 3d 30</CITATION>

<NAME id="8201_81" start="5569" all_names="ALITO" local_name_id="12" end="5574" >Alito</NAME>

<ORGANIZATION start="5609" end="5614" id="8201_82" >Court</ORGANIZATION>

<PERSON start="5625" end="5632" id="8201_83" >Roberts</PERSON>

<PERSON start="5645" end="5651" id="8201_84" >Scalia</PERSON>

<PERSON start="5653" end="5660" id="8201_85" >Kennedy</PERSON>

<PERSON start="5666" plural="True" end="5676" id="8201_86" >Thomas, JJ</PERSON>

<PERSON start="5687" end="5693" id="8201_87" >Breyer</PERSON>

<PERSON start="5736" end="5741" id="8201_88" >Kagan</PERSON>

<PERSON start="5755" end="5764" id="8201_89" >Sotomayor</PERSON>

<PERSON start="5807" end="5815" id="8201_90" >Ginsburg</PERSON>

<ORGANIZATION start="5844" end="5849" id="8201_91" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="13" page_number="____" start="5851" lookup_key="u.s._570_____" standard_reporter="U.S." end="5872" year="2013" reporter="U. S." citation_local_level_id="15" citation_global_level_id="364507.001" id="8201_92" id1="Dummy_File_364508" volume="570" no_current_file="True" >570 U. S. ____ (2013)</CITATION>

<DATE start="5867" citation_local_level_id="15" citation_global_level_id="364507.001" end="5871" id="8201_93" >2013</DATE>

<PERSON start="5873" end="5879" id="8201_96" >NOTICE</PERSON>

<NAME id="8201_97" start="5982" all_names="STATESREPORTS" local_name_id="13" end="5996" >States Reports</NAME>

<PROFESSION start="6034" end="6042" id="8201_98" >Reporter</PROFESSION>

<ORGANIZATION start="6057" end="6070" id="8201_99" >Supreme Court</ORGANIZATION>

<NAME id="8201_100" start="6085" all_names="STATES" local_name_id="14" end="6091" >States</NAME>

<GPE start="6093" end="6103" id="8201_101" >Washington</GPE>

<DATE start="6111" end="6115" id="8201_95" >2054</DATE>

<DOCKET start="6249" entry_type="docket" line="15" end="6255" id="8201_102" >12-142</DOCKET>

<CITATION entry_type="party_key" line="16" id1="Dummy_File_364770" start="6256" lookup_key="companybartlett#1" party2_short="BARTLETT" end="6323" citation_local_level_id="16" party1="MUTUAL PHARMACEUTICAL COMPANY, INC.," party2="KAREN L. BARTLETT" id="8201_103" no_current_file="True" party1_role="petitioner" citation_global_level_id="364769.001" party1_short="COMPANY" >MUTUAL PHARMACEUTICAL COMPANY, INC.,PETITIONER v. KAREN L. BARTLETT</CITATION>

<NAME id="8201_104" start="6256" all_names="MUTUALPHARMACEUTICALCOMPANYINC" local_name_id="15" end="6292" party1_of="8201_103" >MUTUAL PHARMACEUTICAL COMPANY, INC.,</NAME>

<ORGANIZATION start="6256" end="6290" id="8201_107" >MUTUAL PHARMACEUTICAL COMPANY, INC</ORGANIZATION>

<LEGAL_ROLE start="6292" end="6302" id="8201_106" >PETITIONER</LEGAL_ROLE>

<PERSON start="6306" party2_of="8201_103" end="6323" id="8201_105" >KAREN L. BARTLETT</PERSON>

<DATE start="6407" end="6420" id="8201_111" >June 24, 2013</DATE>

<PROFESSION start="6423" document_level_name_id="12" party="ALITO" end="6430" id="8201_112" >Justice</PROFESSION>

<NAME id="8201_113" start="6431" all_names="ALITO" local_name_id="12" end="6436" >Alito</NAME>

<ORGANIZATION start="6466" end="6471" id="8201_114" >Court</ORGANIZATION>

<GPE start="6523" end="6536" id="8201_126" >New Hampshire</GPE>

<LEGAL_ROLE start="6569" local_name_id="16" name="Karen Bartlett" end="6579" id="8201_127" >respondent</LEGAL_ROLE>

<PERSON start="6580" plural="True" end="6594" id="8201_128" >Karen Bartlett</PERSON>

<LEGAL_ROLE start="6618" local_name_id="17" name="Mutual Pharmaceutical" end="6628" id="8201_129" >petitioner</LEGAL_ROLE>

<NAME id="8201_130" start="6629" all_names="MUTUALPHARMACEUTICAL" local_name_id="17" end="6650" >Mutual Pharmaceutical</NAME>

<NAME id="8201_131" start="6737" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="6754" >New Hampshire law</NAME>

<GPE start="7077" end="7090" id="8201_132" >New Hampshire</GPE>

<ORGANIZATION start="7224" end="7229" id="8201_133" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361047" start="7263" alternative_keys="['u.s._564____']" line="20" party2_short="Mensing" end="7285" citation_local_level_id="17" party1="PLIVA, Inc." party2="Mensing" id="8201_118" citation_global_level_id="361046.038" party1_short="PLIVA" >PLIVA, Inc. v. Mensing</CITATION>

<ORGANIZATION start="7263" party1_of="8201_118" end="7274" id="8201_120" >PLIVA, Inc.</ORGANIZATION>

<ORGANIZATION start="7263" end="7273" id="8201_134" >PLIVA, Inc</ORGANIZATION>

<PERSON start="7278" party2_of="8201_118" end="7285" id="8201_121" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="20" page_number="___" start="7287" lookup_key="u.s._564____" standard_reporter="U.S." end="7307" year="2011" reporter="U. S." citation_local_level_id="18" citation_global_level_id="361046.001" id="8201_116" id1="Dummy_File_361047" volume="564" no_current_file="True" >564 U. S. ___ (2011)</CITATION>

<DATE start="7302" citation_local_level_id="18" citation_global_level_id="361046.001" end="7306" id="8201_124" >2011</DATE>

<NAME id="8201_135" start="7497" all_names="SUPREMACYCLAUSE" local_name_id="9" end="7513" >Supremacy Clause</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_332696" start="7626" alternative_keys="['u.s._451_725']" line="20" party2_short="Louisiana" end="7647" citation_local_level_id="19" party1="Maryland" party2="Louisiana" id="8201_119" citation_global_level_id="332695.007" party1_short="Maryland" >Maryland v. Louisiana</CITATION>

<GPE start="7626" party1_of="8201_119" end="7634" id="8201_122" >Maryland</GPE>

<GPE start="7638" party2_of="8201_119" end="7647" id="8201_123" >Louisiana</GPE>

<CITATION entry_type="standard_key" page_number="725" start="7649" line="20" standard_reporter="U.S." end="7674" year="1981" lookup_key="u.s._451_725" reporter="U. S." citation_local_level_id="20" paragraph_number="746" id="8201_117" id1="Dummy_File_332696" volume="451" no_current_file="True" citation_global_level_id="332695.003" >451 U. S. 725, 746 (1981)</CITATION>

<DATE start="7669" citation_local_level_id="20" citation_global_level_id="332695.003" end="7673" id="8201_125" >1981</DATE>

<ORGANIZATION start="7681" end="7686" id="8201_146" >Court</ORGANIZATION>

<ORGANIZATION start="7863" end="7868" id="8201_147" >Court</ORGANIZATION>

<ORGANIZATION start="7987" end="7992" id="8201_148" >Court</ORGANIZATION>

<NAME id="8201_149" start="8158" all_names="PLIVA" local_name_id="7" end="8163" >PLIVA</NAME>

<ORGANIZATION start="8201" end="8206" id="8201_150" >Court</ORGANIZATION>

<NAME id="8201_157" start="8238" all_names="FEDERALFOOD" local_name_id="1" end="8250" >Federal Food</NAME>

<NAME id="8201_158" start="8262" all_names="COSMETICACT" local_name_id="2" end="8274" >Cosmetic Act</NAME>

<NAME id="8201_159" start="8295" all_names="STAT" local_name_id="18" end="8299" >Stat</NAME>

<NAME id="8201_160" start="8399" all_names="STATESFOOD" local_name_id="19" end="8410" >States Food</NAME>

<ORGANIZATION start="8420" end="8434" id="8201_161" >Administration</ORGANIZATION>

<LEGAL_ROLE start="8915" end="8924" id="8201_162" >applicant</LEGAL_ROLE>

<DATE start="8978" end="8982" id="8201_155" >2012</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_331307" start="9607" alternative_keys="['u.s._529_120']" line="24" party2_short="Tobacco" end="9645" citation_local_level_id="21" party1="FDA" party2="Brown &amp; Williamson Tobacco Corp" id="8201_152" citation_global_level_id="331306.024" party1_short="FDA" >FDA v. Brown &amp; Williamson Tobacco Corp</CITATION>

<ORGANIZATION start="9607" party1_of="8201_152" end="9610" id="8201_153" >FDA</ORGANIZATION>

<ORGANIZATION start="9614" party2_of="8201_152" end="9645" id="8201_154" >Brown &amp; Williamson Tobacco Corp</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="120" start="9648" line="24" standard_reporter="U.S." end="9673" year="2000" lookup_key="u.s._529_120" reporter="U. S." citation_local_level_id="22" paragraph_number="140" id="8201_151" id1="Dummy_File_331307" volume="529" no_current_file="True" citation_global_level_id="331306.003" >529 U. S. 120, 140 (2000)</CITATION>

<DATE start="9668" citation_local_level_id="22" citation_global_level_id="331306.003" end="9672" id="8201_156" >2000</DATE>

<NAME id="8201_170" start="9752" all_names="CONGRESSIONALREQUESTERS" local_name_id="20" end="9776" >Congressional Requesters</NAME>

<ORGANIZATION start="9778" end="9810" id="8201_171" >Government Accountability Office</ORGANIZATION>

<DATE start="9812" end="9821" id="8201_167" >Nov. 2006</DATE>

<NAME id="8201_172" start="9823" all_names="NEWDRUGDEVELOPMENT" local_name_id="21" end="9843" >New Drug Development</NAME>

<PROFESSION start="9848" end="9868" id="8201_173" >Biotechnology L. Rep</PROFESSION>

<DATE start="9878" end="9882" id="8201_168" >2007</DATE>

<PERSON start="10054" end="10062" id="8201_174" >Congress</PERSON>

<NAME id="8201_175" start="10079" all_names="PRICECOMPETITION" local_name_id="22" end="10096" >Price Competition</NAME>

<NAME id="8201_176" start="10113" all_names="RESTORATIONACT" local_name_id="23" end="10128" >Restoration Act</NAME>

<DATE start="10132" end="10136" id="8201_169" >1984</DATE>

<NAME id="8201_177" start="10141" all_names="STAT" local_name_id="18" end="10145" >Stat</NAME>

<NAME id="8201_178" start="10177" all_names="HATCH-WAXMANACT" local_name_id="24" end="10193" >Hatch-Waxman Act</NAME>

<NAME id="8201_179" start="10202" all_names="HATCH-WAXMAN" local_name_id="25" end="10214" >Hatch-Waxman</NAME>

<PROFESSION start="11231" end="11236" id="8201_180" >major</PROFESSION>

<DATE start="11714" end="11718" id="8201_184" >1978</DATE>

<NAME id="8201_190" start="11823" all_names="CLINORIL" local_name_id="3" end="11831" >Clinoril</NAME>

<NAME id="8201_191" start="11838" all_names="CLINORIL" local_name_id="3" end="11846" >Clinoril</NAME>

<NAME id="8201_192" start="11939" all_names="MUTUALPHARMACEUTICAL" local_name_id="17" end="11960" >Mutual Pharmaceutical</NAME>

<CITATION entry_type="standard_key" line="29" id1="Dummy_File_364769" start="11962" lookup_key="f.3d_678_30" standard_reporter="F.3D" end="11978" page_number="30" reporter="F. 3d" citation_local_level_id="23" paragraph_number="34" id="8201_182" volume="678" no_current_file="True" citation_global_level_id="364768.001" >678 F. 3d 30, 34</CITATION>

<GPE start="11980" end="11982" id="8201_193" >CA</GPE>

<DATE start="11984" end="11988" id="8201_185" >2012</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<PERSON start="12004" end="12007" id="8201_194" >App</PERSON>

<NAME id="8201_195" start="12021" all_names="CERT" local_name_id="26" end="12025" >Cert</NAME>

<NAME id="8201_196" start="12159" all_names="COX" local_name_id="27" end="12162" >Cox</NAME>

<FAMILY start="12368" end="12374" id="8201_197" >cousin</FAMILY>

<NAME id="8201_198" start="12376" all_names="STEVENS-JOHNSONSYNDROME" local_name_id="28" end="12400" >Stevens-Johnson Syndrome</NAME>

<CITATION entry_type="standard_key" line="29" id1="Dummy_File_364771" start="12402" lookup_key="f.3d_678_34" standard_reporter="F.3D" end="12418" page_number="34" reporter="F. 3d" citation_local_level_id="24" citation_global_level_id="364770.001" id="8201_183" volume="678" no_current_file="True" >678 F. 3d, at 34</CITATION>

<PERSON start="12427" end="12434" id="8201_199" >Dorland</PERSON>

<NAME id="8201_200" start="12449" all_names="MEDICALDICTIONARY" local_name_id="29" end="12467" >Medical Dictionary</NAME>

<DATE start="12468" end="12472" id="8201_186" >1872</DATE>

<DATE start="12483" end="12487" id="8201_187" >2007</DATE>

<NAME id="8201_201" start="12490" all_names="PHYSICIANS'DESKREFERENCE" local_name_id="30" end="12516" >Physicians' Desk Reference</NAME>

<DATE start="12539" end="12543" id="8201_188" >2013</DATE>

<PERSON start="12546" end="12554" id="8201_202" >Friedman</PERSON>

<NAME id="8201_203" start="12556" all_names="ORLET" local_name_id="31" end="12561" >Orlet</NAME>

<NAME id="8201_204" start="12572" all_names="LAW" local_name_id="32" end="12575" >Law</NAME>

<NAME id="8201_205" start="12577" all_names="TOXICEPIDERMALNECROLYSISDUE" local_name_id="33" end="12607" >Toxic Epidermal Necrolysis Due</NAME>

<ORGANIZATION start="12611" end="12625" id="8201_206" >Administration</ORGANIZATION>

<NAME id="8201_207" start="12629" all_names="CELECOBIX" local_name_id="34" end="12638" >Celecobix</NAME>

<NAME id="8201_208" start="12640" all_names="CELEBREX" local_name_id="35" end="12648" >Celebrex</NAME>

<NAME id="8201_209" start="12654" all_names="SOUTHERNMEDICALJ" local_name_id="36" end="12672" >Southern Medical J</NAME>

<DATE start="12691" end="12695" id="8201_189" >2002</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<DATE start="12702" end="12715" id="8201_210" >December 2004</DATE>

<LEGAL_ROLE start="12717" local_name_id="37" name="Karen L. Bartlett" end="12727" id="8201_211" >respondent</LEGAL_ROLE>

<PERSON start="12728" plural="True" end="12745" id="8201_212" >Karen L. Bartlett</PERSON>

<NAME id="8201_213" start="12761" all_names="CLINORIL" local_name_id="3" end="12769" >Clinoril</NAME>

<LEGAL_ROLE start="12868" local_name_id="38" name="Mutual Pharmaceutical" end="12878" id="8201_214" >petitioner</LEGAL_ROLE>

<NAME id="8201_215" start="12879" all_names="MUTUALPHARMACEUTICAL" local_name_id="38" end="12900" >Mutual Pharmaceutical</NAME>

<LEGAL_ROLE start="12902" local_name_id="39" name="Mutual Pharmaceutical" end="12912" id="8201_216" >Respondent</LEGAL_ROLE>

<LEGAL_ROLE start="13046" end="13056" id="8201_217" >respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<LEGAL_ROLE start="13332" end="13342" id="8201_230" >respondent</LEGAL_ROLE>

<NAME id="8201_231" start="13415" all_names="STEVENS-JOHNSONSYNDROME" local_name_id="28" end="13439" >Stevens-Johnson Syndrome</NAME>

<PERSON start="13554" end="13557" id="8201_232" >App</PERSON>

<CITATION entry_type="standard_key" line="31" id1="Dummy_File_364772" start="13564" lookup_key="f.supp.2d_731_135" standard_reporter="F.SUPP.2D" end="13588" page_number="135" reporter="F. Supp. 2d" citation_local_level_id="25" paragraph_number="142" id="8201_222" volume="731" no_current_file="True" citation_global_level_id="364771.001" >731 F. Supp. 2d 135, 142</CITATION>

<GPE start="13590" end="13592" id="8201_233" >NH</GPE>

<DATE start="13593" end="13597" id="8201_225" >2010</DATE>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<NAME id="8201_234" start="13644" all_names="STEVENS-JOHNSONSYNDROME" local_name_id="28" end="13668" >Stevens-Johnson Syndrome</NAME>

<CITATION entry_type="standard_key" line="31" id1="Dummy_File_364773" start="13773" lookup_key="f.3d_678_36" standard_reporter="F.3D" end="13789" page_number="36" reporter="F. 3d" citation_local_level_id="26" citation_global_level_id="364772.001" id="8201_223" volume="678" no_current_file="True" >678 F. 3d, at 36</CITATION>

<DATE start="13800" end="13804" id="8201_226" >2005</DATE>

<LEGAL_ROLE start="13812" end="13822" id="8201_235" >respondent</LEGAL_ROLE>

<NAME id="8201_236" start="14033" all_names="DECISIONLETTER" local_name_id="40" end="14048" >Decision Letter</NAME>

<DOCKET start="14065" entry_type="docket" line="31" end="14075" id="8201_224" >2005P-0072</DOCKET>

<DATE start="14065" end="14069" id="8201_227" >2005</DATE>

<DATE start="14087" end="14100" id="8201_228" >June 22, 2006</DATE>

<DATE start="14201" end="14214" id="8201_229" >June 18, 2013</DATE>

<PROFESSION start="14233" end="14238" id="8201_237" >Clerk</PROFESSION>

<ORGANIZATION start="14242" end="14247" id="8201_238" >Court</ORGANIZATION>

<PERSON start="14429" end="14432" id="8201_239" >App</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<LEGAL_ROLE start="14473" end="14483" id="8201_242" >Respondent</LEGAL_ROLE>

<GPE start="14499" end="14512" id="8201_243" >New Hampshire</GPE>

<LEGAL_ROLE start="14572" end="14582" id="8201_244" >Respondent</LEGAL_ROLE>

<ORGANIZATION start="14657" end="14671" id="8201_245" >District Court</ORGANIZATION>

<PROFESSION start="14721" end="14727" id="8201_246" >doctor</PROFESSION>

<CITATION entry_type="standard_key" line="32" id1="Dummy_File_364771" start="14790" lookup_key="f.3d_678_34" standard_reporter="F.3D" end="14806" page_number="34" reporter="F. 3d" citation_local_level_id="27" citation_global_level_id="364770.001" id="8201_241" volume="678" no_current_file="True" >678 F. 3d, at 34</CITATION>

<LEGAL_ROLE start="14832" end="14842" id="8201_247" >respondent</LEGAL_ROLE>

<LEGAL_ROLE start="14905" end="14915" id="8201_248" >respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<ORGANIZATION start="14950" end="14955" id="8201_257" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_364769" start="14977" lookup_key="f.3d_678_30" standard_reporter="F.3D" end="14989" page_number="30" reporter="F. 3d" citation_local_level_id="28" citation_global_level_id="364768.001" id="8201_249" volume="678" no_current_file="True" >678 F. 3d 30</CITATION>

<LEGAL_ROLE start="15072" end="15082" id="8201_258" >respondent</LEGAL_ROLE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361047" start="15124" alternative_keys="['u.s._564____']" line="33" party2_short="Mensing" end="15146" citation_local_level_id="29" party1="PLIVA, Inc." party2="Mensing" id="8201_253" citation_global_level_id="361046.039" party1_short="PLIVA" >PLIVA, Inc. v. Mensing</CITATION>

<ORGANIZATION start="15124" party1_of="8201_253" end="15135" id="8201_254" >PLIVA, Inc.</ORGANIZATION>

<ORGANIZATION start="15124" end="15134" id="8201_259" >PLIVA, Inc</ORGANIZATION>

<PERSON start="15139" party2_of="8201_253" end="15146" id="8201_255" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_361047" start="15148" lookup_key="u.s._564____" standard_reporter="U.S." end="15161" page_number="___" reporter="U. S." citation_local_level_id="30" citation_global_level_id="361046.001" id="8201_250" volume="564" no_current_file="True" >564 U. S. ___</CITATION>

<ORGANIZATION start="15177" end="15182" id="8201_260" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_364774" start="15488" lookup_key="f.3d_678_37" standard_reporter="F.3D" end="15504" page_number="37" reporter="F. 3d" citation_local_level_id="31" citation_global_level_id="364773.001" id="8201_251" volume="678" no_current_file="True" >678 F. 3d, at 37</CITATION>

<CITATION entry_type="standard_key" line="33" page_number="___" start="15529" lookup_key="u.s._568____" standard_reporter="U.S." end="15549" year="2012" reporter="U. S." citation_local_level_id="32" citation_global_level_id="363274.003" id="8201_252" id1="Dummy_File_363275" volume="568" no_current_file="True" >568 U. S. ___ (2012)</CITATION>

<DATE start="15544" citation_local_level_id="32" citation_global_level_id="363274.003" end="15548" id="8201_256" >2012</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<NAME id="8201_279" start="15560" all_names="SUPREMACYCLAUSE" local_name_id="9" end="15576" >Supremacy Clause</NAME>

<NAME id="8201_280" start="15627" all_names="STATES" local_name_id="14" end="15633" >States</NAME>

<NAME id="8201_281" start="15656" all_names="LAW" local_name_id="32" end="15659" >Law</NAME>

<NAME id="8201_282" start="15667" all_names="LAND" local_name_id="41" end="15671" >Land</NAME>

<NAME id="8201_283" start="15711" all_names="LAWS" local_name_id="42" end="15715" >Laws</NAME>

<NAME id="8201_284" start="15723" all_names="STATE" local_name_id="43" end="15728" >State</NAME>

<NAME id="8201_285" start="15777" all_names="ART" local_name_id="44" end="15780" >Art</NAME>

<GPE start="15782" end="15784" id="8201_286" >VI</GPE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_285115" start="15900" alternative_keys="['u.s._451_746']" line="35" party2_short="Louisiana" end="15921" citation_local_level_id="33" party1="Maryland" party2="Louisiana" id="8201_268" citation_global_level_id="285114.004" party1_short="Maryland" >Maryland v. Louisiana</CITATION>

<GPE start="15900" party1_of="8201_268" end="15908" id="8201_271" >Maryland</GPE>

<GPE start="15912" party2_of="8201_268" end="15921" id="8201_272" >Louisiana</GPE>

<CITATION entry_type="standard_key" line="35" id1="Dummy_File_285115" start="15923" lookup_key="u.s._451_746" standard_reporter="U.S." end="15940" page_number="746" reporter="U. S." citation_local_level_id="34" citation_global_level_id="285114.003" id="8201_265" volume="451" no_current_file="True" >451 U. S., at 746</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_5848" start="15942" alternative_keys="['u.s.(wheat.)_4_316']" line="35" party2_short="Maryland" end="15963" citation_local_level_id="35" party1="McCulloch" party2="Maryland" id="8201_269" citation_global_level_id="5847.215" party1_short="McCulloch" >McCulloch v. Maryland</CITATION>

<PERSON start="15942" party1_of="8201_269" end="15951" id="8201_273" >McCulloch</PERSON>

<GPE start="15955" party2_of="8201_269" end="15963" id="8201_274" >Maryland</GPE>

<CITATION entry_type="standard_key" page_number="316" start="15965" alternative_keys="['mccullochstate#1']" line="35" standard_reporter="U.S.(WHEAT.)" end="15989" year="1819" lookup_key="u.s.(wheat.)_4_316" reporter="Wheat." citation_local_level_id="36" paragraph_number="427" id="8201_266" id1="Dummy_File_5848" volume="4" no_current_file="True" citation_global_level_id="5847.003" >4 Wheat. 316, 427 (1819)</CITATION>

<DATE start="15984" citation_local_level_id="36" citation_global_level_id="5847.003" end="15988" id="8201_277" >1819</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329371" start="16000" alternative_keys="['u.s._505_88']" line="35" party2_short="Management" end="16045" citation_local_level_id="37" party1="Gade" party2="National Solid Wastes Management Assn" id="8201_270" citation_global_level_id="329370.013" party1_short="Gade" >Gade v. National Solid Wastes Management Assn</CITATION>

<PERSON start="16000" party1_of="8201_270" end="16004" id="8201_275" >Gade</PERSON>

<ORGANIZATION start="16008" party2_of="8201_270" end="16045" id="8201_276" >National Solid Wastes Management Assn</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="88" start="16048" line="35" standard_reporter="U.S." end="16072" year="1992" lookup_key="u.s._505_88" reporter="U. S." citation_local_level_id="38" paragraph_number="108" id="8201_267" id1="Dummy_File_329371" volume="505" no_current_file="True" citation_global_level_id="329370.003" >505 U. S. 88, 108 (1992)</CITATION>

<DATE start="16067" citation_local_level_id="38" citation_global_level_id="329370.003" end="16071" id="8201_278" >1992</DATE>

<NAME id="8201_287" start="16087" all_names="SUPREMACYCLAUSE" local_name_id="9" end="16103" >Supremacy Clause</NAME>

<NAME id="8201_288" start="16193" all_names="STATE" local_name_id="43" end="16198" >State</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<ORGANIZATION start="16385" end="16390" id="8201_311" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364775" start="16535" line="36" party2_short="Elec" end="16558" citation_local_level_id="39" party1="English" citation_global_level_id="364774.001" id="8201_303" no_current_file="True" party2="General Elec" party1_short="English" >English v. General Elec</CITATION>

<NAME id="8201_305" start="16535" all_names="ENGLISH" local_name_id="10" end="16542" party1_of="8201_303" >English</NAME>

<NAME all_names="GENERALELEC" id="8201_306" start="16546" party2_of="8201_303" local_name_id="45" end="16558" >General Elec</NAME>

<PROFESSION start="16546" end="16553" id="8201_312" >General</PROFESSION>

<CITATION entry_type="standard_key" page_number="72" start="16565" line="36" standard_reporter="U.S." end="16588" year="1990" lookup_key="u.s._496_72" reporter="U. S." citation_local_level_id="40" paragraph_number="79" id="8201_301" id1="Dummy_File_329350" volume="496" no_current_file="True" citation_global_level_id="329349.001" >496 U. S. 72, 79 (1990)</CITATION>

<DATE start="16583" citation_local_level_id="40" citation_global_level_id="329349.001" end="16587" id="8201_309" >1990</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329388" start="16599" alternative_keys="['u.s._373_132']" line="36" party2_short="Paul" end="16643" citation_local_level_id="41" party1="Florida Lime &amp; Avocado Growers, Inc." party2="Paul" id="8201_304" citation_global_level_id="329387.011" party1_short="Growers" >Florida Lime &amp; Avocado Growers, Inc. v. Paul</CITATION>

<ORGANIZATION start="16599" party1_of="8201_304" end="16635" id="8201_307" >Florida Lime &amp; Avocado Growers, Inc.</ORGANIZATION>

<ORGANIZATION start="16599" end="16634" id="8201_313" >Florida Lime &amp; Avocado Growers, Inc</ORGANIZATION>

<PERSON start="16639" party2_of="8201_304" end="16643" id="8201_308" >Paul</PERSON>

<CITATION entry_type="standard_key" line="36" id1="Dummy_File_329388" start="16645" lookup_key="u.s._373_132" standard_reporter="U.S." end="16667" page_number="132" reporter="U. S." citation_local_level_id="42" paragraph_number="142-143" id="8201_302" volume="373" no_current_file="True" citation_global_level_id="329387.003" >373 U. S. 132, 142-143</CITATION>

<DATE start="16669" citation_local_level_id="42" citation_global_level_id="329387.003" end="16673" id="8201_310" >1963</DATE>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<LEGAL_ROLE start="17175" end="17185" id="8201_321" >petitioner</LEGAL_ROLE>

<LEGAL_ROLE start="17234" end="17244" id="8201_322" >respondent</LEGAL_ROLE>

<GPE start="17287" end="17300" id="8201_323" >New Hampshire</GPE>

<LEGAL_ROLE start="17377" end="17387" id="8201_324" >Respondent</LEGAL_ROLE>

<NAME id="8201_325" start="17392" all_names="RATHER" local_name_id="46" end="17398" >Rather</NAME>

<GPE start="17400" end="17413" id="8201_326" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<LEGAL_ROLE start="17492" end="17502" id="8201_335" >Respondent</LEGAL_ROLE>

<GPE start="17519" end="17532" id="8201_336" >New Hampshire</GPE>

<NAME id="8201_337" start="17602" all_names="SECTION" local_name_id="47" end="17609" >Section</NAME>

<NAME id="8201_338" start="17646" all_names="TORTS" local_name_id="48" end="17651" >Torts</NAME>

<DATE start="17696" end="17700" id="8201_332" >1963</DATE>

<DATE start="17705" end="17709" id="8201_333" >1964</DATE>

<CITATION entry_type="party_key" line="40" id1="Dummy_File_364776" start="17745" alternative_keys="['a.2d_260_111', 'n.h._110_36']" lookup_key="buttricksons#1" party2_short="Sons" end="17783" standard_reporter="N.H." citation_local_level_id="43" volume="110" party1="Buttrick" party2="Arthur Lessard &amp; Sons, Inc" id="8201_329" no_current_file="True" page_number="36" citation_global_level_id="364775.004" party1_short="Buttrick" >Buttrick v. Arthur Lessard &amp; Sons, Inc</CITATION>

<PERSON start="17745" party1_of="8201_329" end="17753" id="8201_330" >Buttrick</PERSON>

<ORGANIZATION start="17757" party2_of="8201_329" end="17783" id="8201_331" >Arthur Lessard &amp; Sons, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="40" id1="Dummy_File_364776" start="17786" alternative_keys="['buttricksons#1', 'a.2d_260_111']" lookup_key="n.h._110_36" standard_reporter="N.H." end="17805" page_number="36" reporter="N. H." citation_local_level_id="44" paragraph_number="37-39" id="8201_327" volume="110" no_current_file="True" citation_global_level_id="364775.004" >110 N. H. 36, 37-39</CITATION>

<CITATION entry_type="standard_key" page_number="111" start="17807" alternative_keys="['buttricksons#1', 'n.h._110_36']" line="40" standard_reporter="A.2D" end="17836" year="1969" lookup_key="a.2d_260_111" reporter="A. 2d" citation_local_level_id="45" paragraph_number="112-113" id="8201_328" id1="Dummy_File_364776" volume="260" no_current_file="True" citation_global_level_id="364775.004" >260 A. 2d 111, 112-113 (1969)</CITATION>

<DATE start="17831" citation_local_level_id="45" citation_global_level_id="364775.004" end="17835" id="8201_334" >1969</DATE>

<GPE start="17886" end="17899" id="8201_339" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<LEGAL_ROLE start="18220" end="18230" id="8201_378" >respondent</LEGAL_ROLE>

<GPE start="18548" end="18561" id="8201_379" >New Hampshire</GPE>

<ORGANIZATION start="18614" end="18641" id="8201_380" >New Hampshire Supreme Court</ORGANIZATION>

<CITATION entry_type="party_key" line="41" id1="Dummy_File_364777" start="18788" lookup_key="thibaultsears#1" party2_short="Sears" end="18805" citation_local_level_id="46" party1="Thibault" party2="Sears" id="8201_358" no_current_file="True" citation_global_level_id="364776.001" party1_short="Thibault" >Thibault v. Sears</CITATION>

<PERSON start="18788" party1_of="8201_358" end="18796" id="8201_363" >Thibault</PERSON>

<PERSON start="18800" party2_of="8201_358" end="18805" id="8201_364" >Sears</PERSON>

<ORGANIZATION start="18807" end="18819" id="8201_381" >Roebuck &amp; Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364766" start="18822" alternative_keys="['thibaultroebuck#1', 'a.2d_395_843']" lookup_key="n.h._118_802" standard_reporter="N.H." end="18840" page_number="802" reporter="N. H." citation_local_level_id="47" paragraph_number="809" id="8201_348" volume="118" no_current_file="True" citation_global_level_id="364765.004" >118 N. H. 802, 809</CITATION>

<CITATION entry_type="standard_key" page_number="843" start="18842" alternative_keys="['thibaultroebuck#1', 'n.h._118_802']" line="41" standard_reporter="A.2D" end="18867" year="1978" lookup_key="a.2d_395_843" reporter="A. 2d" citation_local_level_id="48" paragraph_number="847" id="8201_349" id1="Dummy_File_364766" volume="395" no_current_file="True" citation_global_level_id="364765.004" >395 A. 2d 843, 847 (1978)</CITATION>

<DATE start="18862" citation_local_level_id="48" citation_global_level_id="364765.004" end="18866" id="8201_373" >1978</DATE>

<CITATION entry_type="party_key" line="41" id1="Dummy_File_364778" start="18878" lookup_key="reidmach#1" party2_short="Mach" end="18898" citation_local_level_id="49" party1="Reid" party2="Spadone Mach" id="8201_359" no_current_file="True" citation_global_level_id="364777.001" party1_short="Reid" >Reid v. Spadone Mach</CITATION>

<PERSON start="18878" party1_of="8201_359" end="18882" id="8201_365" >Reid</PERSON>

<NAME all_names="SPADONEMACH" id="8201_366" start="18886" party2_of="8201_359" local_name_id="49" end="18898" >Spadone Mach</NAME>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364779" start="18905" lookup_key="n.h._119_457" standard_reporter="N.H." end="18923" page_number="457" reporter="N. H." citation_local_level_id="50" paragraph_number="465" id="8201_350" volume="119" no_current_file="True" citation_global_level_id="364778.001" >119 N. H. 457, 465</CITATION>

<CITATION entry_type="standard_key" page_number="1094" start="18925" line="41" standard_reporter="A.2D" end="18952" year="1979" lookup_key="a.2d_404_1094" reporter="A. 2d" citation_local_level_id="51" paragraph_number="1099" id="8201_351" id1="Dummy_File_364780" volume="404" no_current_file="True" citation_global_level_id="364779.001" >404 A. 2d 1094, 1099 (1979)</CITATION>

<DATE start="18947" citation_local_level_id="51" citation_global_level_id="364779.001" end="18951" id="8201_374" >1979</DATE>

<GPE start="18958" end="18971" id="8201_382" >New Hampshire</GPE>

<PROFESSION start="19001" end="19008" id="8201_383" >general</PROFESSION>

<CITATION entry_type="party_key" line="41" id1="Dummy_File_364781" start="19126" alternative_keys="['a.2d_637_148', 'n.h._138_73']" lookup_key="chellmanab#1" party2_short="AB" end="19152" standard_reporter="N.H." citation_local_level_id="52" volume="138" party1="Chellman" party2="Saab-Scania AB" id="8201_360" no_current_file="True" page_number="73" citation_global_level_id="364780.004" party1_short="Chellman" >Chellman v. Saab-Scania AB</CITATION>

<NAME id="8201_367" start="19126" all_names="CHELLMAN" local_name_id="50" end="19134" party1_of="8201_360" >Chellman</NAME>

<NAME all_names="SAAB-SCANIAAB" id="8201_368" start="19138" party2_of="8201_360" local_name_id="51" end="19152" >Saab-Scania AB</NAME>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364781" start="19154" alternative_keys="['chellmanab#1', 'a.2d_637_148']" lookup_key="n.h._138_73" standard_reporter="N.H." end="19170" page_number="73" reporter="N. H." citation_local_level_id="53" paragraph_number="78" id="8201_352" volume="138" no_current_file="True" citation_global_level_id="364780.004" >138 N. H. 73, 78</CITATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364781" start="19172" alternative_keys="['chellmanab#1', 'n.h._138_73']" lookup_key="a.2d_637_148" standard_reporter="A.2D" end="19190" page_number="148" reporter="A. 2d" citation_local_level_id="54" paragraph_number="150" id="8201_353" volume="637" no_current_file="True" citation_global_level_id="364780.004" >637 A. 2d 148, 150</CITATION>

<DATE start="19192" citation_local_level_id="53" citation_global_level_id="364780.004" end="19196" id="8201_375" >1993</DATE>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<PROFESSION start="19232" end="19239" id="8201_384" >general</PROFESSION>

<CITATION entry_type="party_key" line="41" id1="Dummy_File_364782" start="19345" lookup_key="simoneaulathe#1" party2_short="Lathe" end="19373" citation_local_level_id="55" party1="Simoneau" party2="South Bend Lathe" id="8201_361" no_current_file="True" citation_global_level_id="364781.001" party1_short="Simoneau" >Simoneau v. South Bend Lathe</CITATION>

<PERSON start="19345" party1_of="8201_361" end="19353" id="8201_369" >Simoneau</PERSON>

<NAME all_names="SOUTHBENDLATHE" id="8201_370" start="19357" party2_of="8201_361" local_name_id="52" end="19373" >South Bend Lathe</NAME>

<ORGANIZATION start="19375" end="19378" id="8201_385" >Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364783" start="19381" lookup_key="n.h._130_466" standard_reporter="N.H." end="19399" page_number="466" reporter="N. H." citation_local_level_id="56" paragraph_number="469" id="8201_354" volume="130" no_current_file="True" citation_global_level_id="364782.001" >130 N. H. 466, 469</CITATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364784" start="19401" lookup_key="a.2d_543_407" standard_reporter="A.2D" end="19419" page_number="407" reporter="A. 2d" citation_local_level_id="57" paragraph_number="409" id="8201_355" volume="543" no_current_file="True" citation_global_level_id="364783.001" >543 A. 2d 407, 409</CITATION>

<DATE start="19421" citation_local_level_id="56" citation_global_level_id="364782.001" end="19425" id="8201_376" >1988</DATE>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<CITATION entry_type="party_key" line="41" id1="Dummy_File_364785" start="19595" alternative_keys="['a.2d_702_330', 'n.h._142_386']" lookup_key="pricebic#1" party2_short="BIC" end="19612" standard_reporter="N.H." citation_local_level_id="58" volume="142" party1="Price" party2="BIC Corp" id="8201_362" no_current_file="True" page_number="386" citation_global_level_id="364784.004" party1_short="Price" >Price v. BIC Corp</CITATION>

<PERSON start="19595" party1_of="8201_362" end="19600" id="8201_371" >Price</PERSON>

<ORGANIZATION start="19604" party2_of="8201_362" end="19612" id="8201_372" >BIC Corp</ORGANIZATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364785" start="19615" alternative_keys="['pricebic#1', 'a.2d_702_330']" lookup_key="n.h._142_386" standard_reporter="N.H." end="19633" page_number="386" reporter="N. H." citation_local_level_id="59" paragraph_number="390" id="8201_356" volume="142" no_current_file="True" citation_global_level_id="364784.004" >142 N. H. 386, 390</CITATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364785" start="19635" alternative_keys="['pricebic#1', 'n.h._142_386']" lookup_key="a.2d_702_330" standard_reporter="A.2D" end="19653" page_number="330" reporter="A. 2d" citation_local_level_id="60" paragraph_number="333" id="8201_357" volume="702" no_current_file="True" citation_global_level_id="364784.004" >702 A. 2d 330, 333</CITATION>

<DATE start="19655" citation_local_level_id="59" citation_global_level_id="364784.004" end="19659" id="8201_377" >1997</DATE>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<LEGAL_ROLE start="19855" end="19865" id="8201_386" >respondent</LEGAL_ROLE>

<GPE start="19895" end="19908" id="8201_387" >New Hampshire</GPE>

<LEGAL_ROLE start="19995" end="20005" id="8201_388" >Respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<GPE start="20019" end="20032" id="8201_411" >New Hampshire</GPE>

<GPE start="20192" end="20205" id="8201_412" >New Hampshire</GPE>

<ORGANIZATION start="20330" end="20357" id="8201_413" >New Hampshire Supreme Court</ORGANIZATION>

<NAME id="8201_414" start="20537" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="20554" >New Hampshire law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<LEGAL_ROLE start="20610" end="20620" id="8201_424" >Respondent</LEGAL_ROLE>

<NAME id="8201_425" start="20642" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="20659" >New Hampshire law</NAME>

<LEGAL_ROLE start="20832" end="20842" id="8201_426" >Respondent</LEGAL_ROLE>

<GPE start="20918" end="20931" id="8201_427" >New Hampshire</GPE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364767" start="21069" alternative_keys="['a.2d_784_1178', 'n.h._147_150']" line="44" party2_short="Industries" end="21115" citation_local_level_id="61" party1="Vautour" party2="Body Masters Sports Industries, Inc" id="8201_420" citation_global_level_id="364766.005" party1_short="Vautour" >Vautour v. Body Masters Sports Industries, Inc</CITATION>

<PERSON start="21069" party1_of="8201_420" end="21076" id="8201_421" >Vautour</PERSON>

<ORGANIZATION start="21080" party2_of="8201_420" end="21115" id="8201_422" >Body Masters Sports Industries, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="44" id1="Dummy_File_364767" start="21118" alternative_keys="['vautourindustries#1', 'a.2d_784_1178']" lookup_key="n.h._147_150" standard_reporter="N.H." end="21136" page_number="150" reporter="N. H." citation_local_level_id="62" paragraph_number="153" id="8201_415" volume="147" no_current_file="True" citation_global_level_id="364766.004" >147 N. H. 150, 153</CITATION>

<CITATION entry_type="standard_key" page_number="1178" start="21138" alternative_keys="['vautourindustries#1', 'n.h._147_150']" line="44" standard_reporter="A.2D" end="21165" year="2001" lookup_key="a.2d_784_1178" reporter="A. 2d" citation_local_level_id="63" paragraph_number="1181" id="8201_416" id1="Dummy_File_364767" volume="784" no_current_file="True" citation_global_level_id="364766.004" >784 A. 2d 1178, 1181 (2001)</CITATION>

<DATE start="21160" citation_local_level_id="63" citation_global_level_id="364766.004" end="21164" id="8201_423" >2001</DATE>

<NAME id="8201_428" start="21167" all_names="CHELLMAN" local_name_id="50" end="21175" >Chellman</NAME>

<CITATION entry_type="standard_key" line="44" id1="Dummy_File_364786" start="21191" lookup_key="a.2d_637_150" standard_reporter="A.2D" end="21208" page_number="150" reporter="A. 2d" citation_local_level_id="64" citation_global_level_id="364785.001" id="8201_417" volume="637" no_current_file="True" >637 A. 2d, at 150</CITATION>

<ORGANIZATION start="21274" end="21301" id="8201_429" >New Hampshire Supreme Court</ORGANIZATION>

<PERSON start="21454" end="21461" id="8201_430" >Vautour</PERSON>

<CITATION entry_type="standard_key" line="44" id1="Dummy_File_364768" start="21478" lookup_key="a.2d_784_1182" standard_reporter="A.2D" end="21496" page_number="1182" reporter="A. 2d" citation_local_level_id="65" citation_global_level_id="364767.001" id="8201_418" volume="784" no_current_file="True" >784 A. 2d, at 1182</CITATION>

<PERSON start="21705" end="21713" id="8201_431" >Thibault</PERSON>

<CITATION entry_type="standard_key" line="44" id1="Dummy_File_364787" start="21730" lookup_key="a.2d_395_847" standard_reporter="A.2D" end="21747" page_number="847" reporter="A. 2d" citation_local_level_id="66" citation_global_level_id="364786.001" id="8201_419" volume="395" no_current_file="True" >395 A. 2d, at 847</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<ORGANIZATION start="21830" end="21857" id="8201_440" >New Hampshire Supreme Court</ORGANIZATION>

<PERSON start="22281" end="22288" id="8201_441" >Vautour</PERSON>

<CITATION entry_type="standard_key" line="45" id1="Dummy_File_364768" start="22305" lookup_key="a.2d_784_1182" standard_reporter="A.2D" end="22323" page_number="1182" reporter="A. 2d" citation_local_level_id="67" citation_global_level_id="364767.001" id="8201_437" volume="784" no_current_file="True" >784 A. 2d, at 1182</CITATION>

<PERSON start="22334" end="22339" id="8201_442" >Price</PERSON>

<CITATION entry_type="standard_key" line="45" id1="Dummy_File_364788" start="22356" lookup_key="a.2d_702_333" standard_reporter="A.2D" end="22373" page_number="333" reporter="A. 2d" citation_local_level_id="68" citation_global_level_id="364787.001" id="8201_438" volume="702" no_current_file="True" >702 A. 2d, at 333</CITATION>

<NAME id="8201_443" start="22382" all_names="CHELLMAN" local_name_id="50" end="22390" >Chellman</NAME>

<CITATION entry_type="standard_key" line="45" id1="Dummy_File_364786" start="22409" lookup_key="a.2d_637_150" standard_reporter="A.2D" end="22426" page_number="150" reporter="A. 2d" citation_local_level_id="69" citation_global_level_id="364785.001" id="8201_439" volume="637" no_current_file="True" >637 A. 2d, at 150</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<DATE start="22735" end="22739" id="8201_444" >2012</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<ORGANIZATION start="23357" end="23362" id="8201_447" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="47" id1="Dummy_File_364774" start="23466" lookup_key="f.3d_678_37" standard_reporter="F.3D" end="23482" page_number="37" reporter="F. 3d" citation_local_level_id="70" citation_global_level_id="364773.001" id="8201_445" volume="678" no_current_file="True" >678 F. 3d, at 37</CITATION>

<CITATION entry_type="standard_key" line="47" id1="Dummy_File_364774" start="23962" lookup_key="f.3d_678_37" standard_reporter="F.3D" end="23978" page_number="37" reporter="F. 3d" citation_local_level_id="71" citation_global_level_id="364773.001" id="8201_446" volume="678" no_current_file="True" >678 F. 3d, at 37</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<PERSON start="24453" end="24460" id="8201_451" >Vautour</PERSON>

<CITATION entry_type="standard_key" line="48" id1="Dummy_File_364768" start="24477" lookup_key="a.2d_784_1182" standard_reporter="A.2D" end="24495" page_number="1182" reporter="A. 2d" citation_local_level_id="72" citation_global_level_id="364767.001" id="8201_448" volume="784" no_current_file="True" >784 A. 2d, at 1182</CITATION>

<NAME id="8201_452" start="24506" all_names="CHELLMAN" local_name_id="50" end="24514" >Chellman</NAME>

<CITATION entry_type="standard_key" line="48" id1="Dummy_File_364789" start="24516" lookup_key="n.h._138_78" standard_reporter="N.H." end="24532" page_number="78" reporter="N. H." citation_local_level_id="73" citation_global_level_id="364788.001" id="8201_449" volume="138" no_current_file="True" >138 N. H., at 78</CITATION>

<CITATION entry_type="standard_key" line="48" id1="Dummy_File_364786" start="24534" lookup_key="a.2d_637_150" standard_reporter="A.2D" end="24551" page_number="150" reporter="A. 2d" citation_local_level_id="74" citation_global_level_id="364785.001" id="8201_450" volume="637" no_current_file="True" >637 A. 2d, at 150</CITATION>

<PROFESSION start="24586" end="24593" id="8201_453" >general</PROFESSION>

<GPE start="24944" end="24957" id="8201_454" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<LEGAL_ROLE start="25174" end="25184" id="8201_460" >Respondent</LEGAL_ROLE>

<DATE start="25303" end="25307" id="8201_457" >2005</DATE>

<LEGAL_ROLE start="25315" end="25325" id="8201_461" >respondent</LEGAL_ROLE>

<PERSON start="25354" end="25357" id="8201_462" >App</PERSON>

<PROFESSION start="25372" end="25379" id="8201_463" >counsel</PROFESSION>

<NAME id="8201_464" start="25456" all_names="SULINDAC" local_name_id="53" end="25464" >Sulindac</NAME>

<NAME id="8201_465" start="25634" all_names="TR" local_name_id="54" end="25636" >Tr</NAME>

<DATE start="25647" end="25660" id="8201_458" >Aug. 17, 2010</DATE>

<ORGANIZATION start="25672" end="25686" id="8201_466" >District Court</ORGANIZATION>

<PERSON start="25835" end="25838" id="8201_467" >App</PERSON>

<NAME id="8201_468" start="25932" all_names="SULINDAC" local_name_id="53" end="25940" >Sulindac</NAME>

<ORGANIZATION start="26197" end="26211" id="8201_469" >District Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="49" id1="Dummy_File_364790" start="26403" lookup_key="f.supp.2d_760_220" standard_reporter="F.SUPP.2D" end="26427" page_number="220" reporter="F. Supp. 2d" citation_local_level_id="75" paragraph_number="231" id="8201_456" volume="760" no_current_file="True" citation_global_level_id="364789.001" >760 F. Supp. 2d 220, 231</CITATION>

<DATE start="26429" citation_local_level_id="75" citation_global_level_id="364789.001" end="26433" id="8201_459" >2011</DATE>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<NAME id="8201_471" start="26695" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="26712" >New Hampshire law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<CITATION entry_type="standard_key" line="52" id1="Dummy_File_361047" start="27166" lookup_key="u.s._564____" standard_reporter="U.S." end="27183" page_number="___" reporter="U. S." citation_local_level_id="76" citation_global_level_id="361046.001" id="8201_473" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<NAME id="8201_474" start="27790" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="27807" >New Hampshire law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<GPE start="27907" end="27915" id="8201_482" >Maryland</GPE>

<CITATION entry_type="standard_key" line="56" id1="Dummy_File_285115" start="27917" lookup_key="u.s._451_746" standard_reporter="U.S." end="27934" page_number="746" reporter="U. S." citation_local_level_id="77" citation_global_level_id="285114.003" id="8201_479" volume="451" no_current_file="True" >451 U. S., at 746</CITATION>

<GPE start="28059" end="28072" id="8201_483" >New Hampshire</GPE>

<ORGANIZATION start="28206" end="28211" id="8201_484" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="56" id1="Dummy_File_364774" start="28379" lookup_key="f.3d_678_37" standard_reporter="F.3D" end="28395" page_number="37" reporter="F. 3d" citation_local_level_id="78" citation_global_level_id="364773.001" id="8201_480" volume="678" no_current_file="True" >678 F. 3d, at 37</CITATION>

<CITATION entry_type="standard_key" line="56" id1="Dummy_File_361047" start="28801" lookup_key="u.s._564____" standard_reporter="U.S." end="28818" page_number="___" reporter="U. S." citation_local_level_id="79" citation_global_level_id="361046.001" id="8201_481" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<ORGANIZATION start="28979" end="28984" id="8201_486" >Court</ORGANIZATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<ORGANIZATION start="29216" end="29227" id="8201_487" >PLIVA Court</ORGANIZATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<ORGANIZATION start="30124" end="30129" id="8201_497" >Court</ORGANIZATION>

<ORGANIZATION start="30267" end="30272" id="8201_498" >Court</ORGANIZATION>

<PERSON start="30314" end="30321" id="8201_499" >Mensing</PERSON>

<NAME id="8201_500" start="30427" all_names="FIRSTCIRCUIT" local_name_id="6" end="30440" >First Circuit</NAME>

<CITATION entry_type="party_key" line="59" id1="Dummy_File_364791" start="30469" alternative_keys="['f.3d_588_603']" lookup_key="mensingwyeth#1" party2_short="Wyeth" end="30490" standard_reporter="F.3D" citation_local_level_id="80" volume="588" party1="Mensing" party2="Wyeth, Inc" id="8201_493" no_current_file="True" page_number="603" citation_global_level_id="364790.003" party1_short="Mensing" >Mensing v. Wyeth, Inc</CITATION>

<PERSON start="30469" party1_of="8201_493" end="30476" id="8201_494" >Mensing</PERSON>

<ORGANIZATION start="30480" party2_of="8201_493" end="30490" id="8201_495" >Wyeth, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="59" id1="Dummy_File_364791" start="30493" alternative_keys="['mensingwyeth#1']" lookup_key="f.3d_588_603" standard_reporter="F.3D" end="30511" page_number="603" reporter="F. 3d" citation_local_level_id="81" paragraph_number="611" id="8201_490" volume="588" no_current_file="True" citation_global_level_id="364790.003" >588 F. 3d 603, 611</CITATION>

<GPE start="30513" end="30515" id="8201_501" >CA</GPE>

<DATE start="30517" end="30521" id="8201_496" >2009</DATE>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<LEGAL_ROLE start="30535" plural="True" end="30545" id="8201_502" >defendants</LEGAL_ROLE>

<PERSON start="30707" end="30714" id="8201_503" >Mensing</PERSON>

<ORGANIZATION start="30793" end="30798" id="8201_504" >Court</ORGANIZATION>

<PERSON start="30830" end="30833" id="8201_505" >Reh</PERSON>

<DOCKET start="30843" entry_type="docket" line="59" end="30849" id="8201_492" >09-993</DOCKET>

<ORGANIZATION start="30880" end="30885" id="8201_506" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="59" id1="Dummy_File_361047" start="30996" lookup_key="u.s._564____" standard_reporter="U.S." end="31013" page_number="___" reporter="U. S." citation_local_level_id="82" citation_global_level_id="361046.001" id="8201_491" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<NAME id="8201_513" start="31048" all_names="FIRSTCIRCUIT" local_name_id="6" end="31061" >First Circuit</NAME>

<ORGANIZATION start="31187" end="31192" id="8201_514" >Court</ORGANIZATION>

<PROFESSION start="31609" document_level_name_id="12" party="ALITO" end="31616" id="8201_515" >Justice</PROFESSION>

<PERSON start="31617" end="31626" id="8201_516" >Sotomayor</PERSON>

<LEGAL_ROLE start="31693" end="31703" id="8201_517" >respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<GPE start="32091" end="32104" id="8201_531" >New Hampshire</GPE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329343" start="32713" alternative_keys="['u.s._514_280']" line="63" party2_short="Myrick" end="32741" citation_local_level_id="83" party1="Freightliner Corp." party2="Myrick" id="8201_523" citation_global_level_id="329342.012" party1_short="Freightliner" >Freightliner Corp. v. Myrick</CITATION>

<ORGANIZATION start="32713" party1_of="8201_523" end="32731" id="8201_525" >Freightliner Corp.</ORGANIZATION>

<ORGANIZATION start="32713" end="32730" id="8201_532" >Freightliner Corp</ORGANIZATION>

<PERSON start="32735" party2_of="8201_523" end="32741" id="8201_526" >Myrick</PERSON>

<CITATION entry_type="standard_key" line="63" id1="Dummy_File_329343" start="32743" alternative_keys="['freightlinermyrick#1']" lookup_key="u.s._514_280" standard_reporter="U.S." end="32761" page_number="280" reporter="U. S." citation_local_level_id="84" paragraph_number="287" id="8201_520" volume="514" no_current_file="True" citation_global_level_id="329342.003" >514 U. S. 280, 287</CITATION>

<DATE start="32763" citation_local_level_id="84" citation_global_level_id="329342.003" end="32767" id="8201_529" >1995</DATE>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<CITATION entry_type="standard_key" line="63" id1="Dummy_File_329365" start="32787" lookup_key="u.s._496_78" standard_reporter="U.S." end="32803" page_number="78" reporter="U. S." citation_local_level_id="85" citation_global_level_id="329364.001" id="8201_521" volume="496" no_current_file="True" >496 U. S., at 78</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_333493" start="33109" alternative_keys="['u.s._487_131']" line="63" party2_short="Casey" end="33124" citation_local_level_id="86" party1="Felder" party2="Casey" id="8201_524" citation_global_level_id="333492.007" party1_short="Felder" >Felder v. Casey</CITATION>

<PERSON start="33109" party1_of="8201_524" end="33115" id="8201_527" >Felder</PERSON>

<PERSON start="33119" party2_of="8201_524" end="33124" id="8201_528" >Casey</PERSON>

<CITATION entry_type="standard_key" page_number="131" start="33126" line="63" standard_reporter="U.S." end="33151" year="1988" lookup_key="u.s._487_131" reporter="U. S." citation_local_level_id="87" paragraph_number="138" id="8201_522" id1="Dummy_File_333493" volume="487" no_current_file="True" citation_global_level_id="333492.003" >487 U. S. 131, 138 (1988)</CITATION>

<DATE start="33146" citation_local_level_id="87" citation_global_level_id="333492.003" end="33150" id="8201_530" >1988</DATE>

<NAME id="8201_533" start="33211" all_names="FEDERALLAW" local_name_id="55" end="33222" >Federal law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<NAME id="8201_543" start="33340" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="33357" >New Hampshire law</NAME>

<PERSON start="34365" end="34384" id="8201_544" >Calabresi &amp; Melamed</PERSON>

<NAME id="8201_545" start="34386" all_names="PROPERTYRULES" local_name_id="56" end="34400" >Property Rules</NAME>

<NAME id="8201_546" start="34402" all_names="LIABILITYRULES" local_name_id="57" end="34417" >Liability Rules</NAME>

<NAME id="8201_547" start="34423" all_names="INALIENABILITY" local_name_id="58" end="34437" >Inalienability</NAME>

<NAME id="8201_548" start="34443" all_names="VIEW" local_name_id="59" end="34447" >View</NAME>

<ORGANIZATION start="34455" end="34464" id="8201_549" >Cathedral</ORGANIZATION>

<NAME id="8201_550" start="34469" all_names="HARV" local_name_id="60" end="34473" >Harv</NAME>

<DATE start="34489" end="34493" id="8201_542" >1972</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345369" start="34934" alternative_keys="['u.s._544_431']" line="65" party2_short="LLC" end="34963" citation_local_level_id="88" party1="Bates" party2="Dow Agrosciences LLC" id="8201_556" citation_global_level_id="345368.021" party1_short="Bates" >Bates v. Dow Agrosciences LLC</CITATION>

<PERSON start="34934" party1_of="8201_556" end="34939" id="8201_557" >Bates</PERSON>

<NAME all_names="DOWAGROSCIENCESLLC" id="8201_558" start="34943" party2_of="8201_556" local_name_id="61" end="34963" >Dow Agrosciences LLC</NAME>

<CITATION entry_type="standard_key" line="65" page_number="431" start="34965" lookup_key="u.s._544_431" standard_reporter="U.S." end="34985" year="2005" reporter="U. S." citation_local_level_id="89" citation_global_level_id="345368.003" id="8201_551" id1="Dummy_File_345369" volume="544" no_current_file="True" >544 U. S. 431 (2005)</CITATION>

<DATE start="34980" citation_local_level_id="89" citation_global_level_id="345368.003" end="34984" id="8201_559" >2005</DATE>

<PERSON start="35056" end="35061" id="8201_560" >Bates</PERSON>

<GPE start="35069" end="35074" id="8201_561" >Texas</GPE>

<ORGANIZATION start="35477" end="35488" id="8201_562" >Bates Court</ORGANIZATION>

<NAME id="8201_563" start="35547" all_names="STATE" local_name_id="43" end="35552" >State</NAME>

<ORGANIZATION start="35618" end="35623" id="8201_564" >Court</ORGANIZATION>

<PERSON start="35806" end="35811" id="8201_565" >Bates</PERSON>

<PERSON start="36112" end="36117" id="8201_566" >Bates</PERSON>

<CITATION entry_type="standard_key" line="65" id1="Dummy_File_364792" start="36351" lookup_key="u.s._544_445" standard_reporter="U.S." end="36368" page_number="445" reporter="U. S." citation_local_level_id="90" citation_global_level_id="364791.001" id="8201_552" volume="544" no_current_file="True" >544 U. S., at 445</CITATION>

<GPE start="36510" end="36523" id="8201_567" >New Hampshire</GPE>

<PERSON start="36557" end="36564" id="8201_568" >Vautour</PERSON>

<CITATION entry_type="standard_key" line="65" id1="Dummy_File_364793" start="36566" lookup_key="n.h._147_153" standard_reporter="N.H." end="36583" page_number="153" reporter="N. H." citation_local_level_id="91" citation_global_level_id="364792.001" id="8201_553" volume="147" no_current_file="True" >147 N. H., at 153</CITATION>

<CITATION entry_type="standard_key" line="65" id1="Dummy_File_364794" start="36585" lookup_key="a.2d_784_1181" standard_reporter="A.2D" end="36603" page_number="1181" reporter="A. 2d" citation_local_level_id="92" citation_global_level_id="364793.001" id="8201_554" volume="784" no_current_file="True" >784 A. 2d, at 1181</CITATION>

<CITATION entry_type="standard_key" line="65" id1="Dummy_File_364768" start="37035" lookup_key="a.2d_784_1182" standard_reporter="A.2D" end="37053" page_number="1182" reporter="A. 2d" citation_local_level_id="93" citation_global_level_id="364767.001" id="8201_555" volume="784" no_current_file="True" >784 A. 2d, at 1182</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<PERSON start="37290" end="37298" id="8201_579" >Congress</PERSON>

<ORGANIZATION start="37404" end="37409" id="8201_580" >Court</ORGANIZATION>

<PERSON start="37424" end="37432" id="8201_581" >Congress</PERSON>

<ORGANIZATION start="37576" end="37581" id="8201_582" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_359981" start="37650" alternative_keys="['u.s._555_555']" line="66" party2_short="Levine" end="37665" citation_local_level_id="94" party1="Wyeth" party2="Levine" id="8201_575" citation_global_level_id="359980.01" party1_short="Wyeth" >Wyeth v. Levine</CITATION>

<ORGANIZATION start="37650" party1_of="8201_575" end="37655" id="8201_576" >Wyeth</ORGANIZATION>

<PERSON start="37659" party2_of="8201_575" end="37665" id="8201_577" >Levine</PERSON>

<CITATION entry_type="standard_key" line="66" page_number="555" start="37667" lookup_key="u.s._555_555" standard_reporter="U.S." end="37687" year="2009" reporter="U. S." citation_local_level_id="95" citation_global_level_id="359980.003" id="8201_573" id1="Dummy_File_359981" volume="555" no_current_file="True" >555 U. S. 555 (2009)</CITATION>

<DATE start="37682" citation_local_level_id="95" citation_global_level_id="359980.003" end="37686" id="8201_578" >2009</DATE>

<CITATION entry_type="standard_key" line="66" id1="Dummy_File_361047" start="37696" lookup_key="u.s._564____" standard_reporter="U.S." end="37709" page_number="___" reporter="U. S." citation_local_level_id="96" citation_global_level_id="361046.001" id="8201_574" volume="564" no_current_file="True" >564 U. S. ___</CITATION>

<PERSON start="38106" end="38114" id="8201_583" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<LEGAL_ROLE start="38407" end="38417" id="8201_588" >respondent</LEGAL_ROLE>

<LEGAL_ROLE start="38569" end="38579" id="8201_589" >respondent</LEGAL_ROLE>

<PERSON start="38643" end="38651" id="8201_590" >Congress</PERSON>

<LEGAL_ROLE start="38872" end="38882" id="8201_591" >Respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<PERSON start="39048" end="39054" id="8201_592" >Breyer</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<CITATION entry_type="standard_key" line="71" page_number="____" start="39072" lookup_key="u.s._570_____" standard_reporter="U.S." end="39093" year="2013" reporter="U. S." citation_local_level_id="97" citation_global_level_id="364507.001" id="8201_593" id1="Dummy_File_364508" volume="570" no_current_file="True" >570 U. S. ____ (2013)</CITATION>

<DATE start="39088" citation_local_level_id="97" citation_global_level_id="364507.001" end="39092" id="8201_594" >2013</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<DOCKET lookup_key="companybartlett#1" citation_local_level_id="16" entry_type="docket" id="8201_596" start="39098" citation_global_level_id="364769.001" no_current_file="True" line="72" id1="Dummy_File_364770" end="39104" >12-142</DOCKET>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364508" start="39105" alternative_keys="['u.s._570_____']" line="73" party2_short="BARTLETT" end="39173" citation_local_level_id="98" party1="MUTUAL PHARMACEUTICAL COMPANY, INC.," party2="KAREN L. BARTLETT" id="8201_597" party1_role="petitioner" citation_global_level_id="364507.021" party1_short="COMPANY" >MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT</CITATION>

<NAME id="8201_598" start="39105" all_names="MUTUALPHARMACEUTICALCOMPANYINC" local_name_id="15" end="39141" party1_of="8201_597" >MUTUAL PHARMACEUTICAL COMPANY, INC.,</NAME>

<ORGANIZATION start="39105" end="39139" id="8201_601" >MUTUAL PHARMACEUTICAL COMPANY, INC</ORGANIZATION>

<LEGAL_ROLE start="39142" end="39152" id="8201_600" >PETITIONER</LEGAL_ROLE>

<PERSON start="39156" party2_of="8201_597" end="39173" id="8201_599" >KAREN L. BARTLETT</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<DATE start="39257" end="39270" id="8201_606" >June 24, 2013</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<PROFESSION start="39273" document_level_name_id="12" party="ALITO" end="39280" id="8201_607" >Justice</PROFESSION>

<PERSON start="39281" end="39287" id="8201_608" >Breyer</PERSON>

<PROFESSION start="39299" document_level_name_id="12" party="ALITO" end="39306" id="8201_609" >Justice</PROFESSION>

<PERSON start="39307" end="39312" id="8201_610" >Kagan</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<LEGAL_ROLE start="39388" end="39398" id="8201_618" >petitioner</LEGAL_ROLE>

<NAME id="8201_619" start="39525" all_names="STATE" local_name_id="43" end="39530" >State</NAME>

<PERSON start="39660" end="39669" id="8201_620" >Sotomayor</PERSON>

<NAME id="8201_621" start="39759" all_names="STATE" local_name_id="43" end="39764" >State</NAME>

<CITATION entry_type="party_key" line="77" id1="Dummy_File_338434" start="40029" alternative_keys="['u.s._530_363']" lookup_key="crosbycil#1" party2_short="cil" end="40070" citation_local_level_id="99" party1="Crosby" party2="National Foreign Trade Coun-cil" id="8201_614" citation_global_level_id="338433.02" party1_short="Crosby" >Crosby v. National Foreign Trade Coun-cil</CITATION>

<PERSON start="40029" party1_of="8201_614" end="40035" id="8201_615" >Crosby</PERSON>

<NAME all_names="NATIONALFOREIGNTRADECOUN-CIL" id="8201_616" start="40039" party2_of="8201_614" local_name_id="62" end="40070" >National Foreign Trade Coun-cil</NAME>

<CITATION entry_type="standard_key" page_number="363" start="40072" alternative_keys="['crosbycil#1']" line="77" standard_reporter="U.S." end="40097" year="2000" lookup_key="u.s._530_363" reporter="U. S." citation_local_level_id="100" paragraph_number="373" id="8201_613" id1="Dummy_File_338434" volume="530" no_current_file="True" citation_global_level_id="338433.003" >530 U. S. 363, 373 (2000)</CITATION>

<DATE start="40092" citation_local_level_id="100" citation_global_level_id="338433.003" end="40096" id="8201_617" >2000</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_323726" start="40142" alternative_keys="['u.s._518_470']" line="78" party2_short="Lohr" end="40165" citation_local_level_id="101" party1="Medtronic, Inc." party2="Lohr" id="8201_635" citation_global_level_id="323725.04" party1_short="Medtronic" >Medtronic, Inc. v. Lohr</CITATION>

<ORGANIZATION start="40142" party1_of="8201_635" end="40157" id="8201_642" >Medtronic, Inc.</ORGANIZATION>

<PERSON start="40161" party2_of="8201_635" end="40165" id="8201_643" >Lohr</PERSON>

<CITATION entry_type="standard_key" line="78" id1="Dummy_File_323726" start="40167" lookup_key="u.s._518_470" standard_reporter="U.S." end="40185" page_number="470" reporter="U. S." citation_local_level_id="102" paragraph_number="503" id="8201_627" volume="518" no_current_file="True" citation_global_level_id="323725.001" >518 U. S. 470, 503</CITATION>

<DATE start="40187" citation_local_level_id="102" citation_global_level_id="323725.001" end="40191" id="8201_656" >1996</DATE>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<ORGANIZATION start="40388" end="40402" id="8201_663" >Administration</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_328416" start="40696" alternative_keys="['u.s._517_735']" line="78" party2_short="A" end="40735" citation_local_level_id="103" party1="Smiley" party2="Citibank (South Dakota), N. A" id="8201_636" citation_global_level_id="328415.012" party1_short="Smiley" >Smiley v. Citibank (South Dakota), N. A</CITATION>

<PERSON start="40696" party1_of="8201_636" end="40702" id="8201_644" >Smiley</PERSON>

<NAME all_names="CITIBANK(SOUTHDAKOTA)NA" id="8201_645" start="40706" party2_of="8201_636" local_name_id="63" end="40735" >Citibank (South Dakota), N. A</NAME>

<CITATION entry_type="standard_key" page_number="735" start="40738" line="78" standard_reporter="U.S." end="40767" year="1996" lookup_key="u.s._517_735" reporter="U. S." citation_local_level_id="104" paragraph_number="739-741" id="8201_628" id1="Dummy_File_328416" volume="517" no_current_file="True" citation_global_level_id="328415.001" >517 U. S. 735, 739-741 (1996)</CITATION>

<DATE start="40762" citation_local_level_id="104" citation_global_level_id="328415.001" end="40766" id="8201_657" >1996</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329362" start="40769" alternative_keys="['u.s._471_707']" line="78" party2_short="Laboratories" end="40827" citation_local_level_id="105" party1="Hillsborough County" party2="Automated Medical Laboratories, Inc" id="8201_637" citation_global_level_id="329361.01" party1_short="County" >Hillsborough County v. Automated Medical Laboratories, Inc</CITATION>

<GPE start="40769" party1_of="8201_637" end="40788" id="8201_646" >Hillsborough County</GPE>

<ORGANIZATION start="40792" party2_of="8201_637" end="40827" id="8201_647" >Automated Medical Laboratories, Inc</ORGANIZATION>

<ORGANIZATION start="40802" end="40827" id="8201_664" >Medical Laboratories, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="707" start="40830" line="78" standard_reporter="U.S." end="40855" year="1985" lookup_key="u.s._471_707" reporter="U. S." citation_local_level_id="106" paragraph_number="721" id="8201_629" id1="Dummy_File_329362" volume="471" no_current_file="True" citation_global_level_id="329361.001" >471 U. S. 707, 721 (1985)</CITATION>

<DATE start="40850" citation_local_level_id="106" citation_global_level_id="329361.001" end="40854" id="8201_658" >1985</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364795" start="40857" line="78" party2_short="Dist" end="40901" citation_local_level_id="107" party1="Lawrence County" citation_global_level_id="364794.001" id="8201_638" no_current_file="True" party2="Lead-Deadwood School Dist" party1_short="County" >Lawrence County v. Lead-Deadwood School Dist</CITATION>

<NAME id="8201_648" start="40857" all_names="LAWRENCECOUNTY" local_name_id="64" end="40872" party1_of="8201_638" >Lawrence County</NAME>

<ORGANIZATION start="40876" party2_of="8201_638" end="40901" id="8201_649" >Lead-Deadwood School Dist</ORGANIZATION>

<DOCKET citation_local_level_id="107" entry_type="docket" id="8201_634" start="40907" citation_global_level_id="364794.001" line="78" end="40911" >40-1</DOCKET>

<CITATION entry_type="standard_key" page_number="256" start="40913" line="78" standard_reporter="U.S." end="40942" year="1985" lookup_key="u.s._469_256" reporter="U. S." citation_local_level_id="108" paragraph_number="261-262" id="8201_630" id1="Dummy_File_335876" volume="469" no_current_file="True" citation_global_level_id="335875.001" >469 U. S. 256, 261-262 (1985)</CITATION>

<DATE start="40937" citation_local_level_id="108" citation_global_level_id="335875.001" end="40941" id="8201_659" >1985</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_334286" start="40944" alternative_keys="['u.s._467_837']" line="78" party2_short="Council" end="41007" citation_local_level_id="109" party1="Chevron U. S. A. Inc." party2="Natural Resources Defense Council, Inc" id="8201_639" citation_global_level_id="334285.117" party1_short="A" >Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc</CITATION>

<ORGANIZATION start="40944" party1_of="8201_639" end="40965" id="8201_650" >Chevron U. S. A. Inc.</ORGANIZATION>

<ORGANIZATION start="40969" party2_of="8201_639" end="41007" id="8201_651" >Natural Resources Defense Council, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="837" start="41010" alternative_keys="['f.3d_225_667', False, 'u.s._463_29']" line="78" standard_reporter="U.S." end="41039" year="1984" lookup_key="u.s._467_837" reporter="U. S." citation_local_level_id="110" paragraph_number="842-845" id="8201_631" id1="Dummy_File_324121" volume="467" no_current_file="True" citation_global_level_id="324120.021" >467 U. S. 837, 842-845 (1984)</CITATION>

<DATE start="41034" citation_local_level_id="110" citation_global_level_id="334285.005" end="41038" id="8201_660" >1984</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_359981" start="41051" alternative_keys="['u.s._555_555']" line="78" party2_short="Levine" end="41066" citation_local_level_id="111" party1="Wyeth" party2="Levine" id="8201_640" citation_global_level_id="359980.011" party1_short="Wyeth" >Wyeth v. Levine</CITATION>

<ORGANIZATION start="41051" party1_of="8201_640" end="41056" id="8201_652" >Wyeth</ORGANIZATION>

<PERSON start="41060" party2_of="8201_640" end="41066" id="8201_653" >Levine</PERSON>

<CITATION entry_type="standard_key" page_number="555" start="41068" line="78" standard_reporter="U.S." end="41097" year="2009" lookup_key="u.s._555_555" reporter="U. S." citation_local_level_id="112" paragraph_number="576-577" id="8201_632" id1="Dummy_File_359981" volume="555" no_current_file="True" citation_global_level_id="359980.003" >555 U. S. 555, 576-577 (2009)</CITATION>

<DATE start="41092" citation_local_level_id="112" citation_global_level_id="359980.003" end="41096" id="8201_661" >2009</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_324049" start="41103" alternative_keys="['u.s._323_134']" line="78" party2_short="Swift" end="41125" citation_local_level_id="113" party1="Skidmore" party2="Swift &amp; Co" id="8201_641" citation_global_level_id="324048.073" party1_short="Skidmore" >Skidmore v. Swift &amp; Co</CITATION>

<PERSON start="41103" party1_of="8201_641" end="41111" id="8201_654" >Skidmore</PERSON>

<ORGANIZATION start="41115" party2_of="8201_641" end="41125" id="8201_655" >Swift &amp; Co</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="134" start="41128" alternative_keys="['u.s._467_837']" line="78" standard_reporter="U.S." end="41153" year="1944" lookup_key="u.s._323_134" reporter="U. S." citation_local_level_id="114" paragraph_number="140" id="8201_633" id1="Dummy_File_324049" volume="323" no_current_file="True" citation_global_level_id="324048.008" >323 U. S. 134, 140 (1944)</CITATION>

<DATE start="41148" citation_local_level_id="114" citation_global_level_id="324048.008" end="41152" id="8201_662" >1944</DATE>

<PERSON start="41393" end="41401" id="8201_665" >Congress</PERSON>

<NAME id="8201_666" start="41423" all_names="STATE" local_name_id="43" end="41428" >State</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<PERSON start="41941" end="41947" id="8201_695" >Breyer</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<CITATION lookup_key="fda'sviews#1" citation_local_level_id="115" entry_type="case_key" name="FDA's views" id="8201_707" start="42046" id1="Dummy_File_364796" no_current_file="True" line="80" citation_global_level_id="364795.001" end="42057" >FDA's views</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_325585" start="42416" alternative_keys="['u.s._488_204']" line="80" party2_short="Hospital" end="42450" citation_local_level_id="116" party1="Bowen" party2="Georgetown Univ. Hospital" id="8201_699" citation_global_level_id="325584.012" party1_short="Bowen" >Bowen v. Georgetown Univ. Hospital</CITATION>

<PERSON start="42416" party1_of="8201_699" end="42421" id="8201_701" >Bowen</PERSON>

<GPE start="42425" party2_of="8201_699" end="42450" id="8201_702" >Georgetown Univ. Hospital</GPE>

<ORGANIZATION start="42442" end="42450" id="8201_708" >Hospital</ORGANIZATION>

<CITATION entry_type="standard_key" line="80" id1="Dummy_File_325585" start="42452" alternative_keys="['u.s._504_374']" lookup_key="u.s._488_204" standard_reporter="U.S." end="42474" page_number="204" reporter="U. S." citation_local_level_id="117" paragraph_number="212-213" id="8201_697" volume="488" no_current_file="True" citation_global_level_id="325584.005" >488 U. S. 204, 212-213</CITATION>

<DATE start="42476" citation_local_level_id="117" citation_global_level_id="325584.005" end="42480" id="8201_705" >1988</DATE>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_331313" start="42643" alternative_keys="['u.s._529_576']" line="80" party2_short="County" end="42671" citation_local_level_id="118" party1="Christensen" party2="Harris County" id="8201_700" citation_global_level_id="331312.027" party1_short="Christensen" >Christensen v. Harris County</CITATION>

<PERSON start="42643" party1_of="8201_700" end="42654" id="8201_703" >Christensen</PERSON>

<NAME all_names="HARRISCOUNTY" id="8201_704" start="42658" party2_of="8201_700" local_name_id="65" end="42671" >Harris County</NAME>

<CITATION entry_type="standard_key" page_number="576" start="42673" line="80" standard_reporter="U.S." end="42698" year="2000" lookup_key="u.s._529_576" reporter="U. S." citation_local_level_id="119" paragraph_number="587" id="8201_698" id1="Dummy_File_331313" volume="529" no_current_file="True" citation_global_level_id="331312.003" >529 U. S. 576, 587 (2000)</CITATION>

<DATE start="42693" citation_local_level_id="119" citation_global_level_id="331312.003" end="42697" id="8201_706" >2000</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<PROFESSION start="42758" end="42765" id="8201_739" >general</PROFESSION>

<NAME id="8201_740" start="42939" all_names="STATES" local_name_id="14" end="42945" >States</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361047" start="43038" alternative_keys="['u.s._564____']" line="81" party2_short="Mensing" end="43060" citation_local_level_id="120" party1="PLIVA, Inc." party2="Mensing" id="8201_723" citation_global_level_id="361046.04" party1_short="PLIVA" >PLIVA, Inc. v. Mensing</CITATION>

<ORGANIZATION start="43038" party1_of="8201_723" end="43049" id="8201_727" >PLIVA, Inc.</ORGANIZATION>

<ORGANIZATION start="43038" end="43048" id="8201_741" >PLIVA, Inc</ORGANIZATION>

<PERSON start="43053" party2_of="8201_723" end="43060" id="8201_728" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="81" id1="Dummy_File_361047" start="43062" lookup_key="u.s._564____" standard_reporter="U.S." end="43075" page_number="___" reporter="U. S." citation_local_level_id="121" citation_global_level_id="361046.001" id="8201_719" volume="564" no_current_file="True" >564 U. S. ___</CITATION>

<DATE start="43093" end="43097" id="8201_735" >2011</DATE>

<NAME id="8201_742" start="43164" all_names="STATES" local_name_id="14" end="43170" >States</NAME>

<NAME id="8201_743" start="43263" all_names="STATES" local_name_id="14" end="43269" >States</NAME>

<NAME id="8201_744" start="43273" all_names="AMICUSCURIAE" local_name_id="66" end="43286" >Amicus Curiae</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_348030" start="43336" alternative_keys="['u.s._545_967']" line="81" party2_short="Services" end="43406" citation_local_level_id="122" party1="National Cable &amp; Telecommunications Assn." party2="Brand X Internet Services" id="8201_724" citation_global_level_id="348029.026" party1_short="Telecommunications" >National Cable &amp; Telecommunications Assn. v. Brand X Internet Services</CITATION>

<ORGANIZATION start="43336" party1_of="8201_724" end="43377" id="8201_729" >National Cable &amp; Telecommunications Assn.</ORGANIZATION>

<NAME all_names="BRANDXINTERNETSERVICES" id="8201_730" start="43381" party2_of="8201_724" local_name_id="67" end="43406" >Brand X Internet Services</NAME>

<CITATION entry_type="standard_key" line="81" id1="Dummy_File_348030" start="43408" lookup_key="u.s._545_967" standard_reporter="U.S." end="43426" page_number="967" reporter="U. S." citation_local_level_id="123" paragraph_number="981" id="8201_720" volume="545" no_current_file="True" citation_global_level_id="348029.003" >545 U. S. 967, 981</CITATION>

<DATE start="43428" citation_local_level_id="123" citation_global_level_id="348029.003" end="43432" id="8201_736" >2005</DATE>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_324121" start="43495" alternative_keys="['u.s._463_29']" line="81" party2_short="Ins" end="43581" citation_local_level_id="124" party1="Motor Vehicle Mfrs. Assn. of United States, Inc." party2="State Farm Mut. Automobile Ins. Co" id="8201_725" citation_global_level_id="324120.018" party1_short="Mfrs" >Motor Vehicle Mfrs. Assn. of United States, Inc. v. State Farm Mut. Automobile Ins. Co</CITATION>

<ORGANIZATION start="43495" party1_of="8201_725" end="43543" id="8201_731" >Motor Vehicle Mfrs. Assn. of United States, Inc.</ORGANIZATION>

<ORGANIZATION start="43531" end="43542" id="8201_745" >States, Inc</ORGANIZATION>

<ORGANIZATION start="43547" party2_of="8201_725" end="43581" id="8201_732" >State Farm Mut. Automobile Ins. Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="81" id1="Dummy_File_324121" start="43584" lookup_key="u.s._463_29" standard_reporter="U.S." end="43603" page_number="29" reporter="U. S." citation_local_level_id="125" paragraph_number="41-42" id="8201_721" volume="463" no_current_file="True" citation_global_level_id="324120.001" >463 U. S. 29, 41-42</CITATION>

<DATE start="43605" citation_local_level_id="125" citation_global_level_id="324120.001" end="43609" id="8201_737" >1983</DATE>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_339140" start="43619" alternative_keys="['u.s._535_467']" line="81" party2_short="FCC" end="43653" citation_local_level_id="126" party1="Verizon Communications Inc." party2="FCC" id="8201_726" citation_global_level_id="339139.015" party1_short="Communications" >Verizon Communications Inc. v. FCC</CITATION>

<ORGANIZATION start="43619" party1_of="8201_726" end="43646" id="8201_733" >Verizon Communications Inc.</ORGANIZATION>

<ORGANIZATION start="43619" end="43645" id="8201_746" >Verizon Communications Inc</ORGANIZATION>

<ORGANIZATION start="43650" party2_of="8201_726" end="43653" id="8201_734" >FCC</ORGANIZATION>

<CITATION entry_type="standard_key" line="81" id1="Dummy_File_339140" start="43655" lookup_key="u.s._535_467" standard_reporter="U.S." end="43673" page_number="467" reporter="U. S." citation_local_level_id="127" paragraph_number="502" id="8201_722" volume="535" no_current_file="True" citation_global_level_id="339139.003" >535 U. S. 467, 502</CITATION>

<DATE start="43682" end="43686" id="8201_738" >2002</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<LEGAL_ROLE start="43794" end="43804" id="8201_761" >petitioner</LEGAL_ROLE>

<LEGAL_ROLE start="43967" end="43977" id="8201_762" >petitioner</LEGAL_ROLE>

<PROFESSION start="44033" plural="True" end="44046" id="8201_763" >Commissioners</PROFESSION>

<PERSON start="44190" plural="True" end="44204" id="8201_764" >Donald Kennedy</PERSON>

<NAME id="8201_765" start="44215" all_names="AMICICURIAE5SEE" local_name_id="68" end="44234" >Amici Curiae 5. See</NAME>

<PERSON start="44279" end="44287" id="8201_766" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<PROFESSION start="44535" end="44542" id="8201_768" >general</PROFESSION>

<CITATION entry_type="standard_key" line="83" id1="Dummy_File_331189" start="44567" lookup_key="u.s._518_481" standard_reporter="U.S." end="44584" page_number="481" reporter="U. S." citation_local_level_id="128" citation_global_level_id="331188.001" id="8201_767" volume="518" no_current_file="True" >518 U. S., at 481</CITATION>

<PERSON start="44664" end="44672" id="8201_769" >Congress</PERSON>

<GPE start="44834" end="44847" id="8201_770" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<LEGAL_ROLE start="45049" plural="True" end="45059" id="8201_771" >defendants</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<PERSON start="45397" end="45406" id="8201_772" >Sotomayor</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<CITATION entry_type="standard_key" line="87" page_number="____" start="45424" lookup_key="u.s._570_____" standard_reporter="U.S." end="45445" year="2013" reporter="U. S." citation_local_level_id="129" citation_global_level_id="364507.001" id="8201_773" id1="Dummy_File_364508" volume="570" no_current_file="True" >570 U. S. ____ (2013)</CITATION>

<DATE start="45440" citation_local_level_id="129" citation_global_level_id="364507.001" end="45444" id="8201_774" >2013</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<DOCKET lookup_key="companybartlett#1" citation_local_level_id="16" entry_type="docket" id="8201_776" start="45450" citation_global_level_id="364769.001" no_current_file="True" line="88" id1="Dummy_File_364770" end="45456" >12-142</DOCKET>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364508" start="45457" alternative_keys="['u.s._570_____']" line="89" party2_short="BARTLETT" end="45525" citation_local_level_id="130" party1="MUTUAL PHARMACEUTICAL COMPANY, INC.," party2="KAREN L. BARTLETT" id="8201_777" party1_role="petitioner" citation_global_level_id="364507.022" party1_short="COMPANY" >MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT</CITATION>

<NAME id="8201_778" start="45457" all_names="MUTUALPHARMACEUTICALCOMPANYINC" local_name_id="15" end="45493" party1_of="8201_777" >MUTUAL PHARMACEUTICAL COMPANY, INC.,</NAME>

<ORGANIZATION start="45457" end="45491" id="8201_781" >MUTUAL PHARMACEUTICAL COMPANY, INC</ORGANIZATION>

<LEGAL_ROLE start="45494" end="45504" id="8201_780" >PETITIONER</LEGAL_ROLE>

<PERSON start="45508" party2_of="8201_777" end="45525" id="8201_779" >KAREN L. BARTLETT</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<DATE start="45609" end="45622" id="8201_786" >June 24, 2013</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<PROFESSION start="45625" document_level_name_id="12" party="ALITO" end="45632" id="8201_787" >Justice</PROFESSION>

<PERSON start="45633" end="45642" id="8201_788" >Sotomayor</PERSON>

<PROFESSION start="45654" document_level_name_id="12" party="ALITO" end="45661" id="8201_789" >Justice</PROFESSION>

<PERSON start="45662" end="45670" id="8201_790" >Ginsburg</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361047" start="45694" alternative_keys="['u.s._564____']" line="93" party2_short="Mensing" end="45716" citation_local_level_id="131" party1="PLIVA, Inc." party2="Mensing" id="8201_794" citation_global_level_id="361046.041" party1_short="PLIVA" >PLIVA, Inc. v. Mensing</CITATION>

<ORGANIZATION start="45694" party1_of="8201_794" end="45705" id="8201_795" >PLIVA, Inc.</ORGANIZATION>

<ORGANIZATION start="45694" end="45704" id="8201_798" >PLIVA, Inc</ORGANIZATION>

<PERSON start="45709" party2_of="8201_794" end="45716" id="8201_796" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="93" page_number="___" start="45718" lookup_key="u.s._564____" standard_reporter="U.S." end="45738" year="2011" reporter="U. S." citation_local_level_id="132" citation_global_level_id="361046.001" id="8201_793" id1="Dummy_File_361047" volume="564" no_current_file="True" >564 U. S. ___ (2011)</CITATION>

<DATE start="45733" citation_local_level_id="132" citation_global_level_id="361046.001" end="45737" id="8201_797" >2011</DATE>

<ORGANIZATION start="45745" end="45750" id="8201_799" >Court</ORGANIZATION>

<ORGANIZATION start="45888" end="45893" id="8201_800" >Court</ORGANIZATION>

<PERSON start="45944" end="45951" id="8201_801" >Mensing</PERSON>

<GPE start="45964" end="45977" id="8201_802" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<ORGANIZATION start="46045" end="46050" id="8201_807" >Court</ORGANIZATION>

<LEGAL_ROLE start="46086" local_name_id="69" name="Mutual Pharmaceutical" end="46096" id="8201_808" >petitioner</LEGAL_ROLE>

<NAME id="8201_809" start="46097" all_names="MUTUALPHARMACEUTICAL" local_name_id="69" end="46118" >Mutual Pharmaceutical</NAME>

<ORGANIZATION start="46192" end="46206" id="8201_810" >District Court</ORGANIZATION>

<ORGANIZATION start="46338" end="46343" id="8201_811" >Court</ORGANIZATION>

<LEGAL_ROLE start="46379" local_name_id="70" name="Karen Bartlett" end="46389" id="8201_812" >respondent</LEGAL_ROLE>

<PERSON start="46390" plural="True" end="46404" id="8201_813" >Karen Bartlett</PERSON>

<ORGANIZATION start="46608" end="46613" id="8201_814" >Court</ORGANIZATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<PERSON start="46895" plural="True" end="46909" id="8201_820" >Karen Bartlett</PERSON>

<CITATION entry_type="standard_key" line="95" id1="Dummy_File_364790" start="47260" lookup_key="f.supp.2d_760_220" standard_reporter="F.SUPP.2D" end="47288" page_number="220" reporter="F. Supp. 2d" citation_local_level_id="133" paragraph_number="233-241" id="8201_817" volume="760" no_current_file="True" citation_global_level_id="364789.001" >760 F. Supp. 2d 220, 233-241</CITATION>

<GPE start="47299" end="47301" id="8201_821" >NH</GPE>

<DATE start="47302" end="47306" id="8201_818" >2011</DATE>

<ORGANIZATION start="47313" end="47318" id="8201_822" >Court</ORGANIZATION>

<PERSON start="47401" plural="True" end="47415" id="8201_823" >Karen Bartlett</PERSON>

<ORGANIZATION start="47479" end="47484" id="8201_824" >Court</ORGANIZATION>

<NAME id="8201_825" start="47571" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="47588" >New Hampshire law</NAME>

<NAME id="8201_826" start="47657" all_names="KAREN" local_name_id="71" end="47662" >Karen</NAME>

<CITATION lookup_key="bartlett'srecovery#1" citation_local_level_id="134" entry_type="case_key" name="Bartlett's recovery" id="8201_819" start="47663" id1="Dummy_File_364797" no_current_file="True" line="95" citation_global_level_id="364796.001" end="47682" >Bartlett's recovery</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_359981" start="47778" alternative_keys="['u.s._555_555']" line="97" party2_short="Levine" end="47793" citation_local_level_id="135" party1="Wyeth" party2="Levine" id="8201_831" citation_global_level_id="359980.012" party1_short="Wyeth" >Wyeth v. Levine</CITATION>

<ORGANIZATION start="47778" party1_of="8201_831" end="47783" id="8201_835" >Wyeth</ORGANIZATION>

<PERSON start="47787" party2_of="8201_831" end="47793" id="8201_836" >Levine</PERSON>

<CITATION entry_type="standard_key" page_number="555" start="47795" line="97" standard_reporter="U.S." end="47820" year="2009" lookup_key="u.s._555_555" reporter="U. S." citation_local_level_id="136" paragraph_number="565" id="8201_827" id1="Dummy_File_359981" volume="555" no_current_file="True" citation_global_level_id="359980.003" >555 U. S. 555, 565 (2009)</CITATION>

<DATE start="47815" citation_local_level_id="136" citation_global_level_id="359980.003" end="47819" id="8201_843" >2009</DATE>

<PERSON start="47933" end="47941" id="8201_847" >Congress</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_323726" start="48013" alternative_keys="['u.s._518_470']" line="97" party2_short="Lohr" end="48036" citation_local_level_id="137" party1="Medtronic, Inc." party2="Lohr" id="8201_832" citation_global_level_id="323725.041" party1_short="Medtronic" >Medtronic, Inc. v. Lohr</CITATION>

<ORGANIZATION start="48013" party1_of="8201_832" end="48028" id="8201_837" >Medtronic, Inc.</ORGANIZATION>

<PERSON start="48032" party2_of="8201_832" end="48036" id="8201_838" >Lohr</PERSON>

<CITATION entry_type="standard_key" page_number="470" start="48038" line="97" standard_reporter="U.S." end="48063" year="1996" lookup_key="u.s._518_470" reporter="U. S." citation_local_level_id="138" paragraph_number="485" id="8201_828" id1="Dummy_File_323726" volume="518" no_current_file="True" citation_global_level_id="323725.001" >518 U. S. 470, 485 (1996)</CITATION>

<DATE start="48058" citation_local_level_id="138" citation_global_level_id="323725.001" end="48062" id="8201_844" >1996</DATE>

<PROFESSION start="48122" end="48128" id="8201_848" >police</PROFESSION>

<NAME id="8201_849" start="48143" all_names="STATES" local_name_id="14" end="48149" >States</NAME>

<NAME id="8201_850" start="48184" all_names="FEDERALACT" local_name_id="72" end="48195" >Federal Act</NAME>

<PERSON start="48246" end="48254" id="8201_851" >Congress</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_323729" start="48257" alternative_keys="['u.s._331_218']" line="97" party2_short="Elevator" end="48287" citation_local_level_id="139" party1="Rice" party2="Santa Fe Elevator Corp" id="8201_833" citation_global_level_id="323728.021" party1_short="Rice" >Rice v. Santa Fe Elevator Corp</CITATION>

<PERSON start="48257" party1_of="8201_833" end="48261" id="8201_839" >Rice</PERSON>

<ORGANIZATION start="48265" party2_of="8201_833" end="48287" id="8201_840" >Santa Fe Elevator Corp</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="218" start="48290" line="97" standard_reporter="U.S." end="48315" year="1947" lookup_key="u.s._331_218" reporter="U. S." citation_local_level_id="140" paragraph_number="230" id="8201_829" id1="Dummy_File_323729" volume="331" no_current_file="True" citation_global_level_id="323728.001" >331 U. S. 218, 230 (1947)</CITATION>

<DATE start="48310" citation_local_level_id="140" citation_global_level_id="323728.001" end="48314" id="8201_845" >1947</DATE>

<PERSON start="48415" end="48423" id="8201_852" >Congress</PERSON>

<NAME id="8201_853" start="48480" all_names="STATES" local_name_id="14" end="48486" >States</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364612" start="48489" alternative_keys="['u.s._555_70']" line="97" party2_short="Good" end="48515" citation_local_level_id="141" party1="Altria Group, Inc." party2="Good" id="8201_834" citation_global_level_id="364611.004" party1_short="Group" >Altria Group, Inc. v. Good</CITATION>

<ORGANIZATION start="48489" party1_of="8201_834" end="48507" id="8201_841" >Altria Group, Inc.</ORGANIZATION>

<ORGANIZATION start="48489" end="48506" id="8201_854" >Altria Group, Inc</ORGANIZATION>

<PERSON start="48511" party2_of="8201_834" end="48515" id="8201_842" >Good</PERSON>

<CITATION entry_type="standard_key" page_number="70" start="48517" line="97" standard_reporter="U.S." end="48540" year="2008" lookup_key="u.s._555_70" reporter="U. S." citation_local_level_id="142" paragraph_number="77" id="8201_830" id1="Dummy_File_364612" volume="555" no_current_file="True" citation_global_level_id="364611.003" >555 U. S. 70, 77 (2008)</CITATION>

<DATE start="48535" citation_local_level_id="142" citation_global_level_id="364611.003" end="48539" id="8201_846" >2008</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<ORGANIZATION start="48548" end="48553" id="8201_874" >Court</ORGANIZATION>

<NAME id="8201_875" start="48594" all_names="FED-ERALFOOD" local_name_id="73" end="48607" >Fed-eral Food</NAME>

<NAME id="8201_876" start="48619" all_names="COSMETICACT" local_name_id="2" end="48631" >Cosmetic Act</NAME>

<NAME id="8201_877" start="48652" all_names="STAT" local_name_id="18" end="48656" >Stat</NAME>

<PERSON start="48705" end="48711" id="8201_878" >Levine</PERSON>

<CITATION entry_type="standard_key" line="98" id1="Dummy_File_364798" start="48836" lookup_key="u.s._555_581" standard_reporter="U.S." end="48853" page_number="581" reporter="U. S." citation_local_level_id="143" citation_global_level_id="364797.001" id="8201_871" volume="555" no_current_file="True" >555 U. S., at 581</CITATION>

<DATE start="48911" end="48915" id="8201_873" >1906</DATE>

<NAME id="8201_879" start="48916" all_names="FEDERALFOOD" local_name_id="1" end="48928" >Federal Food</NAME>

<NAME id="8201_880" start="48947" all_names="STAT" local_name_id="18" end="48951" >Stat</NAME>

<NAME id="8201_881" start="48981" all_names="MAJORAMENDMENTS" local_name_id="74" end="48997" >major amendments</NAME>

<ORGANIZATION start="49003" end="49008" id="8201_882" >Court</ORGANIZATION>

<PERSON start="49151" end="49157" id="8201_883" >Levine</PERSON>

<CITATION entry_type="standard_key" line="98" id1="Dummy_File_364799" start="49159" lookup_key="u.s._555_566" standard_reporter="U.S." end="49176" page_number="566" reporter="U. S." citation_local_level_id="144" citation_global_level_id="364798.001" id="8201_872" volume="555" no_current_file="True" >555 U. S., at 566</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<NAME id="8201_886" start="49407" all_names="STATESFOOD" local_name_id="19" end="49418" >States Food</NAME>

<ORGANIZATION start="49428" end="49442" id="8201_887" >Administration</ORGANIZATION>

<PERSON start="49872" end="49878" id="8201_888" >Levine</PERSON>

<CITATION entry_type="standard_key" line="99" id1="Dummy_File_364800" start="49880" lookup_key="u.s._555_578" standard_reporter="U.S." end="49897" page_number="578" reporter="U. S." citation_local_level_id="145" citation_global_level_id="364799.001" id="8201_884" volume="555" no_current_file="True" >555 U. S., at 578</CITATION>

<DATE start="50133" end="50137" id="8201_885" >2012</DATE>

<NAME id="8201_889" start="50361" all_names="STATES" local_name_id="14" end="50367" >States</NAME>

<NAME id="8201_890" start="50371" all_names="AMICUSCURIAE" local_name_id="66" end="50384" >Amicus Curiae</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<PERSON start="50715" end="50721" id="8201_900" >Levine</PERSON>

<CITATION entry_type="standard_key" line="100" id1="Dummy_File_364800" start="50723" lookup_key="u.s._555_578" standard_reporter="U.S." end="50740" page_number="578" reporter="U. S." citation_local_level_id="146" citation_global_level_id="364799.001" id="8201_892" volume="555" no_current_file="True" >555 U. S., at 578</CITATION>

<NAME id="8201_901" start="50742" all_names="FEDERALLAW" local_name_id="55" end="50753" >Federal law</NAME>

<PERSON start="50920" end="50928" id="8201_902" >Congress</PERSON>

<DATE start="51016" end="51020" id="8201_898" >1962</DATE>

<PERSON start="51113" end="51121" id="8201_903" >Congress</PERSON>

<NAME id="8201_904" start="51291" all_names="STAT" local_name_id="18" end="51295" >Stat</NAME>

<PERSON start="51412" end="51418" id="8201_905" >Levine</PERSON>

<CITATION entry_type="standard_key" line="100" id1="Dummy_File_364801" start="51420" lookup_key="u.s._555_567" standard_reporter="U.S." end="51437" page_number="567" reporter="U. S." citation_local_level_id="147" citation_global_level_id="364800.001" id="8201_893" volume="555" no_current_file="True" >555 U. S., at 567</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361598" start="51447" alternative_keys="['u.s._552_312']" line="100" party2_short="Medtronic" end="51471" citation_local_level_id="148" party1="Riegel" party2="Medtronic, Inc" id="8201_895" citation_global_level_id="361597.002" party1_short="Riegel" >Riegel v. Medtronic, Inc</CITATION>

<PERSON start="51447" party1_of="8201_895" end="51453" id="8201_896" >Riegel</PERSON>

<ORGANIZATION start="51457" party2_of="8201_895" end="51471" id="8201_897" >Medtronic, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="100" id1="Dummy_File_361598" start="51474" lookup_key="u.s._552_312" standard_reporter="U.S." end="51492" page_number="312" reporter="U. S." citation_local_level_id="149" paragraph_number="340" id="8201_894" volume="552" no_current_file="True" citation_global_level_id="361597.001" >552 U. S. 312, 340</CITATION>

<DATE start="51494" citation_local_level_id="149" citation_global_level_id="361597.001" end="51498" id="8201_899" >2008</DATE>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<PERSON start="51529" end="51537" id="8201_906" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<PERSON start="51723" end="51731" id="8201_920" >Congress</PERSON>

<PERSON start="52184" end="52201" id="8201_921" >Kessler &amp; Vladeck</PERSON>

<NAME id="8201_922" start="52250" all_names="PREEMPTFAILURE-TO-WARNCLAIMS96GEO" local_name_id="75" end="52288" >Preempt Failure-to-Warn Claims, 96 Geo</NAME>

<DATE start="52306" end="52310" id="8201_916" >2008</DATE>

<ORGANIZATION start="52317" plural="True" end="52335" id="8201_923" >National Academies</ORGANIZATION>

<ORGANIZATION start="52337" end="52346" id="8201_924" >Institute</ORGANIZATION>

<NAME id="8201_925" start="52350" all_names="MEDICINE" local_name_id="76" end="52358" >Medicine</NAME>

<CITATION lookup_key="thefutureofdrugsafety#2" citation_local_level_id="150" entry_type="case_key" name="The Future of Drug Safety" id="8201_919" start="52360" id1="Dummy_File_364802" no_current_file="True" line="101" citation_global_level_id="364801.001" end="52385" >The Future of Drug Safety</CITATION>

<NAME id="8201_926" start="52430" all_names="PUBLIC" local_name_id="77" end="52436" >Public</NAME>

<DATE start="52444" end="52448" id="8201_917" >2007</DATE>

<PERSON start="52797" end="52803" id="8201_927" >Levine</PERSON>

<CITATION entry_type="standard_key" line="101" id1="Dummy_File_364800" start="52805" lookup_key="u.s._555_578" standard_reporter="U.S." end="52822" page_number="578" reporter="U. S." citation_local_level_id="151" citation_global_level_id="364799.001" id="8201_911" volume="555" no_current_file="True" >555 U. S., at 578</CITATION>

<PROFESSION start="52849" end="52887" id="8201_928" >Former FDA Commissioner Donald Kennedy</PROFESSION>

<NAME id="8201_929" start="52898" all_names="AMICICURIAE" local_name_id="78" end="52910" >Amici Curiae</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345369" start="53053" alternative_keys="['u.s._544_431']" line="101" party2_short="LLC" end="53082" citation_local_level_id="152" party1="Bates" party2="Dow Agrosciences LLC" id="8201_913" citation_global_level_id="345368.022" party1_short="Bates" >Bates v. Dow Agrosciences LLC</CITATION>

<PERSON start="53053" party1_of="8201_913" end="53058" id="8201_914" >Bates</PERSON>

<NAME all_names="DOWAGROSCIENCESLLC" id="8201_915" start="53062" party2_of="8201_913" local_name_id="61" end="53082" >Dow Agrosciences LLC</NAME>

<CITATION entry_type="standard_key" page_number="431" start="53084" line="101" standard_reporter="U.S." end="53109" year="2005" lookup_key="u.s._544_431" reporter="U. S." citation_local_level_id="153" paragraph_number="451" id="8201_912" id1="Dummy_File_345369" volume="544" no_current_file="True" citation_global_level_id="345368.003" >544 U. S. 431, 451 (2005)</CITATION>

<DATE start="53104" citation_local_level_id="153" citation_global_level_id="345368.003" end="53108" id="8201_918" >2005</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<PERSON start="53187" plural="True" end="53201" id="8201_947" >Karen Bartlett</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_339646" start="53442" alternative_keys="['u.s._537_51']" line="102" party2_short="Marine" end="53469" citation_local_level_id="154" party1="Sprietsma" party2="Mercury Marine" id="8201_939" citation_global_level_id="339645.016" party1_short="Sprietsma" >Sprietsma v. Mercury Marine</CITATION>

<NAME id="8201_941" start="53442" all_names="SPRIETSMA" local_name_id="79" end="53451" party1_of="8201_939" >Sprietsma</NAME>

<NAME all_names="MERCURYMARINE" id="8201_942" start="53455" party2_of="8201_939" local_name_id="80" end="53469" >Mercury Marine</NAME>

<CITATION entry_type="standard_key" page_number="51" start="53471" alternative_keys="['sprietsmamarine#1']" line="102" standard_reporter="U.S." end="53494" year="2002" lookup_key="u.s._537_51" reporter="U. S." citation_local_level_id="155" paragraph_number="64" id="8201_934" id1="Dummy_File_339646" volume="537" no_current_file="True" citation_global_level_id="339645.003" >537 U. S. 51, 64 (2002)</CITATION>

<DATE start="53489" citation_local_level_id="155" citation_global_level_id="339645.003" end="53493" id="8201_945" >2002</DATE>

<ORGANIZATION start="53506" end="53511" id="8201_948" >Court</ORGANIZATION>

<PERSON start="53685" end="53693" id="8201_949" >Congress</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329359" start="53728" alternative_keys="['u.s._464_238']" line="102" party2_short="McGee" end="53755" citation_local_level_id="156" party1="Silkwood" party2="Kerr-McGee Corp" id="8201_940" citation_global_level_id="329358.02" party1_short="Silkwood" >Silkwood v. Kerr-McGee Corp</CITATION>

<PERSON start="53728" party1_of="8201_940" end="53736" id="8201_943" >Silkwood</PERSON>

<ORGANIZATION start="53740" party2_of="8201_940" end="53755" id="8201_944" >Kerr-McGee Corp</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="238" start="53758" line="102" standard_reporter="U.S." end="53783" year="1984" lookup_key="u.s._464_238" reporter="U. S." citation_local_level_id="157" paragraph_number="251" id="8201_935" id1="Dummy_File_329359" volume="464" no_current_file="True" citation_global_level_id="329358.001" >464 U. S. 238, 251 (1984)</CITATION>

<DATE start="53778" citation_local_level_id="157" citation_global_level_id="329358.001" end="53782" id="8201_946" >1984</DATE>

<PERSON start="53795" end="53800" id="8201_950" >Bates</PERSON>

<CITATION entry_type="standard_key" line="102" id1="Dummy_File_350394" start="53802" lookup_key="u.s._544_449" standard_reporter="U.S." end="53819" page_number="449" reporter="U. S." citation_local_level_id="158" citation_global_level_id="350393.001" id="8201_936" volume="544" no_current_file="True" >544 U. S., at 449</CITATION>

<PERSON start="53821" end="53825" id="8201_951" >Lohr</PERSON>

<CITATION entry_type="standard_key" line="102" id1="Dummy_File_350398" start="53827" lookup_key="u.s._518_487" standard_reporter="U.S." end="53844" page_number="487" reporter="U. S." citation_local_level_id="159" citation_global_level_id="350397.001" id="8201_937" volume="518" no_current_file="True" >518 U. S., at 487</CITATION>

<PERSON start="53929" end="53937" id="8201_952" >Congress</PERSON>

<PERSON start="54104" end="54110" id="8201_953" >Levine</PERSON>

<CITATION entry_type="standard_key" line="102" id1="Dummy_File_364803" start="54112" lookup_key="u.s._555_574" standard_reporter="U.S." end="54129" page_number="574" reporter="U. S." citation_local_level_id="160" citation_global_level_id="364802.001" id="8201_938" volume="555" no_current_file="True" >555 U. S., at 574</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<GPE start="54250" end="54263" id="8201_967" >New Hampshire</GPE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329388" start="54479" alternative_keys="['u.s._373_132']" line="104" party2_short="Paul" end="54523" citation_local_level_id="161" party1="Florida Lime &amp; Avocado Growers, Inc." party2="Paul" id="8201_963" citation_global_level_id="329387.012" party1_short="Growers" >Florida Lime &amp; Avocado Growers, Inc. v. Paul</CITATION>

<ORGANIZATION start="54479" party1_of="8201_963" end="54515" id="8201_964" >Florida Lime &amp; Avocado Growers, Inc.</ORGANIZATION>

<ORGANIZATION start="54479" end="54514" id="8201_968" >Florida Lime &amp; Avocado Growers, Inc</ORGANIZATION>

<PERSON start="54519" party2_of="8201_963" end="54523" id="8201_965" >Paul</PERSON>

<CITATION entry_type="standard_key" page_number="132" start="54525" line="104" standard_reporter="U.S." end="54554" year="1963" lookup_key="u.s._373_132" reporter="U. S." citation_local_level_id="162" paragraph_number="142-143" id="8201_962" id1="Dummy_File_329388" volume="373" no_current_file="True" citation_global_level_id="329387.003" >373 U. S. 132, 142-143 (1963)</CITATION>

<DATE start="54549" citation_local_level_id="162" citation_global_level_id="329387.003" end="54553" id="8201_966" >1963</DATE>

<GPE start="54644" end="54657" id="8201_969" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<CITATION entry_type="standard_key" line="106" id1="Dummy_File_364804" start="54829" lookup_key="u.s._555_573" standard_reporter="U.S." end="54846" page_number="573" reporter="U. S." citation_local_level_id="163" citation_global_level_id="364803.001" id="8201_974" volume="555" no_current_file="True" >555 U. S., at 573</CITATION>

<LEGAL_ROLE start="54866" end="54875" id="8201_982" >defendant</LEGAL_ROLE>

<PERSON start="54958" end="54966" id="8201_983" >Silkwood</PERSON>

<CITATION entry_type="standard_key" line="106" id1="Dummy_File_237833" start="54968" lookup_key="u.s._464_256" standard_reporter="U.S." end="54985" page_number="256" reporter="U. S." citation_local_level_id="164" citation_global_level_id="237832.003" id="8201_975" volume="464" no_current_file="True" >464 U. S., at 256</CITATION>

<PERSON start="55211" end="55219" id="8201_984" >Congress</PERSON>

<PERSON start="55316" end="55328" id="8201_985" >Florida Lime</PERSON>

<CITATION entry_type="standard_key" line="106" id1="Dummy_File_136548" start="55330" lookup_key="u.s._373_142" standard_reporter="U.S." end="55347" page_number="142" reporter="U. S." citation_local_level_id="165" citation_global_level_id="136547.001" id="8201_976" volume="373" no_current_file="True" >373 U. S., at 142</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_333493" start="55578" alternative_keys="['u.s._487_131']" line="106" party2_short="Casey" end="55593" citation_local_level_id="166" party1="Felder" party2="Casey" id="8201_978" citation_global_level_id="333492.008" party1_short="Felder" >Felder v. Casey</CITATION>

<PERSON start="55578" party1_of="8201_978" end="55584" id="8201_979" >Felder</PERSON>

<PERSON start="55588" party2_of="8201_978" end="55593" id="8201_980" >Casey</PERSON>

<CITATION entry_type="standard_key" page_number="131" start="55595" line="106" standard_reporter="U.S." end="55620" year="1988" lookup_key="u.s._487_131" reporter="U. S." citation_local_level_id="167" paragraph_number="138" id="8201_977" id1="Dummy_File_333493" volume="487" no_current_file="True" citation_global_level_id="333492.003" >487 U. S. 131, 138 (1988)</CITATION>

<DATE start="55615" citation_local_level_id="167" citation_global_level_id="333492.003" end="55619" id="8201_981" >1988</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<NAME id="8201_1007" start="55869" all_names="CALIFORNIAFED" local_name_id="81" end="55883" >California Fed</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_342604" start="55892" alternative_keys="['u.s._479_272']" line="107" party2_short="Guerra" end="55912" citation_local_level_id="168" party1="Loan Assn." party2="Guerra" id="8201_993" citation_global_level_id="342603.006" party1_short="Loan" >Loan Assn. v. Guerra</CITATION>

<ORGANIZATION start="55892" party1_of="8201_993" end="55902" id="8201_996" >Loan Assn.</ORGANIZATION>

<PERSON start="55906" party2_of="8201_993" end="55912" id="8201_997" >Guerra</PERSON>

<CITATION entry_type="standard_key" page_number="272" start="55914" line="107" standard_reporter="U.S." end="55939" year="1987" lookup_key="u.s._479_272" reporter="U. S." citation_local_level_id="169" paragraph_number="292" id="8201_990" id1="Dummy_File_342604" volume="479" no_current_file="True" citation_global_level_id="342603.003" >479 U. S. 272, 292 (1987)</CITATION>

<DATE start="55934" citation_local_level_id="169" citation_global_level_id="342603.003" end="55938" id="8201_1004" >1987</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_335790" start="56091" alternative_keys="['u.s._517_25']" line="107" party2_short="Nelson" end="56135" citation_local_level_id="170" party1="Barnett Bank of Marion Cty., N. A." party2="Nelson" id="8201_994" citation_global_level_id="335789.009" party1_short="Bank" >Barnett Bank of Marion Cty., N. A. v. Nelson</CITATION>

<ORGANIZATION start="56091" party1_of="8201_994" end="56125" id="8201_998" >Barnett Bank of Marion Cty., N. A.</ORGANIZATION>

<ORGANIZATION start="56091" end="56103" id="8201_1008" >Barnett Bank</ORGANIZATION>

<PERSON start="56129" party2_of="8201_994" end="56135" id="8201_999" >Nelson</PERSON>

<CITATION entry_type="standard_key" page_number="25" start="56137" alternative_keys="['banknelson#1']" line="107" standard_reporter="U.S." end="56160" year="1996" lookup_key="u.s._517_25" reporter="U. S." citation_local_level_id="171" paragraph_number="31" id="8201_991" id1="Dummy_File_335790" volume="517" no_current_file="True" citation_global_level_id="335789.003" >517 U. S. 25, 31 (1996)</CITATION>

<DATE start="56155" citation_local_level_id="171" citation_global_level_id="335789.003" end="56159" id="8201_1005" >1996</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364805" start="56162" alternative_keys="['u.s._467_461']" line="107" party2_short="Marketing" end="56245" standard_reporter="U.S." citation_local_level_id="172" volume="467" party1="Michigan Canners &amp; Freezers Assn., Inc." party2="Agricultural Marketing and Bargaining Bd" id="8201_995" no_current_file="True" page_number="461" lookup_key="u.s._467_461" citation_global_level_id="364804.003" party1_short="Freezers" >Michigan Canners &amp; Freezers Assn., Inc. v. Agricultural Marketing and Bargaining Bd</CITATION>

<ORGANIZATION start="56162" party1_of="8201_995" end="56201" id="8201_1000" >Michigan Canners &amp; Freezers Assn., Inc.</ORGANIZATION>

<NAME all_names="AGRICULTURALMARKETINGANDBARGAININGBD" id="8201_1003" start="56205" party2_of="8201_995" local_name_id="82" end="56245" >Agricultural Marketing and Bargaining Bd</NAME>

<CITATION entry_type="standard_key" line="107" id1="Dummy_File_364805" start="56248" lookup_key="u.s._467_461" standard_reporter="U.S." end="56266" page_number="461" reporter="U. S." citation_local_level_id="173" paragraph_number="478" id="8201_992" volume="467" no_current_file="True" citation_global_level_id="364804.003" >467 U. S. 461, 478</CITATION>

<DATE start="56275" end="56279" id="8201_1006" >1984</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<ORGANIZATION start="56786" plural="True" end="56792" id="8201_1025" >Courts</ORGANIZATION>

<PERSON start="57115" end="57123" id="8201_1026" >Congress</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_338434" start="57176" alternative_keys="['u.s._530_363']" line="108" party2_short="Council" end="57216" citation_local_level_id="174" party1="Crosby" party2="National Foreign Trade Council" id="8201_1021" citation_global_level_id="338433.021" party1_short="Crosby" >Crosby v. National Foreign Trade Council</CITATION>

<PERSON start="57176" party1_of="8201_1021" end="57182" id="8201_1022" >Crosby</PERSON>

<ORGANIZATION start="57186" party2_of="8201_1021" end="57216" id="8201_1023" >National Foreign Trade Council</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="363" start="57218" line="108" standard_reporter="U.S." end="57247" year="2000" lookup_key="u.s._530_363" reporter="U. S." citation_local_level_id="175" paragraph_number="372-373" id="8201_1020" id1="Dummy_File_338434" volume="530" no_current_file="True" citation_global_level_id="338433.003" >530 U. S. 363, 372-373 (2000)</CITATION>

<DATE start="57242" citation_local_level_id="175" citation_global_level_id="338433.003" end="57246" id="8201_1024" >2000</DATE>

<PERSON start="57403" end="57411" id="8201_1027" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<PERSON start="57718" end="57724" id="8201_1034" >Abrams</PERSON>

<GPE start="57726" end="57757" id="8201_1035" >Plenary Power Preemption, 99 Va</GPE>

<DATE start="57777" end="57781" id="8201_1033" >2013</DATE>

<PERSON start="57784" end="57791" id="8201_1036" >Mensing</PERSON>

<ORGANIZATION start="57814" end="57819" id="8201_1037" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="109" id1="Dummy_File_361047" start="58012" lookup_key="u.s._564____" standard_reporter="U.S." end="58029" page_number="___" reporter="U. S." citation_local_level_id="176" citation_global_level_id="361046.001" id="8201_1032" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<PERSON start="58071" end="58078" id="8201_1038" >Mensing</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<GPE start="58345" end="58358" id="8201_1039" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<GPE start="58442" end="58455" id="8201_1042" >New Hampshire</GPE>

<PERSON start="58576" end="58584" id="8201_1043" >Bartlett</PERSON>

<PERSON start="58807" end="58814" id="8201_1044" >Mensing</PERSON>

<PERSON start="58921" end="58928" id="8201_1045" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="112" id1="Dummy_File_361047" start="58930" lookup_key="u.s._564____" standard_reporter="U.S." end="58947" page_number="___" reporter="U. S." citation_local_level_id="177" citation_global_level_id="361046.001" id="8201_1041" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="59116" end="59129" id="8201_1046" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="59258" end="59271" id="8201_1048" >New Hampshire</GPE>

<GPE start="59688" end="59701" id="8201_1049" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<DATE start="59950" end="59954" id="8201_1054" >1963</DATE>

<DATE start="59955" end="59959" id="8201_1055" >1964</DATE>

<NAME id="8201_1057" start="59974" all_names="SECONDRESTATEMENT" local_name_id="83" end="59992" >Second Restatement</NAME>

<GPE start="59995" end="60008" id="8201_1058" >New Hampshire</GPE>

<CITATION entry_type="party_key" line="116" id1="Dummy_File_364806" start="60147" alternative_keys="['f.3d_49_26']" lookup_key="centergrace#1" party2_short="Grace" end="60190" standard_reporter="F.3D" citation_local_level_id="178" volume="49" party1="Cheshire Medical Center" party2="W. R. Grace &amp; Co" id="8201_1051" no_current_file="True" page_number="26" citation_global_level_id="364805.003" party1_short="Center" >Cheshire Medical Center v. W. R. Grace &amp; Co</CITATION>

<NAME id="8201_1052" start="60147" all_names="CHESHIREMEDICALCENTER" local_name_id="84" end="60170" party1_of="8201_1051" >Cheshire Medical Center</NAME>

<ORGANIZATION start="60174" party2_of="8201_1051" end="60190" id="8201_1053" >W. R. Grace &amp; Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="116" id1="Dummy_File_364806" start="60193" alternative_keys="['centergrace#1']" lookup_key="f.3d_49_26" standard_reporter="F.3D" end="60208" page_number="26" reporter="F. 3d" citation_local_level_id="179" paragraph_number="29" id="8201_1050" volume="49" no_current_file="True" citation_global_level_id="364805.003" >49 F. 3d 26, 29</CITATION>

<GPE start="60210" end="60212" id="8201_1059" >CA</GPE>

<DATE start="60214" end="60218" id="8201_1056" >1995</DATE>

<ORGANIZATION start="60233" end="60247" id="8201_1060" >District Court</ORGANIZATION>

<PERSON start="60283" end="60291" id="8201_1061" >Bartlett</PERSON>

<GPE start="60322" end="60335" id="8201_1062" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<NAME id="8201_1079" start="60439" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="60456" >New Hampshire law</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364807" start="60506" line="117" party2_short="Sears" end="60523" citation_local_level_id="180" party1="Thibault" citation_global_level_id="364806.001" id="8201_1070" no_current_file="True" party2="Sears" party1_short="Thibault" >Thibault v. Sears</CITATION>

<PERSON start="60506" party1_of="8201_1070" end="60514" id="8201_1072" >Thibault</PERSON>

<PERSON start="60518" party2_of="8201_1070" end="60523" id="8201_1073" >Sears</PERSON>

<ORGANIZATION start="60525" end="60537" id="8201_1080" >Roebuck &amp; Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="117" id1="Dummy_File_364766" start="60540" alternative_keys="['thibaultroebuck#1', 'a.2d_395_843']" lookup_key="n.h._118_802" standard_reporter="N.H." end="60558" page_number="802" reporter="N. H." citation_local_level_id="181" paragraph_number="807" id="8201_1066" volume="118" no_current_file="True" citation_global_level_id="364765.004" >118 N. H. 802, 807</CITATION>

<CITATION entry_type="standard_key" page_number="843" start="60560" alternative_keys="['thibaultroebuck#1', 'n.h._118_802']" line="117" standard_reporter="A.2D" end="60585" year="1978" lookup_key="a.2d_395_843" reporter="A. 2d" citation_local_level_id="182" paragraph_number="846" id="8201_1067" id1="Dummy_File_364766" volume="395" no_current_file="True" citation_global_level_id="364765.004" >395 A. 2d 843, 846 (1978)</CITATION>

<DATE start="60580" citation_local_level_id="182" citation_global_level_id="364765.004" end="60584" id="8201_1076" >1978</DATE>

<NAME id="8201_1081" start="60775" all_names="NEWHAMP-SHIRE" local_name_id="85" end="60789" >New Hamp-shire</NAME>

<NAME id="8201_1082" start="60877" all_names="PRODUCTSLIABILITY" local_name_id="86" end="60895" >Products Liability</NAME>

<DATE start="60903" end="60907" id="8201_1077" >1997</DATE>

<NAME id="8201_1083" start="60922" all_names="THIRDRESTATEMENT" local_name_id="87" end="60939" >Third Restatement</NAME>

<LEGAL_ROLE start="60949" end="60958" id="8201_1084" >plaintiff</LEGAL_ROLE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364767" start="61210" alternative_keys="['a.2d_784_1178', 'n.h._147_150']" line="117" party2_short="Industries" end="61256" citation_local_level_id="183" party1="Vautour" party2="Body Masters Sports Industries, Inc" id="8201_1071" citation_global_level_id="364766.006" party1_short="Vautour" >Vautour v. Body Masters Sports Industries, Inc</CITATION>

<PERSON start="61210" party1_of="8201_1071" end="61217" id="8201_1074" >Vautour</PERSON>

<ORGANIZATION start="61221" party2_of="8201_1071" end="61256" id="8201_1075" >Body Masters Sports Industries, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="117" id1="Dummy_File_364767" start="61259" alternative_keys="['vautourindustries#1', 'a.2d_784_1178']" lookup_key="n.h._147_150" standard_reporter="N.H." end="61277" page_number="150" reporter="N. H." citation_local_level_id="184" paragraph_number="156" id="8201_1068" volume="147" no_current_file="True" citation_global_level_id="364766.004" >147 N. H. 150, 156</CITATION>

<CITATION entry_type="standard_key" page_number="1178" start="61279" alternative_keys="['vautourindustries#1', 'n.h._147_150']" line="117" standard_reporter="A.2D" end="61306" year="2001" lookup_key="a.2d_784_1178" reporter="A. 2d" citation_local_level_id="185" paragraph_number="1183" id="8201_1069" id1="Dummy_File_364767" volume="784" no_current_file="True" citation_global_level_id="364766.004" >784 A. 2d 1178, 1183 (2001)</CITATION>

<DATE start="61301" citation_local_level_id="185" citation_global_level_id="364766.004" end="61305" id="8201_1078" >2001</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="61404" end="61417" id="8201_1104" >New Hampshire</GPE>

<CITATION entry_type="standard_key" line="118" id1="Dummy_File_364769" start="61549" lookup_key="f.3d_678_30" standard_reporter="F.3D" end="61565" page_number="30" reporter="F. 3d" citation_local_level_id="186" paragraph_number="35" id="8201_1093" volume="678" no_current_file="True" citation_global_level_id="364768.001" >678 F. 3d 30, 35</CITATION>

<GPE start="61567" end="61569" id="8201_1105" >CA</GPE>

<DATE start="61571" end="61575" id="8201_1101" >2012</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_359151" start="61585" alternative_keys="['f.2d_642_652']" line="118" party2_short="Pharmaceutical" end="61620" citation_local_level_id="187" party1="Brochu" party2="Ortho Pharmaceutical Corp" id="8201_1098" citation_global_level_id="359150.004" party1_short="Brochu" >Brochu v. Ortho Pharmaceutical Corp</CITATION>

<PERSON start="61585" party1_of="8201_1098" end="61591" id="8201_1099" >Brochu</PERSON>

<ORGANIZATION start="61595" party2_of="8201_1098" end="61620" id="8201_1100" >Ortho Pharmaceutical Corp</ORGANIZATION>

<CITATION entry_type="standard_key" line="118" id1="Dummy_File_359151" start="61623" alternative_keys="['brochupharmaceutical#1']" lookup_key="f.2d_642_652" standard_reporter="F.2D" end="61641" page_number="652" reporter="F. 2d" citation_local_level_id="188" paragraph_number="655" id="8201_1094" volume="642" no_current_file="True" citation_global_level_id="359150.003" >642 F. 2d 652, 655</CITATION>

<GPE start="61643" end="61645" id="8201_1106" >CA</GPE>

<DATE start="61647" end="61651" id="8201_1102" >1981</DATE>

<NAME id="8201_1107" start="61664" all_names="THIRDRESTATEMENT" local_name_id="87" end="61681" >Third Restatement</NAME>

<NAME id="8201_1108" start="61686" all_names="COMMENT" local_name_id="88" end="61693" >Comment</NAME>

<GPE start="61763" end="61776" id="8201_1109" >New Hampshire</GPE>

<NAME id="8201_1110" start="61837" all_names="SECONDRESTATEMENT" local_name_id="83" end="61855" >Second Restatement</NAME>

<CITATION entry_type="standard_key" line="118" id1="Dummy_File_364773" start="62029" lookup_key="f.3d_678_36" standard_reporter="F.3D" end="62045" page_number="36" reporter="F. 3d" citation_local_level_id="189" citation_global_level_id="364772.001" id="8201_1095" volume="678" no_current_file="True" >678 F. 3d, at 36</CITATION>

<CITATION entry_type="standard_key" line="118" id1="Dummy_File_364772" start="62047" lookup_key="f.supp.2d_731_135" standard_reporter="F.SUPP.2D" end="62075" page_number="135" reporter="F. Supp. 2d" citation_local_level_id="190" paragraph_number="150-151" id="8201_1096" volume="731" no_current_file="True" citation_global_level_id="364771.001" >731 F. Supp. 2d 135, 150-151</CITATION>

<GPE start="62077" end="62079" id="8201_1111" >NH</GPE>

<DATE start="62080" end="62084" id="8201_1103" >2010</DATE>

<GPE start="62087" end="62100" id="8201_1112" >New Hampshire</GPE>

<LEGAL_ROLE start="62158" end="62167" id="8201_1113" >defendant</LEGAL_ROLE>

<PERSON start="62363" end="62369" id="8201_1114" >Brochu</PERSON>

<CITATION entry_type="standard_key" line="118" id1="Dummy_File_364808" start="62371" lookup_key="f.2d_642_657" standard_reporter="F.2D" end="62388" page_number="657" reporter="F. 2d" citation_local_level_id="191" citation_global_level_id="364807.001" id="8201_1097" volume="642" no_current_file="True" >642 F. 2d, at 657</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="62843" end="62856" id="8201_1126" >New Hampshire</GPE>

<PERSON start="63055" end="63062" id="8201_1127" >Vautour</PERSON>

<CITATION entry_type="standard_key" line="120" id1="Dummy_File_364809" start="63064" lookup_key="n.h._147_156" standard_reporter="N.H." end="63081" page_number="156" reporter="N. H." citation_local_level_id="192" citation_global_level_id="364808.001" id="8201_1118" volume="147" no_current_file="True" >147 N. H., at 156</CITATION>

<CITATION entry_type="standard_key" line="120" id1="Dummy_File_364810" start="63083" lookup_key="a.2d_784_1183" standard_reporter="A.2D" end="63101" page_number="1183" reporter="A. 2d" citation_local_level_id="193" citation_global_level_id="364809.001" id="8201_1119" volume="784" no_current_file="True" >784 A. 2d, at 1183</CITATION>

<NAME id="8201_1128" start="63234" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="63251" >New Hampshire law</NAME>

<ORGANIZATION start="63325" end="63352" id="8201_1129" >New Hampshire Supreme Court</ORGANIZATION>

<CITATION entry_type="party_key" line="120" id1="Dummy_File_364811" start="63456" alternative_keys="['a.2d_891_477', 'n.h._152_813']" lookup_key="kellehercedar#1" party2_short="Cedar" end="63492" standard_reporter="N.H." citation_local_level_id="194" volume="152" party1="Kelleher" party2="Marvin Lumber &amp; Cedar Co" id="8201_1122" no_current_file="True" page_number="813" citation_global_level_id="364810.004" party1_short="Kelleher" >Kelleher v. Marvin Lumber &amp; Cedar Co</CITATION>

<PERSON start="63456" party1_of="8201_1122" end="63464" id="8201_1123" >Kelleher</PERSON>

<ORGANIZATION start="63468" party2_of="8201_1122" end="63492" id="8201_1124" >Marvin Lumber &amp; Cedar Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="120" id1="Dummy_File_364811" start="63495" alternative_keys="['kellehercedar#1', 'a.2d_891_477']" lookup_key="n.h._152_813" standard_reporter="N.H." end="63513" page_number="813" reporter="N. H." citation_local_level_id="195" paragraph_number="831" id="8201_1120" volume="152" no_current_file="True" citation_global_level_id="364810.004" >152 N. H. 813, 831</CITATION>

<CITATION entry_type="standard_key" page_number="477" start="63515" alternative_keys="['kellehercedar#1', 'n.h._152_813']" line="120" standard_reporter="A.2D" end="63540" year="2006" lookup_key="a.2d_891_477" reporter="A. 2d" citation_local_level_id="196" paragraph_number="492" id="8201_1121" id1="Dummy_File_364811" volume="891" no_current_file="True" citation_global_level_id="364810.004" >891 A. 2d 477, 492 (2006)</CITATION>

<DATE start="63535" citation_local_level_id="196" citation_global_level_id="364810.004" end="63539" id="8201_1125" >2006</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="63705" end="63718" id="8201_1146" >New Hampshire</GPE>

<LEGAL_ROLE start="63879" end="63889" id="8201_1147" >respondent</LEGAL_ROLE>

<GPE start="63942" end="63955" id="8201_1148" >New Hampshire</GPE>

<LEGAL_ROLE start="64017" end="64027" id="8201_1149" >Respondent</LEGAL_ROLE>

<GPE start="64032" end="64034" id="8201_1150" >As</GPE>

<GPE start="64082" end="64095" id="8201_1151" >New Hampshire</GPE>

<CITATION entry_type="party_key" line="121" id1="Dummy_File_364812" start="64216" lookup_key="heathsears#1" party2_short="Sears" end="64230" citation_local_level_id="197" party1="Heath" party2="Sears" id="8201_1138" no_current_file="True" citation_global_level_id="364811.001" party1_short="Heath" >Heath v. Sears</CITATION>

<PERSON start="64216" party1_of="8201_1138" end="64221" id="8201_1140" >Heath</PERSON>

<PERSON start="64225" party2_of="8201_1138" end="64230" id="8201_1141" >Sears</PERSON>

<ORGANIZATION start="64232" end="64244" id="8201_1152" >Roebuck &amp; Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="121" id1="Dummy_File_364813" start="64247" lookup_key="n.h._123_512" standard_reporter="N.H." end="64269" page_number="512" reporter="N. H." citation_local_level_id="198" paragraph_number="521-522" id="8201_1135" volume="123" no_current_file="True" citation_global_level_id="364812.001" >123 N. H. 512, 521-522</CITATION>

<CITATION entry_type="standard_key" page_number="288" start="64271" line="121" standard_reporter="A.2D" end="64296" year="1983" lookup_key="a.2d_464_288" reporter="A. 2d" citation_local_level_id="199" paragraph_number="293" id="8201_1136" id1="Dummy_File_364814" volume="464" no_current_file="True" citation_global_level_id="364813.001" >464 A. 2d 288, 293 (1983)</CITATION>

<DATE start="64291" citation_local_level_id="199" citation_global_level_id="364813.001" end="64295" id="8201_1144" >1983</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329358" start="64395" alternative_keys="['u.s._486_174']" line="121" party2_short="Miller" end="64426" citation_local_level_id="200" party1="Goodyear Atomic Corp." party2="Miller" id="8201_1139" citation_global_level_id="329357.005" party1_short="Atomic" >Goodyear Atomic Corp. v. Miller</CITATION>

<ORGANIZATION start="64395" party1_of="8201_1139" end="64416" id="8201_1142" >Goodyear Atomic Corp.</ORGANIZATION>

<ORGANIZATION start="64395" end="64415" id="8201_1153" >Goodyear Atomic Corp</ORGANIZATION>

<PERSON start="64420" party2_of="8201_1139" end="64426" id="8201_1143" >Miller</PERSON>

<CITATION entry_type="standard_key" page_number="174" start="64428" line="121" standard_reporter="U.S." end="64457" year="1988" lookup_key="u.s._486_174" reporter="U. S." citation_local_level_id="201" paragraph_number="185-186" id="8201_1137" id1="Dummy_File_329358" volume="486" no_current_file="True" citation_global_level_id="329357.003" >486 U. S. 174, 185-186 (1988)</CITATION>

<DATE start="64452" citation_local_level_id="201" citation_global_level_id="329357.003" end="64456" id="8201_1145" >1988</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<PERSON start="64773" end="64778" id="8201_1162" >Bates</PERSON>

<CITATION entry_type="standard_key" line="122" id1="Dummy_File_364815" start="65137" lookup_key="u.s._544_444" standard_reporter="U.S." end="65154" page_number="444" reporter="U. S." citation_local_level_id="202" citation_global_level_id="364814.001" id="8201_1161" volume="544" no_current_file="True" >544 U. S., at 444</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<PERSON start="65891" end="65898" id="8201_1164" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="123" id1="Dummy_File_361047" start="66171" lookup_key="u.s._564____" standard_reporter="U.S." end="66188" page_number="___" reporter="U. S." citation_local_level_id="203" citation_global_level_id="361046.001" id="8201_1163" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<GPE start="66219" end="66232" id="8201_1165" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<PERSON start="66584" end="66592" id="8201_1176" >Bartlett</PERSON>

<PERSON start="66691" end="66694" id="8201_1177" >App</PERSON>

<CITATION entry_type="standard_key" line="126" id1="Dummy_File_364816" start="66709" lookup_key="f.supp.2d_659_279" standard_reporter="F.SUPP.2D" end="66733" page_number="279" reporter="F. Supp. 2d" citation_local_level_id="204" paragraph_number="282" id="8201_1166" volume="659" no_current_file="True" citation_global_level_id="364815.001" >659 F. Supp. 2d 279, 282</CITATION>

<GPE start="66735" end="66737" id="8201_1178" >NH</GPE>

<DATE start="66738" end="66742" id="8201_1173" >2009</DATE>

<NAME id="8201_1179" start="66786" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="66803" >New Hampshire law</NAME>

<CITATION entry_type="party_key" line="126" id1="Dummy_File_364817" start="66880" alternative_keys="['a.2d_688_556', 'n.h._141_579']" lookup_key="leblancmotor#1" party2_short="Motor" end="66914" standard_reporter="N.H." citation_local_level_id="205" volume="141" party1="LeBlanc" party2="American Honda Motor Co" id="8201_1170" no_current_file="True" page_number="579" citation_global_level_id="364816.004" party1_short="LeBlanc" >LeBlanc v. American Honda Motor Co</CITATION>

<PERSON start="66880" party1_of="8201_1170" end="66887" id="8201_1171" >LeBlanc</PERSON>

<ORGANIZATION start="66891" party2_of="8201_1170" end="66914" id="8201_1172" >American Honda Motor Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="126" id1="Dummy_File_364817" start="66917" alternative_keys="['leblancmotor#1', 'a.2d_688_556']" lookup_key="n.h._141_579" standard_reporter="N.H." end="66935" page_number="579" reporter="N. H." citation_local_level_id="206" paragraph_number="586" id="8201_1167" volume="141" no_current_file="True" citation_global_level_id="364816.004" >141 N. H. 579, 586</CITATION>

<CITATION entry_type="standard_key" page_number="556" start="66937" alternative_keys="['leblancmotor#1', 'n.h._141_579']" line="126" standard_reporter="A.2D" end="66962" year="1997" lookup_key="a.2d_688_556" reporter="A. 2d" citation_local_level_id="207" paragraph_number="562" id="8201_1168" id1="Dummy_File_364817" volume="688" no_current_file="True" citation_global_level_id="364816.004" >688 A. 2d 556, 562 (1997)</CITATION>

<DATE start="66957" citation_local_level_id="207" citation_global_level_id="364816.004" end="66961" id="8201_1174" >1997</DATE>

<ORGANIZATION start="66974" end="66988" id="8201_1180" >District Court</ORGANIZATION>

<CITATION lookup_key="bartlett'srecovery#2" citation_local_level_id="208" entry_type="case_key" name="Bartlett's recovery" id="8201_1175" start="67171" id1="Dummy_File_364818" no_current_file="True" line="126" citation_global_level_id="364817.001" end="67190" >Bartlett's recovery</CITATION>

<CITATION entry_type="standard_key" line="126" id1="Dummy_File_364819" start="67196" lookup_key="f.supp.2d_760_248" standard_reporter="F.SUPP.2D" end="67219" page_number="248" reporter="F. Supp. 2d" citation_local_level_id="209" citation_global_level_id="364818.001" id="8201_1169" volume="760" no_current_file="True" >760 F. Supp. 2d, at 248</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<ORGANIZATION start="67255" end="67269" id="8201_1188" >District Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="127" id1="Dummy_File_364820" start="67559" lookup_key="f.3d_678_41" standard_reporter="F.3D" end="67575" page_number="41" reporter="F. 3d" citation_local_level_id="210" citation_global_level_id="364819.001" id="8201_1186" volume="678" no_current_file="True" >678 F. 3d, at 41</CITATION>

<ORGANIZATION start="67581" end="67595" id="8201_1189" >District Court</ORGANIZATION>

<PERSON start="67787" end="67790" id="8201_1190" >App</PERSON>

<ORGANIZATION start="68267" end="68281" id="8201_1191" >District Court</ORGANIZATION>

<PERSON start="68322" end="68330" id="8201_1192" >Bartlett</PERSON>

<CITATION entry_type="standard_key" line="127" id1="Dummy_File_364819" start="68499" lookup_key="f.supp.2d_760_248" standard_reporter="F.SUPP.2D" end="68522" page_number="248" reporter="F. Supp. 2d" citation_local_level_id="211" citation_global_level_id="364818.001" id="8201_1187" volume="760" no_current_file="True" >760 F. Supp. 2d, at 248</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<ORGANIZATION start="68554" end="68568" id="8201_1196" >District Court</ORGANIZATION>

<NAME id="8201_1197" start="68666" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="68683" >New Hampshire law</NAME>

<PERSON start="68910" end="68917" id="8201_1198" >LeBlanc</PERSON>

<CITATION entry_type="standard_key" line="128" id1="Dummy_File_364821" start="68919" lookup_key="n.h._141_586" standard_reporter="N.H." end="68936" page_number="586" reporter="N. H." citation_local_level_id="212" citation_global_level_id="364820.001" id="8201_1193" volume="141" no_current_file="True" >141 N. H., at 586</CITATION>

<CITATION entry_type="standard_key" line="128" id1="Dummy_File_364822" start="68938" lookup_key="a.2d_688_562" standard_reporter="A.2D" end="68955" page_number="562" reporter="A. 2d" citation_local_level_id="213" citation_global_level_id="364821.001" id="8201_1194" volume="688" no_current_file="True" >688 A. 2d, at 562</CITATION>

<ORGANIZATION start="68975" end="68989" id="8201_1199" >District Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="128" id1="Dummy_File_364823" start="69066" lookup_key="f.supp._760_248" standard_reporter="F.SUPP." end="69086" page_number="248" reporter="F. Supp." citation_local_level_id="214" citation_global_level_id="364822.001" id="8201_1195" volume="760" no_current_file="True" >760 F. Supp., at 248</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="69122" end="69135" id="8201_1200" >New Hampshire</GPE>

<PROFESSION start="69257" end="69262" id="8201_1201" >judge</PROFESSION>

<NAME id="8201_1202" start="69589" all_names="FDCA" local_name_id="89" end="69593" >FDCA</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<NAME id="8201_1205" start="70054" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="70071" >New Hampshire law</NAME>

<PERSON start="70703" end="70711" id="8201_1206" >Thibault</PERSON>

<CITATION entry_type="standard_key" line="131" id1="Dummy_File_364824" start="70713" lookup_key="n.h._118_808" standard_reporter="N.H." end="70730" page_number="808" reporter="N. H." citation_local_level_id="215" citation_global_level_id="364823.001" id="8201_1203" volume="118" no_current_file="True" >118 N. H., at 808</CITATION>

<CITATION entry_type="standard_key" line="131" id1="Dummy_File_364787" start="70732" lookup_key="a.2d_395_847" standard_reporter="A.2D" end="70749" page_number="847" reporter="A. 2d" citation_local_level_id="216" citation_global_level_id="364786.001" id="8201_1204" volume="395" no_current_file="True" >395 A. 2d, at 847</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<NAME id="8201_1209" start="71211" all_names="STATE" local_name_id="43" end="71216" >State</NAME>

<NAME id="8201_1210" start="71358" all_names="STATE" local_name_id="43" end="71363" >State</NAME>

<PERSON start="71590" end="71596" id="8201_1211" >Crosby</PERSON>

<CITATION entry_type="standard_key" line="132" id1="Dummy_File_338475" start="71598" lookup_key="u.s._530_373" standard_reporter="U.S." end="71615" page_number="373" reporter="U. S." citation_local_level_id="217" citation_global_level_id="338474.001" id="8201_1207" volume="530" no_current_file="True" >530 U. S., at 373</CITATION>

<PERSON start="72089" end="72095" id="8201_1212" >Levine</PERSON>

<CITATION entry_type="standard_key" line="132" id1="Dummy_File_364324" start="72097" lookup_key="u.s._555_583" standard_reporter="U.S." end="72114" page_number="583" reporter="U. S." citation_local_level_id="218" citation_global_level_id="364323.001" id="8201_1208" volume="555" no_current_file="True" >555 U. S., at 583</CITATION>

<PERSON start="72116" end="72122" id="8201_1213" >Thomas</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<NAME id="8201_1214" start="72480" all_names="FEDERALLAW" local_name_id="55" end="72491" >Federal law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="73310" end="73323" id="8201_1215" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<GPE start="73762" end="73775" id="8201_1218" >New Hampshire</GPE>

<PERSON start="74041" end="74048" id="8201_1219" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="136" id1="Dummy_File_361047" start="74050" lookup_key="u.s._564____" standard_reporter="U.S." end="74067" page_number="___" reporter="U. S." citation_local_level_id="219" citation_global_level_id="361046.001" id="8201_1217" volume="564" no_current_file="True" >564 U. S., at ___</CITATION>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<ORGANIZATION start="74161" end="74166" id="8201_1220" >Court</ORGANIZATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<GPE start="74445" end="74458" id="8201_1222" >New Hampshire</GPE>

<GPE start="74904" end="74917" id="8201_1223" >New Hampshire</GPE>

<PERSON start="75206" end="75214" id="8201_1224" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="75565" end="75571" id="8201_1226" >Levine</PERSON>

<CITATION entry_type="standard_key" line="138" id1="Dummy_File_364825" start="75573" lookup_key="u.s._555_601" standard_reporter="U.S." end="75590" page_number="601" reporter="U. S." citation_local_level_id="220" citation_global_level_id="364824.001" id="8201_1225" volume="555" no_current_file="True" >555 U. S., at 601</CITATION>

<PERSON start="75596" end="75602" id="8201_1227" >Thomas</PERSON>

<ORGANIZATION start="75718" end="75723" id="8201_1228" >Court</ORGANIZATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<ORGANIZATION start="75870" end="75875" id="8201_1234" >Court</ORGANIZATION>

<PERSON start="75911" end="75919" id="8201_1235" >Congress</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_358913" start="76172" alternative_keys="['u.s._562____']" line="139" party2_short="Motor" end="76213" citation_local_level_id="221" party1="Williamson" party2="Mazda Motor of America, Inc" id="8201_1230" citation_global_level_id="358912.076" party1_short="Williamson" >Williamson v. Mazda Motor of America, Inc</CITATION>

<PERSON start="76172" party1_of="8201_1230" end="76182" id="8201_1231" >Williamson</PERSON>

<ORGANIZATION start="76186" party2_of="8201_1230" end="76213" id="8201_1232" >Mazda Motor of America, Inc</ORGANIZATION>

<ORGANIZATION start="76201" end="76213" id="8201_1236" >America, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="139" id1="Dummy_File_358913" start="76216" lookup_key="u.s._562____" standard_reporter="U.S." end="76229" page_number="___" reporter="U. S." citation_local_level_id="222" citation_global_level_id="358912.001" id="8201_1229" volume="562" no_current_file="True" >562 U. S. ___</CITATION>

<DATE start="76236" end="76240" id="8201_1233" >2011</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="77208" end="77216" id="8201_1240" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="77328" end="77336" id="8201_1241" >Bartlett</PERSON>

<NAME id="8201_1242" start="77473" all_names="HATCH-WAXMANACT98STAT" local_name_id="90" end="77498" >Hatch-Waxman Act, 98 Stat</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<NAME id="8201_1243" start="77713" all_names="NEWHAMP-SHIRE" local_name_id="85" end="77727" >New Hamp-shire</NAME>

<NAME id="8201_1244" start="77995" all_names="STATES" local_name_id="14" end="78001" >States</NAME>

<NAME id="8201_1245" start="78358" all_names="STATE" local_name_id="43" end="78363" >State</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="78995" end="79001" id="8201_1282" >Levine</PERSON>

<CITATION entry_type="standard_key" line="146" id1="Dummy_File_364826" start="79003" lookup_key="u.s._555_576" standard_reporter="U.S." end="79020" page_number="576" reporter="U. S." citation_local_level_id="223" citation_global_level_id="364825.001" id="8201_1269" volume="555" no_current_file="True" >555 U. S., at 576</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_331179" start="79030" alternative_keys="['u.s._529_861']" line="146" party2_short="Motor" end="79062" citation_local_level_id="224" party1="Geier" party2="American Honda Motor Co" id="8201_1274" citation_global_level_id="331178.032" party1_short="Geier" >Geier v. American Honda Motor Co</CITATION>

<PERSON start="79030" party1_of="8201_1274" end="79035" id="8201_1276" >Geier</PERSON>

<ORGANIZATION start="79039" party2_of="8201_1274" end="79062" id="8201_1277" >American Honda Motor Co</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="861" start="79065" alternative_keys="['geiermotor#1']" line="146" standard_reporter="U.S." end="79090" year="2000" lookup_key="u.s._529_861" reporter="U. S." citation_local_level_id="225" paragraph_number="883" id="8201_1270" id1="Dummy_File_331179" volume="529" no_current_file="True" citation_global_level_id="331178.003" >529 U. S. 861, 883 (2000)</CITATION>

<DATE start="79085" citation_local_level_id="225" citation_global_level_id="331178.003" end="79089" id="8201_1280" >2000</DATE>

<CITATION entry_type="standard_key" line="146" id1="Dummy_File_364826" start="79177" lookup_key="u.s._555_576" standard_reporter="U.S." end="79194" page_number="576" reporter="U. S." citation_local_level_id="226" citation_global_level_id="364825.001" id="8201_1271" volume="555" no_current_file="True" >555 U. S., at 576</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_360167" start="79467" alternative_keys="['u.s._563____']" line="146" party2_short="Whiting" end="79532" citation_local_level_id="227" party1="Act,&quot; Chamber of Commerce of United States of America," party2="Whiting" id="8201_1275" citation_global_level_id="360166.06" party1_short="Chamber" >Act,&quot; Chamber of Commerce of United States of America, v. Whiting</CITATION>

<GPE start="79467" party1_of="8201_1275" end="79521" id="8201_1278" >Act,&quot; Chamber of Commerce of United States of America,</GPE>

<PERSON start="79525" party2_of="8201_1275" end="79532" id="8201_1279" >Whiting</PERSON>

<CITATION entry_type="standard_key" line="146" id1="Dummy_File_360167" start="79534" lookup_key="u.s._563____" standard_reporter="U.S." end="79547" page_number="___" reporter="U. S." citation_local_level_id="228" citation_global_level_id="360166.003" id="8201_1272" volume="563" no_current_file="True" >563 U. S. ___</CITATION>

<DATE start="79554" end="79558" id="8201_1281" >2011</DATE>

<PERSON start="79618" end="79626" id="8201_1283" >Silkwood</PERSON>

<CITATION entry_type="standard_key" line="146" id1="Dummy_File_237833" start="79628" lookup_key="u.s._464_256" standard_reporter="U.S." end="79645" page_number="256" reporter="U. S." citation_local_level_id="229" citation_global_level_id="237832.003" id="8201_1273" volume="464" no_current_file="True" >464 U. S., at 256</CITATION>

<PERSON start="79721" end="79727" id="8201_1284" >Levine</PERSON>

<ORGANIZATION start="80184" end="80189" id="8201_1285" >Court</ORGANIZATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="81176" end="81184" id="8201_1302" >Congress</PERSON>

<DATE start="81241" end="81245" id="8201_1299" >1938</DATE>

<DATE start="81274" end="81278" id="8201_1300" >1962</DATE>

<NAME id="8201_1303" start="81368" all_names="SAFETY152YET" local_name_id="91" end="81383" >Safety 152. Yet</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_344952" start="81490" alternative_keys="['u.s._332_689']" line="147" party2_short="Sullivan" end="81515" citation_local_level_id="230" party1="United States" party2="Sullivan" id="8201_1296" citation_global_level_id="344951.005" party1_short="States" >United States v. Sullivan</CITATION>

<GPE start="81490" party1_of="8201_1296" end="81503" id="8201_1297" >United States</GPE>

<PERSON start="81507" party2_of="8201_1296" end="81515" id="8201_1298" >Sullivan</PERSON>

<CITATION entry_type="standard_key" page_number="689" start="81517" line="147" standard_reporter="U.S." end="81542" year="1948" lookup_key="u.s._332_689" reporter="U. S." citation_local_level_id="231" paragraph_number="696" id="8201_1293" id1="Dummy_File_344952" volume="332" no_current_file="True" citation_global_level_id="344951.003" >332 U. S. 689, 696 (1948)</CITATION>

<DATE start="81537" citation_local_level_id="231" citation_global_level_id="344951.003" end="81541" id="8201_1301" >1948</DATE>

<PERSON start="81733" end="81741" id="8201_1304" >Congress</PERSON>

<PERSON start="81949" end="81957" id="8201_1305" >Congress</PERSON>

<PERSON start="81996" end="82002" id="8201_1306" >Riegel</PERSON>

<CITATION entry_type="standard_key" line="147" id1="Dummy_File_364827" start="82004" lookup_key="u.s._552_338" standard_reporter="U.S." end="82021" page_number="338" reporter="U. S." citation_local_level_id="232" citation_global_level_id="364826.001" id="8201_1294" volume="552" no_current_file="True" >552 U. S., at 338</CITATION>

<PERSON start="82023" end="82031" id="8201_1307" >Ginsburg</PERSON>

<PERSON start="82058" end="82062" id="8201_1308" >Lohr</PERSON>

<CITATION entry_type="standard_key" line="147" id1="Dummy_File_350398" start="82064" lookup_key="u.s._518_487" standard_reporter="U.S." end="82081" page_number="487" reporter="U. S." citation_local_level_id="233" citation_global_level_id="350397.001" id="8201_1295" volume="518" no_current_file="True" >518 U. S., at 487</CITATION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="82357" end="82365" id="8201_1317" >Congress</PERSON>

<PERSON start="82576" end="82582" id="8201_1318" >Riegel</PERSON>

<CITATION entry_type="standard_key" line="148" id1="Dummy_File_364828" start="82584" lookup_key="u.s._552_323" standard_reporter="U.S." end="82601" page_number="323" reporter="U. S." citation_local_level_id="234" citation_global_level_id="364827.001" id="8201_1313" volume="552" no_current_file="True" >552 U. S., at 323</CITATION>

<PERSON start="82811" end="82819" id="8201_1319" >Congress</PERSON>

<PERSON start="83151" end="83157" id="8201_1320" >Levine</PERSON>

<CITATION entry_type="standard_key" line="148" id1="Dummy_File_364800" start="83159" lookup_key="u.s._555_578" standard_reporter="U.S." end="83176" page_number="578" reporter="U. S." citation_local_level_id="235" citation_global_level_id="364799.001" id="8201_1314" volume="555" no_current_file="True" >555 U. S., at 578</CITATION>

<PERSON start="83182" end="83187" id="8201_1321" >Bates</PERSON>

<CITATION entry_type="standard_key" line="148" id1="Dummy_File_359123" start="83189" lookup_key="u.s._544_451" standard_reporter="U.S." end="83206" page_number="451" reporter="U. S." citation_local_level_id="236" citation_global_level_id="359122.001" id="8201_1315" volume="544" no_current_file="True" >544 U. S., at 451</CITATION>

<NAME id="8201_1322" start="83285" all_names="PRODUCTSLIABILITY" local_name_id="86" end="83303" >Products Liability</NAME>

<PERSON start="83309" end="83318" id="8201_1323" >Yale L. J</PERSON>

<DATE start="83332" end="83336" id="8201_1316" >2000</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<PERSON start="83771" end="83779" id="8201_1332" >Congress</PERSON>

<PERSON start="83974" end="83982" id="8201_1333" >Congress</PERSON>

<NAME id="8201_1334" start="84072" all_names="STATES" local_name_id="14" end="84078" >States</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_358913" start="84081" alternative_keys="['u.s._562____']" line="149" party2_short="LLC" end="84104" citation_local_level_id="237" party1="Bruesewitz" party2="Wyeth LLC" id="8201_1327" citation_global_level_id="358912.077" party1_short="Bruesewitz" >Bruesewitz v. Wyeth LLC</CITATION>

<NAME id="8201_1328" start="84081" all_names="BRUESEWITZ" local_name_id="92" end="84091" party1_of="8201_1327" >Bruesewitz</NAME>

<NAME all_names="WYETHLLC" id="8201_1329" start="84095" party2_of="8201_1327" local_name_id="93" end="84104" >Wyeth LLC</NAME>

<CITATION entry_type="standard_key" line="149" id1="Dummy_File_358913" start="84106" lookup_key="u.s._562____" standard_reporter="U.S." end="84119" page_number="___" reporter="U. S." citation_local_level_id="238" citation_global_level_id="358912.001" id="8201_1325" volume="562" no_current_file="True" >562 U. S. ___</CITATION>

<DATE start="84126" end="84130" id="8201_1330" >2011</DATE>

<DATE start="84153" end="84157" id="8201_1331" >1986</DATE>

<PERSON start="84244" end="84252" id="8201_1335" >Congress</PERSON>

<NAME id="8201_1336" start="84265" all_names="NATIONALCHILDHOODVACCINEINJURYACT" local_name_id="94" end="84302" >National Childhood Vaccine Injury Act</NAME>

<NAME id="8201_1337" start="84304" all_names="VACCINEACT" local_name_id="95" end="84315" >Vaccine Act</NAME>

<ORGANIZATION start="84549" end="84554" id="8201_1338" >Court</ORGANIZATION>

<NAME id="8201_1339" start="84565" all_names="BRUESEWITZ" local_name_id="92" end="84575" >Bruesewitz</NAME>

<CITATION entry_type="standard_key" line="149" id1="Dummy_File_358913" start="84666" lookup_key="u.s._562____" standard_reporter="U.S." end="84683" page_number="___" reporter="U. S." citation_local_level_id="239" citation_global_level_id="358912.001" id="8201_1326" volume="562" no_current_file="True" >562 U. S., at ___</CITATION>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<PERSON start="84709" end="84716" id="8201_1345" >Members</PERSON>

<ORGANIZATION start="84725" end="84730" id="8201_1346" >Court</ORGANIZATION>

<NAME id="8201_1347" start="84782" all_names="VACCINEACT" local_name_id="95" end="84793" >Vaccine Act</NAME>

<PERSON start="84853" end="84861" id="8201_1348" >Congress</PERSON>

<PERSON start="85155" end="85163" id="8201_1349" >Congress</PERSON>

<PERSON start="85249" end="85257" id="8201_1350" >Congress</PERSON>

<PERSON start="85355" end="85362" id="8201_1351" >Metzger</PERSON>

<ORGANIZATION start="85379" end="85412" id="8201_1352" >Fed-eral Agency Reform, 111 Colum</ORGANIZATION>

<DATE start="85429" end="85433" id="8201_1344" >2011</DATE>

<PERSON start="85499" end="85507" id="8201_1353" >Congress</PERSON>

<PERSON start="85562" plural="True" end="85576" id="8201_1354" >Karen Bartlett</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<ORGANIZATION start="85626" end="85631" id="8201_1355" >Court</ORGANIZATION>

<PERSON start="85735" end="85742" id="8201_1356" >Members</PERSON>

<PERSON start="85788" plural="True" end="85802" id="8201_1357" >Karen Bartlett</PERSON>

<ORGANIZATION start="85812" end="85817" id="8201_1358" >Court</ORGANIZATION>

<PERSON start="85930" end="85938" id="8201_1359" >Congress</PERSON>

<ORGANIZATION start="86065" end="86070" id="8201_1360" >Court</ORGANIZATION>

<PERSON start="86077" end="86085" id="8201_1361" >Congress</PERSON>

<ORGANIZATION start="86192" end="86197" id="8201_1362" >Court</ORGANIZATION>

<PERSON start="86263" end="86271" id="8201_1363" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<NAME id="8201_1376" start="86365" all_names="FOOTNOTE1WE" local_name_id="96" end="86378" >Footnote 1 We</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364829" start="86684" line="155" party2_short="Medtronic" end="86703" citation_local_level_id="240" party1="Riegel" citation_global_level_id="364828.001" id="8201_1367" no_current_file="True" party2="Medtronic" party1_short="Riegel" >Riegel v. Medtronic</CITATION>

<PERSON start="86684" party1_of="8201_1367" end="86690" id="8201_1369" >Riegel</PERSON>

<ORGANIZATION start="86694" party2_of="8201_1367" end="86703" id="8201_1370" >Medtronic</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="312" start="86711" line="155" standard_reporter="U.S." end="86740" year="2008" lookup_key="u.s._552_312" reporter="U. S." citation_local_level_id="241" paragraph_number="323-324" id="8201_1364" id1="Dummy_File_361598" volume="552" no_current_file="True" citation_global_level_id="361597.001" >552 U. S. 312, 323-324 (2008)</CITATION>

<DATE start="86735" citation_local_level_id="241" citation_global_level_id="361597.001" end="86739" id="8201_1373" >2008</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_323726" start="86746" alternative_keys="['u.s._518_470']" line="155" party2_short="Lohr" end="86770" citation_local_level_id="242" party1="[Medtronic, Inc." party2="Lohr" id="8201_1368" citation_global_level_id="323725.042" party1_short="Medtronic" >[Medtronic, Inc. v. Lohr</CITATION>

<ORGANIZATION start="86746" party1_of="8201_1368" end="86762" id="8201_1371" >[Medtronic, Inc.</ORGANIZATION>

<PERSON start="86766" party2_of="8201_1368" end="86770" id="8201_1372" >Lohr</PERSON>

<CITATION entry_type="standard_key" line="155" page_number="470" start="86772" lookup_key="u.s._518_470" standard_reporter="U.S." end="86792" year="1996" reporter="U. S." citation_local_level_id="243" citation_global_level_id="323725.001" id="8201_1365" id1="Dummy_File_323726" volume="518" no_current_file="True" >518 U. S. 470 (1996)</CITATION>

<DATE start="86787" citation_local_level_id="243" citation_global_level_id="323725.001" end="86791" id="8201_1374" >1996</DATE>

<PROFESSION start="86800" plural="True" end="86808" id="8201_1377" >Justices</PROFESSION>

<NAME id="8201_1378" start="87077" all_names="STATE" local_name_id="43" end="87082" >State</NAME>

<PERSON start="87165" end="87174" id="8201_1379" >Cipollone</PERSON>

<ORGANIZATION start="87179" end="87192" id="8201_1380" >Liggett Group</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="504" start="87194" line="155" standard_reporter="U.S." end="87219" year="1992" lookup_key="u.s._505_504" reporter="U. S." citation_local_level_id="244" paragraph_number="522" id="8201_1366" id1="Dummy_File_324113" volume="505" no_current_file="True" citation_global_level_id="324112.001" >505 U. S. 504, 522 (1992)</CITATION>

<DATE start="87214" citation_local_level_id="244" citation_global_level_id="324112.001" end="87218" id="8201_1375" >1992</DATE>

<LEGAL_ROLE start="87342" end="87351" id="8201_1381" >defendant</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<NAME id="8201_1402" start="87391" all_names="FOOTNOTE2THATMUTUAL" local_name_id="97" end="87413" >Footnote 2 That Mutual</NAME>

<GPE start="87496" end="87509" id="8201_1403" >New Hampshire</GPE>

<NAME id="8201_1404" start="87537" all_names="STATES" local_name_id="14" end="87543" >States</NAME>

<CITATION entry_type="party_key" line="156" id1="Dummy_File_364830" start="87796" alternative_keys="['a.2d_352_723', 'n.h._116_52']" lookup_key="bellottezayre#1" party2_short="Zayre" end="87818" standard_reporter="N.H." citation_local_level_id="245" volume="116" party1="Bellotte" party2="Zayre Corp" id="8201_1393" no_current_file="True" page_number="52" citation_global_level_id="364829.004" party1_short="Bellotte" >Bellotte v. Zayre Corp</CITATION>

<NAME id="8201_1395" start="87796" all_names="BELLOTTE" local_name_id="98" end="87804" party1_of="8201_1393" >Bellotte</NAME>

<ORGANIZATION start="87808" party2_of="8201_1393" end="87818" id="8201_1396" >Zayre Corp</ORGANIZATION>

<CITATION entry_type="standard_key" line="156" id1="Dummy_File_364830" start="87821" alternative_keys="['bellottezayre#1', 'a.2d_352_723']" lookup_key="n.h._116_52" standard_reporter="N.H." end="87840" page_number="52" reporter="N. H." citation_local_level_id="246" paragraph_number="54-55" id="8201_1390" volume="116" no_current_file="True" citation_global_level_id="364829.004" >116 N. H. 52, 54-55</CITATION>

<CITATION entry_type="standard_key" page_number="723" start="87842" alternative_keys="['bellottezayre#1', 'n.h._116_52']" line="156" standard_reporter="A.2D" end="87867" year="1976" lookup_key="a.2d_352_723" reporter="A. 2d" citation_local_level_id="247" paragraph_number="725" id="8201_1391" id1="Dummy_File_364830" volume="352" no_current_file="True" citation_global_level_id="364829.004" >352 A. 2d 723, 725 (1976)</CITATION>

<DATE start="87862" citation_local_level_id="247" citation_global_level_id="364829.004" end="87866" id="8201_1399" >1976</DATE>

<ORGANIZATION start="88060" end="88065" id="8201_1405" >Court</ORGANIZATION>

<DATE start="88099" end="88103" id="8201_1400" >1986</DATE>

<CITATION entry_type="party_key" line="156" id1="Dummy_File_358913" start="88311" alternative_keys="['u.s._562____']" lookup_key="bruesewitzwyeth#1" party2_short="Wyeth" end="88330" citation_local_level_id="248" party1="Bruesewitz" party2="Wyeth" id="8201_1394" citation_global_level_id="358912.078" party1_short="Bruesewitz" >Bruesewitz v. Wyeth</CITATION>

<NAME id="8201_1397" start="88311" all_names="BRUESEWITZ" local_name_id="92" end="88321" party1_of="8201_1394" >Bruesewitz</NAME>

<ORGANIZATION start="88325" party2_of="8201_1394" end="88330" id="8201_1398" >Wyeth</ORGANIZATION>

<CITATION entry_type="standard_key" line="156" id1="Dummy_File_358913" start="88332" alternative_keys="['bruesewitzwyeth#1']" lookup_key="u.s._562____" standard_reporter="U.S." end="88345" page_number="___" reporter="U. S." citation_local_level_id="249" citation_global_level_id="358912.001" id="8201_1392" volume="562" no_current_file="True" >562 U. S. ___</CITATION>

<DATE start="88359" end="88363" id="8201_1401" >2011</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<LEGAL_ROLE start="88474" end="88483" id="8201_1415" >Defendant</LEGAL_ROLE>

<PERSON start="88486" end="88492" id="8201_1416" >Notice</PERSON>

<DOCKET start="88532" entry_type="docket" line="157" end="88544" id="8201_1414" >08-cv-358-JL</DOCKET>

<GPE start="88548" end="88550" id="8201_1417" >NH</GPE>

<LEGAL_ROLE start="88589" end="88599" id="8201_1418" >respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<PROFESSION start="88714" end="88739" id="8201_1430" >Footnote 3 Justice Breyer</PROFESSION>

<NAME id="8201_1431" start="88918" all_names="STATE" local_name_id="43" end="88923" >State</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_329388" start="89361" alternative_keys="['u.s._373_132']" line="158" party2_short="Paul" end="89405" citation_local_level_id="250" party1="Florida Lime &amp; Avocado Growers, Inc." party2="Paul" id="8201_1422" citation_global_level_id="329387.013" party1_short="Growers" >Florida Lime &amp; Avocado Growers, Inc. v. Paul</CITATION>

<ORGANIZATION start="89361" party1_of="8201_1422" end="89397" id="8201_1424" >Florida Lime &amp; Avocado Growers, Inc.</ORGANIZATION>

<ORGANIZATION start="89361" end="89396" id="8201_1432" >Florida Lime &amp; Avocado Growers, Inc</ORGANIZATION>

<PERSON start="89401" party2_of="8201_1422" end="89405" id="8201_1425" >Paul</PERSON>

<CITATION entry_type="standard_key" line="158" id1="Dummy_File_329388" start="89407" lookup_key="u.s._373_132" standard_reporter="U.S." end="89425" page_number="132" reporter="U. S." citation_local_level_id="251" paragraph_number="143" id="8201_1420" volume="373" no_current_file="True" citation_global_level_id="329387.003" >373 U. S. 132, 143</CITATION>

<DATE start="89427" citation_local_level_id="251" citation_global_level_id="329387.003" end="89431" id="8201_1428" >1963</DATE>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<GPE start="89591" end="89601" id="8201_1433" >California</GPE>

<NAME id="8201_1434" start="89625" all_names="STATE" local_name_id="43" end="89630" >State</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_361047" start="89697" alternative_keys="['u.s._564____']" line="158" party2_short="Mensing" end="89719" citation_local_level_id="252" party1="PLIVA, Inc." party2="Mensing" id="8201_1423" citation_global_level_id="361046.042" party1_short="PLIVA" >PLIVA, Inc. v. Mensing</CITATION>

<ORGANIZATION start="89697" party1_of="8201_1423" end="89708" id="8201_1426" >PLIVA, Inc.</ORGANIZATION>

<ORGANIZATION start="89697" end="89707" id="8201_1435" >PLIVA, Inc</ORGANIZATION>

<PERSON start="89712" party2_of="8201_1423" end="89719" id="8201_1427" >Mensing</PERSON>

<CITATION entry_type="standard_key" line="158" page_number="___" start="89721" lookup_key="u.s._564____" standard_reporter="U.S." end="89741" year="2011" reporter="U. S." citation_local_level_id="253" citation_global_level_id="361046.001" id="8201_1421" id1="Dummy_File_361047" volume="564" no_current_file="True" >564 U. S. ___ (2011)</CITATION>

<DATE start="89736" citation_local_level_id="253" citation_global_level_id="361046.001" end="89740" id="8201_1429" >2011</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<NAME id="8201_1453" start="90271" all_names="FOOTNOTE4WE" local_name_id="99" end="90284" >Footnote 4 We</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345369" start="90668" alternative_keys="['u.s._544_431']" line="159" party2_short="LLC" end="90697" citation_local_level_id="254" party1="Bates" party2="Dow Agrosciences LLC" id="8201_1448" citation_global_level_id="345368.023" party1_short="Bates" >Bates v. Dow Agrosciences LLC</CITATION>

<PERSON start="90668" party1_of="8201_1448" end="90673" id="8201_1449" >Bates</PERSON>

<NAME all_names="DOWAGROSCIENCESLLC" id="8201_1450" start="90677" party2_of="8201_1448" local_name_id="61" end="90697" >Dow Agrosciences LLC</NAME>

<CITATION entry_type="standard_key" line="159" id1="Dummy_File_345369" start="90699" lookup_key="u.s._544_431" standard_reporter="U.S." end="90717" page_number="431" reporter="U. S." citation_local_level_id="255" paragraph_number="447" id="8201_1446" volume="544" no_current_file="True" citation_global_level_id="345368.003" >544 U. S. 431, 447</CITATION>

<DATE start="90719" citation_local_level_id="255" citation_global_level_id="345368.003" end="90723" id="8201_1451" >2005</DATE>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<PROFESSION start="90934" end="90944" id="8201_1454" >Government</PROFESSION>

<CITATION entry_type="standard_key" line="159" id1="Dummy_File_364790" start="91381" lookup_key="f.supp.2d_760_220" standard_reporter="F.SUPP.2D" end="91405" page_number="220" reporter="F. Supp. 2d" citation_local_level_id="256" paragraph_number="233" id="8201_1447" volume="760" no_current_file="True" citation_global_level_id="364789.001" >760 F. Supp. 2d 220, 233</CITATION>

<GPE start="91407" end="91409" id="8201_1455" >NH</GPE>

<DATE start="91410" end="91414" id="8201_1452" >2011</DATE>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<LEGAL_ROLE start="91425" end="91435" id="8201_1456" >respondent</LEGAL_ROLE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<LEGAL_ROLE start="91534" end="91555" id="8201_1461" >Footnote 5 Respondent</LEGAL_ROLE>

<LEGAL_ROLE start="91886" end="91896" id="8201_1462" >Respondent</LEGAL_ROLE>

<NAME id="8201_1463" start="91901" all_names="BUT" local_name_id="100" end="91904" >But</NAME>

<NAME id="8201_1464" start="92115" all_names="STATE" local_name_id="43" end="92120" >State</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1470" start="92403" all_names="FOOTNOTE1THE" local_name_id="101" end="92417" >Footnote 1 The</NAME>

<PERSON start="92545" end="92553" id="8201_1471" >Congress</PERSON>

<PERSON start="92727" end="92735" id="8201_1472" >Congress</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_323729" start="92917" alternative_keys="['u.s._331_218']" line="162" party2_short="Elevator" end="92947" citation_local_level_id="257" party1="Rice" party2="Santa Fe Elevator Corp" id="8201_1466" citation_global_level_id="323728.022" party1_short="Rice" >Rice v. Santa Fe Elevator Corp</CITATION>

<PERSON start="92917" party1_of="8201_1466" end="92921" id="8201_1467" >Rice</PERSON>

<ORGANIZATION start="92925" party2_of="8201_1466" end="92947" id="8201_1468" >Santa Fe Elevator Corp</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="218" start="92950" line="162" standard_reporter="U.S." end="92975" year="1947" lookup_key="u.s._331_218" reporter="U. S." citation_local_level_id="258" paragraph_number="230" id="8201_1465" id1="Dummy_File_323729" volume="331" no_current_file="True" citation_global_level_id="323728.001" >331 U. S. 218, 230 (1947)</CITATION>

<DATE start="92970" citation_local_level_id="258" citation_global_level_id="323728.001" end="92974" id="8201_1469" >1947</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1477" start="92977" all_names="FOOTNOTE2SEE21USC" local_name_id="102" end="93002" >Footnote 2 See 21 U. S. C</NAME>

<PERSON start="93203" end="93211" id="8201_1478" >Congress</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1486" start="93456" all_names="FOOTNOTE3THOUGH" local_name_id="103" end="93473" >Footnote 3 Though</NAME>

<GPE start="93564" end="93577" id="8201_1487" >New Hampshire</GPE>

<NAME id="8201_1488" start="93605" all_names="STATES" local_name_id="14" end="93611" >States</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_358913" start="93858" alternative_keys="['u.s._562____']" line="164" party2_short="LLC" end="93881" citation_local_level_id="259" party1="Bruesewitz" party2="Wyeth LLC" id="8201_1480" citation_global_level_id="358912.079" party1_short="Bruesewitz" >Bruesewitz v. Wyeth LLC</CITATION>

<NAME id="8201_1481" start="93858" all_names="BRUESEWITZ" local_name_id="92" end="93868" party1_of="8201_1480" >Bruesewitz</NAME>

<NAME all_names="WYETHLLC" id="8201_1482" start="93872" party2_of="8201_1480" local_name_id="93" end="93881" >Wyeth LLC</NAME>

<CITATION entry_type="standard_key" line="164" id1="Dummy_File_358913" start="93883" lookup_key="u.s._562____" standard_reporter="U.S." end="93896" page_number="___" reporter="U. S." citation_local_level_id="260" citation_global_level_id="358912.001" id="8201_1479" volume="562" no_current_file="True" >562 U. S. ___</CITATION>

<DATE start="93910" end="93914" id="8201_1483" >2011</DATE>

<NAME id="8201_1489" start="94253" all_names="AMERICANLAW" local_name_id="104" end="94265" >American Law</NAME>

<NAME id="8201_1490" start="94269" all_names="PRODUCTSLIABILITY" local_name_id="86" end="94287" >Products Liability</NAME>

<DATE start="94307" end="94311" id="8201_1484" >2010</DATE>

<ORGANIZATION start="94319" plural="True" end="94339" id="8201_1491" >New Hampshire courts</ORGANIZATION>

<DATE start="94475" end="94479" id="8201_1485" >2012</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1495" start="94482" all_names="FOOTNOTE4BECAUSE" local_name_id="105" end="94500" >Footnote 4 Because</NAME>

<NAME id="8201_1496" start="94520" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="94537" >New Hampshire law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1508" start="94714" all_names="FOOTNOTE5THE" local_name_id="106" end="94728" >Footnote 5 The</NAME>

<PERSON start="94761" end="94766" id="8201_1509" >Bates</PERSON>

<ORGANIZATION start="94864" end="94869" id="8201_1510" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364831" start="95023" line="166" party2_short="Medtronic" end="95042" citation_local_level_id="261" party1="Riegel" citation_global_level_id="364830.001" id="8201_1500" no_current_file="True" party2="Medtronic" party1_short="Riegel" >Riegel v. Medtronic</CITATION>

<PERSON start="95023" party1_of="8201_1500" end="95029" id="8201_1502" >Riegel</PERSON>

<ORGANIZATION start="95033" party2_of="8201_1500" end="95042" id="8201_1503" >Medtronic</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="312" start="95050" line="166" standard_reporter="U.S." end="95079" year="2008" lookup_key="u.s._552_312" reporter="U. S." citation_local_level_id="262" paragraph_number="323-324" id="8201_1497" id1="Dummy_File_361598" volume="552" no_current_file="True" citation_global_level_id="361597.001" >552 U. S. 312, 323-324 (2008)</CITATION>

<DATE start="95074" citation_local_level_id="262" citation_global_level_id="361597.001" end="95078" id="8201_1506" >2008</DATE>

<PERSON start="95192" end="95197" id="8201_1511" >Bates</PERSON>

<LEGAL_ROLE start="95294" plural="True" end="95304" id="8201_1512" >plaintiffs</LEGAL_ROLE>

<CITATION entry_type="party_key" line="166" id1="Dummy_File_342963" start="95619" alternative_keys="['f.3d_332_323']" lookup_key="llcbates#1" party2_short="Bates" end="95648" citation_local_level_id="263" party1="Dow Agrosciences LLC" party2="Bates" id="8201_1501" citation_global_level_id="342962.002" party1_short="LLC" >Dow Agrosciences LLC v. Bates</CITATION>

<NAME id="8201_1504" start="95619" all_names="DOWAGROSCIENCESLLC" local_name_id="61" end="95639" party1_of="8201_1501" >Dow Agrosciences LLC</NAME>

<PERSON start="95643" party2_of="8201_1501" end="95648" id="8201_1505" >Bates</PERSON>

<CITATION entry_type="standard_key" line="166" id1="Dummy_File_342963" start="95650" alternative_keys="['llcbates#1']" lookup_key="f.3d_332_323" standard_reporter="F.3D" end="95672" page_number="323" reporter="F. 3d" citation_local_level_id="264" paragraph_number="332-333" id="8201_1498" volume="332" no_current_file="True" citation_global_level_id="342962.001" >332 F. 3d 323, 332-333</CITATION>

<GPE start="95674" end="95676" id="8201_1513" >CA</GPE>

<DATE start="95678" end="95682" id="8201_1507" >2003</DATE>

<ORGANIZATION start="95690" end="95695" id="8201_1514" >Court</ORGANIZATION>

<NAME id="8201_1515" start="95832" all_names="STATE" local_name_id="43" end="95837" >State</NAME>

<CITATION entry_type="standard_key" line="166" id1="Dummy_File_364792" start="95913" lookup_key="u.s._544_445" standard_reporter="U.S." end="95930" page_number="445" reporter="U. S." citation_local_level_id="265" citation_global_level_id="364791.001" id="8201_1499" volume="544" no_current_file="True" >544 U. S., at 445</CITATION>

<GPE start="96050" end="96063" id="8201_1516" >New Hampshire</GPE>

<NAME id="8201_1517" start="96300" all_names="NEWHAMPSHIRELAW" local_name_id="11" end="96317" >New Hampshire law</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1525" start="96368" all_names="FOOTNOTE6FOR" local_name_id="107" end="96382" >Footnote 6 For</NAME>

<ORGANIZATION start="96439" end="96453" id="8201_1526" >District Court</ORGANIZATION>

<PERSON start="96471" end="96479" id="8201_1527" >Bartlett</PERSON>

<NAME id="8201_1528" start="96558" all_names="SULINDAC" local_name_id="53" end="96566" >Sulindac</NAME>

<NAME id="8201_1529" start="96650" all_names="SULINDAC" local_name_id="53" end="96658" >Sulindac</NAME>

<CITATION lookup_key="bartlett'sinjuries#1" citation_local_level_id="266" entry_type="case_key" name="Bartlett's injuries" id="8201_1524" start="96794" id1="Dummy_File_364832" no_current_file="True" line="167" citation_global_level_id="364831.001" end="96813" >Bartlett's injuries</CITATION>

<PERSON start="96816" end="96819" id="8201_1530" >App</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<ORGANIZATION start="96986" end="97000" id="8201_1531" >District Court</ORGANIZATION>

<PROFESSION start="97012" end="97019" id="8201_1532" >counsel</PROFESSION>

<PROFESSION start="97170" end="97177" id="8201_1533" >counsel</PROFESSION>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1536" start="97314" all_names="FOOTNOTE7TO" local_name_id="108" end="97327" >Footnote 7 To</NAME>

<ORGANIZATION start="97370" end="97384" id="8201_1537" >District Court</ORGANIZATION>

<ORGANIZATION start="97558" end="97563" id="8201_1538" >Court</ORGANIZATION>

<PROFESSION start="97579" end="97586" id="8201_1539" >counsel</PROFESSION>

<ORGANIZATION start="97701" end="97706" id="8201_1540" >Court</ORGANIZATION>

<ORGANIZATION start="97750" end="97764" id="8201_1541" >District Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="169" id1="Dummy_File_364769" start="97937" lookup_key="f.3d_678_30" standard_reporter="F.3D" end="97956" page_number="30" reporter="F. 3d" citation_local_level_id="267" paragraph_number="41-42" id="8201_1534" volume="678" no_current_file="True" citation_global_level_id="364768.001" >678 F. 3d 30, 41-42</CITATION>

<GPE start="97958" end="97960" id="8201_1542" >CA</GPE>

<DATE start="97962" end="97966" id="8201_1535" >2012</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1548" start="97969" all_names="FOOTNOTE8THE" local_name_id="109" end="97983" >Footnote 8 The</NAME>

<CITATION entry_type="party_key" line="170" id1="Dummy_File_364833" start="98768" alternative_keys="['u.s._567___']" lookup_key="federationsebelius#1" party2_short="Sebelius" end="98823" standard_reporter="U.S." citation_local_level_id="268" volume="567" party1="National Federation of Independent Business" party2="Sebelius" id="8201_1544" no_current_file="True" page_number="__" citation_global_level_id="364832.003" party1_short="Federation" >National Federation of Independent Business v. Sebelius</CITATION>

<ORGANIZATION start="98768" party1_of="8201_1544" end="98811" id="8201_1545" >National Federation of Independent Business</ORGANIZATION>

<ORGANIZATION start="98768" end="98787" id="8201_1549" >National Federation</ORGANIZATION>

<NAME all_names="SEBELIUS" id="8201_1546" start="98815" party2_of="8201_1544" local_name_id="110" end="98823" >Sebelius</NAME>

<CITATION entry_type="standard_key" line="170" id1="Dummy_File_364833" start="98825" alternative_keys="['federationsebelius#1']" lookup_key="u.s._567___" standard_reporter="U.S." end="98837" page_number="__" reporter="U. S." citation_local_level_id="269" citation_global_level_id="364832.003" id="8201_1543" volume="567" no_current_file="True" >567 U. S. __</CITATION>

<DATE start="98843" end="98847" id="8201_1547" >2012</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1553" start="98981" all_names="FOOTNOTE9THE" local_name_id="111" end="98995" >Footnote 9 The</NAME>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<ORGANIZATION start="99577" end="99625" id="8201_1562" >Footnote 10 See Government Accountability Office</ORGANIZATION>

<NAME id="8201_1563" start="99640" all_names="IMPROVEMENTNEEDED" local_name_id="112" end="99658" >Improvement Needed</NAME>

<NAME id="8201_1564" start="99668" all_names="POSTMARKETDECISION-MAKING" local_name_id="113" end="99694" >Postmarket Decision-making</NAME>

<NAME id="8201_1565" start="99699" all_names="OVERSIGHTPROCESS" local_name_id="114" end="99716" >Oversight Process</NAME>

<NAME id="8201_1566" start="99721" all_names="GAO-" local_name_id="115" end="99725" >GAO-</NAME>

<DATE start="99733" end="99737" id="8201_1554" >2006</DATE>

<DATE start="99815" end="99819" id="8201_1555" >2000</DATE>

<DATE start="99824" end="99828" id="8201_1556" >2006</DATE>

<PERSON start="99831" end="99848" id="8201_1567" >Wysowski &amp; Swartz</PERSON>

<NAME id="8201_1568" start="99850" all_names="ADVERSEDRUGEVENTSURVEILLANCE" local_name_id="116" end="99881" >Adverse Drug Event Surveillance</NAME>

<NAME id="8201_1569" start="99917" all_names="STATES" local_name_id="14" end="99923" >States</NAME>

<DATE start="99925" end="99929" id="8201_1557" >1969</DATE>

<DATE start="99930" end="99934" id="8201_1558" >2002</DATE>

<NAME id="8201_1570" start="99940" all_names="ARCHIVESINTERNALMED" local_name_id="117" end="99961" >Archives Internal Med</NAME>

<DATE start="99969" end="99973" id="8201_1559" >2005</DATE>

<DATE start="100083" end="100087" id="8201_1560" >1969</DATE>

<DATE start="100092" end="100096" id="8201_1561" >2002</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1577" start="100099" all_names="FOOTNOTE11DEFENDING" local_name_id="118" end="100120" >Footnote 11 Defending</NAME>

<PERSON start="100379" end="100396" id="8201_1578" >Kessler &amp; Vladeck</PERSON>

<NAME id="8201_1579" start="100445" all_names="PREEMPTFAILURE-TO-WARNCLAIMS96GEO" local_name_id="75" end="100483" >Preempt Failure-to-Warn Claims, 96 Geo</NAME>

<DATE start="100505" end="100509" id="8201_1575" >2008</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_359981" start="100521" alternative_keys="['u.s._555_555']" line="173" party2_short="Levine" end="100536" citation_local_level_id="270" party1="Wyeth" party2="Levine" id="8201_1572" citation_global_level_id="359980.013" party1_short="Wyeth" >Wyeth v. Levine</CITATION>

<ORGANIZATION start="100521" party1_of="8201_1572" end="100526" id="8201_1573" >Wyeth</ORGANIZATION>

<PERSON start="100530" party2_of="8201_1572" end="100536" id="8201_1574" >Levine</PERSON>

<CITATION entry_type="standard_key" line="173" id1="Dummy_File_359981" start="100538" lookup_key="u.s._555_555" standard_reporter="U.S." end="100560" page_number="555" reporter="U. S." citation_local_level_id="271" paragraph_number="578-579" id="8201_1571" volume="555" no_current_file="True" citation_global_level_id="359980.003" >555 U. S. 555, 578-579</CITATION>

<DATE start="100573" end="100577" id="8201_1576" >2009</DATE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1583" start="100580" all_names="FOOTNOTE12THEFDA" local_name_id="119" end="100599" >Footnote 12 The FDA</NAME>

<NAME id="8201_1584" start="100686" all_names="THIRDRESTATEMENT" local_name_id="87" end="100703" >Third Restatement</NAME>

<GPE start="100822" end="100835" id="8201_1585" >New Hampshire</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1587" start="100962" all_names="FOOTNOTE13I" local_name_id="120" end="100975" >Footnote 13 I</NAME>

<NAME id="8201_1588" start="101229" all_names="FDCA" local_name_id="89" end="101233" >FDCA</NAME>

<PERSON start="101235" end="101241" id="8201_1589" >Levine</PERSON>

<CITATION entry_type="standard_key" line="175" id1="Dummy_File_364834" start="101243" lookup_key="u.s._555_582" standard_reporter="U.S." end="101260" page_number="582" reporter="U. S." citation_local_level_id="272" citation_global_level_id="364833.001" id="8201_1586" volume="555" no_current_file="True" >555 U. S., at 582</CITATION>

<PERSON start="101262" end="101268" id="8201_1590" >Breyer</PERSON>

<PERSON start="101310" end="101316" id="8201_1591" >Breyer</PERSON>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<GPE start="101335" end="101349" id="8201_1592" >Footnote 14 Or</GPE>

<COMMENT start="11991" entry_type="comment" line="29" end="12001" id="8201_181" >case below</COMMENT>

<COMMENT start="13600" entry_type="comment" line="31" end="13632" id="8201_221" >internal quotation marks omitted</COMMENT>

<COMMENT start="16676" entry_type="comment" line="36" end="16910" id="8201_300" >&quot;A holding of federal exclusion of state law is inescapable and requires no inquiry into congressional design where compliance with both federal and state regulations is a physical impossibility for one engaged in interstate commerce&quot;</COMMENT>

<COMMENT start="19199" entry_type="comment" line="41" end="19338" id="8201_345" >&quot;The duty to warn is part of the general duty to design, manufacture and sell products that are reasonably safe for their foreseeable uses&quot;</COMMENT>

<COMMENT start="19428" entry_type="comment" line="41" end="19592" id="8201_346" >&quot;We limit the application of strict tort liability in this jurisdiction by continuing to emphasize that liability without negligence is not liability without fault&quot;</COMMENT>

<COMMENT start="19662" entry_type="comment" line="41" end="19839" id="8201_347" >cautioning &quot;that the term 'unreasonably dangerous' should not be interpreted so broadly as to impose absolute liability on manufacturers or make them insurers of their products&quot;</COMMENT>

<COMMENT start="26436" entry_type="comment" line="49" end="26665" id="8201_455" >&quot;if the jury found that sulin-dac's risks outweighed its benefits, then it could consider whether the warning  regardless of its adequacy  re-duced those risks . . . to such an extent that it eliminated the unreasonable danger&quot;</COMMENT>

<COMMENT start="27203" entry_type="comment" line="52" end="27348" id="8201_472" >&quot;Federal drug regulations, as interpreted by the FDA, prevented the Manufacturers from independently changing their generic drugs' safety labels&quot;</COMMENT>

<COMMENT start="28820" entry_type="comment" line="56" end="28835" id="8201_478" >slip op., at 14</COMMENT>

<COMMENT start="30524" entry_type="comment" line="59" end="30694" id="8201_488" >&quot;[G]eneric defendants were not compelled to market metoclopramide. If they realized their label was insufficient . . . they could have simply stopped selling the product&quot;</COMMENT>

<COMMENT start="31015" entry_type="comment" line="59" end="31030" id="8201_489" >slip op., at 12</COMMENT>

<COMMENT start="32770" entry_type="comment" line="63" end="32806" id="8201_519" >quoting English, 496 U. S., at 78-79</COMMENT>

<COMMENT start="40194" entry_type="comment" line="78" end="40247" id="8201_626" >opinion concurring in part and concurring in judgment</COMMENT>

<COMMENT start="42483" entry_type="comment" line="80" end="42636" id="8201_696" >&quot;[A]gency litigating positions that are wholly unsupported by regulations, rulings, or administrative practice&quot; are entitled to less than ordinary weight</COMMENT>

<COMMENT start="43435" entry_type="comment" line="81" end="43492" id="8201_717" >agency views that vary over time are accorded less weight</COMMENT>

<COMMENT start="43612" entry_type="comment" line="81" end="43616" id="8201_718" >same</COMMENT>

<COMMENT start="51501" entry_type="comment" line="100" end="51525" id="8201_891" >Ginsburg, J., dissenting</COMMENT>

<COMMENT start="58949" entry_type="comment" line="112" end="58964" id="8201_1040" >slip op., at 10</COMMENT>

<COMMENT start="74069" entry_type="comment" line="136" end="74084" id="8201_1216" >slip op., at 14</COMMENT>

<COMMENT start="84685" entry_type="comment" line="149" end="84699" id="8201_1324" >slip op., at 4</COMMENT>

<COMMENT start="89434" entry_type="comment" line="158" end="89678" id="8201_1419" >There would be &quot;impossibility of dual compliance&quot; where &quot;federal orders forbade the picking and marketing of any avocado testing more than 7% oil, while the California test excluded from the State any avocado measuring less than 8% oil content&quot;</COMMENT>

<COMMENT start="90726" entry_type="comment" line="159" end="90911" id="8201_1444" >state-law pesticide labeling requirement not pre-empted under express pre-emption provision, provided it was &quot;equivalent to, and fully consistent with, [federal] misbranding provisions&quot;</COMMENT>

<COMMENT start="91417" entry_type="comment" line="159" end="91531" id="8201_1445" >most of respondent's experts' testimony was &quot;drawn directly from the medical literature or published FDA analyses&quot;</COMMENT>

<NAME id="8201_1593" start="101554" all_names="FOOTNOTE15SEE" local_name_id="121" end="101569" >Footnote 15 See</NAME>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Mutual Pharmaceutical" legal_role="8201_13" id="8201_23" legal_role_string="petitioner" theme="8201_14" ></RELATION>

<RELATION gram_type="apposition" relation_type="asymmetric" theme_string="Mutual Pharmaceutical" legal_role="8201_15" id="8201_24" legal_role_string="Respondent" theme="8201_14" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_5" id="8201_27" standard_case_string="564 U. S. ___" X_vs_Y_string="PLIVA, Inc. v. Mensing" X_vs_Y="8201_6" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_7" party1_string="PLIVA, Inc." theme_string="PLIVA, Inc. v. Mensing" id="8201_25" theme="8201_6" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_8" theme_string="PLIVA, Inc. v. Mensing" id="8201_26" theme="8201_6" party2_string="Mensing" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_30" id="8201_43" standard_case_string="451 U. S. 725, 746" X_vs_Y_string="Maryland v. Louisiana" X_vs_Y="8201_32" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_34" party1_string="Maryland" theme_string="Maryland v. Louisiana" id="8201_41" theme="8201_32" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_35" theme_string="Maryland v. Louisiana" id="8201_42" theme="8201_32" party2_string="Louisiana" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_31" id="8201_46" standard_case_string="496 U. S. 72, 79" X_vs_Y_string="English v. General Elec. Co" X_vs_Y="8201_33" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_36" party1_string="English" theme_string="English v. General Elec. Co" id="8201_44" theme="8201_33" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_37" theme_string="English v. General Elec. Co" id="8201_45" theme="8201_33" party2_string="General Elec. Co" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_48" id="8201_58" standard_case_string="395 A. 2d 843, 847" X_vs_Y_string="Thibault v. Sears, Roebuck &amp; Co" X_vs_Y="8201_49" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_47" id="8201_57" standard_case_string="118 N. H. 802, 809" X_vs_Y_string="Thibault v. Sears, Roebuck &amp; Co" X_vs_Y="8201_49" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_50" party1_string="Thibault" theme_string="Thibault v. Sears, Roebuck &amp; Co" id="8201_55" theme="8201_49" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_51" theme_string="Thibault v. Sears, Roebuck &amp; Co" id="8201_56" theme="8201_49" party2_string="Sears, Roebuck &amp; Co" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_60" id="8201_71" standard_case_string="784 A. 2d 1178, 1181" X_vs_Y_string="Vautour v. Body Masters Sports Industries, Inc" X_vs_Y="8201_62" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_59" id="8201_70" standard_case_string="147 N. H. 150, 153" X_vs_Y_string="Vautour v. Body Masters Sports Industries, Inc" X_vs_Y="8201_62" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_63" party1_string="Vautour" theme_string="Vautour v. Body Masters Sports Industries, Inc" id="8201_68" theme="8201_62" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_64" theme_string="Vautour v. Body Masters Sports Industries, Inc" id="8201_69" theme="8201_62" party2_string="Body Masters Sports Industries, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="570 U. S. ____ (2013)" id="8201_94" at_date_string="2013" theme="8201_92" at_date="8201_93" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_104" party1_string="MUTUAL PHARMACEUTICAL COMPANY, INC.," theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC.,PETITIONER v. KAREN L. BARTLETT" id="8201_108" theme="8201_103" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_105" theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC.,PETITIONER v. KAREN L. BARTLETT" id="8201_109" theme="8201_103" party2_string="KAREN L. BARTLETT" ></RELATION>

<RELATION gram_type="multi_line" relation_type="asymmetric" includes_docket="8201_102" theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC.,PETITIONER v. KAREN L. BARTLETT" id="8201_110" includes_docket_string="12-142" theme="8201_103" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Alito" id="8201_115" theme="8201_113" profession="8201_112" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Karen Bartlett" legal_role="8201_127" id="8201_136" legal_role_string="respondent" theme="8201_128" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Mutual Pharmaceutical" legal_role="8201_129" id="8201_137" legal_role_string="petitioner" theme="8201_130" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_116" id="8201_140" standard_case_string="564 U. S. ___ (2011)" X_vs_Y_string="PLIVA, Inc. v. Mensing" X_vs_Y="8201_118" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_120" party1_string="PLIVA, Inc." theme_string="PLIVA, Inc. v. Mensing" id="8201_138" theme="8201_118" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_121" theme_string="PLIVA, Inc. v. Mensing" id="8201_139" theme="8201_118" party2_string="Mensing" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="564 U. S. ___ (2011)" id="8201_141" at_date_string="2011" theme="8201_116" at_date="8201_124" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_117" id="8201_144" standard_case_string="451 U. S. 725, 746 (1981)" X_vs_Y_string="Maryland v. Louisiana" X_vs_Y="8201_119" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_122" party1_string="Maryland" theme_string="Maryland v. Louisiana" id="8201_142" theme="8201_119" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_123" theme_string="Maryland v. Louisiana" id="8201_143" theme="8201_119" party2_string="Louisiana" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="451 U. S. 725, 746 (1981)" id="8201_145" at_date_string="1981" theme="8201_117" at_date="8201_125" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_151" id="8201_165" standard_case_string="529 U. S. 120, 140 (2000)" X_vs_Y_string="FDA v. Brown &amp; Williamson Tobacco Corp" X_vs_Y="8201_152" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_153" party1_string="FDA" theme_string="FDA v. Brown &amp; Williamson Tobacco Corp" id="8201_163" theme="8201_152" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_154" theme_string="FDA v. Brown &amp; Williamson Tobacco Corp" id="8201_164" theme="8201_152" party2_string="Brown &amp; Williamson Tobacco Corp" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="529 U. S. 120, 140 (2000)" id="8201_166" at_date_string="2000" theme="8201_151" at_date="8201_156" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Karen L. Bartlett" legal_role="8201_211" id="8201_218" legal_role_string="respondent" theme="8201_212" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Mutual Pharmaceutical" legal_role="8201_214" id="8201_219" legal_role_string="petitioner" theme="8201_215" ></RELATION>

<RELATION gram_type="apposition" relation_type="asymmetric" theme_string="Mutual Pharmaceutical" legal_role="8201_216" id="8201_220" legal_role_string="Respondent" theme="8201_215" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="2005P-0072" id="8201_240" at_date_string="2005" theme="8201_224" at_date="8201_227" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_250" id="8201_263" standard_case_string="564 U. S. ___" X_vs_Y_string="PLIVA, Inc. v. Mensing" X_vs_Y="8201_253" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_254" party1_string="PLIVA, Inc." theme_string="PLIVA, Inc. v. Mensing" id="8201_261" theme="8201_253" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_255" theme_string="PLIVA, Inc. v. Mensing" id="8201_262" theme="8201_253" party2_string="Mensing" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="568 U. S. ___ (2012)" id="8201_264" at_date_string="2012" theme="8201_252" at_date="8201_256" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_265" id="8201_291" standard_case_string="451 U. S., at 746" X_vs_Y_string="Maryland v. Louisiana" X_vs_Y="8201_268" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_271" party1_string="Maryland" theme_string="Maryland v. Louisiana" id="8201_289" theme="8201_268" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_272" theme_string="Maryland v. Louisiana" id="8201_290" theme="8201_268" party2_string="Louisiana" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_266" id="8201_294" standard_case_string="4 Wheat. 316, 427 (1819)" X_vs_Y_string="McCulloch v. Maryland" X_vs_Y="8201_269" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_273" party1_string="McCulloch" theme_string="McCulloch v. Maryland" id="8201_292" theme="8201_269" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_274" theme_string="McCulloch v. Maryland" id="8201_293" theme="8201_269" party2_string="Maryland" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="4 Wheat. 316, 427 (1819)" id="8201_295" at_date_string="1819" theme="8201_266" at_date="8201_277" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_267" id="8201_298" standard_case_string="505 U. S. 88, 108 (1992)" X_vs_Y_string="Gade v. National Solid Wastes Management Assn" X_vs_Y="8201_270" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_275" party1_string="Gade" theme_string="Gade v. National Solid Wastes Management Assn" id="8201_296" theme="8201_270" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_276" theme_string="Gade v. National Solid Wastes Management Assn" id="8201_297" theme="8201_270" party2_string="National Solid Wastes Management Assn" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="505 U. S. 88, 108 (1992)" id="8201_299" at_date_string="1992" theme="8201_267" at_date="8201_278" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_305" party1_string="English" theme_string="English v. General Elec" id="8201_314" theme="8201_303" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_306" theme_string="English v. General Elec" id="8201_315" theme="8201_303" party2_string="General Elec" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="496 U. S. 72, 79 (1990)" id="8201_316" at_date_string="1990" theme="8201_301" at_date="8201_309" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_302" id="8201_319" standard_case_string="373 U. S. 132, 142-143" X_vs_Y_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" X_vs_Y="8201_304" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_307" party1_string="Florida Lime &amp; Avocado Growers, Inc." theme_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" id="8201_317" theme="8201_304" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_308" theme_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" id="8201_318" theme="8201_304" party2_string="Paul" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="373 U. S. 132, 142-143" id="8201_320" at_date_string="1963" theme="8201_302" at_date="8201_310" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_328" id="8201_343" standard_case_string="260 A. 2d 111, 112-113 (1969)" X_vs_Y_string="Buttrick v. Arthur Lessard &amp; Sons, Inc" X_vs_Y="8201_329" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_327" id="8201_342" standard_case_string="110 N. H. 36, 37-39" X_vs_Y_string="Buttrick v. Arthur Lessard &amp; Sons, Inc" X_vs_Y="8201_329" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_330" party1_string="Buttrick" theme_string="Buttrick v. Arthur Lessard &amp; Sons, Inc" id="8201_340" theme="8201_329" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_331" theme_string="Buttrick v. Arthur Lessard &amp; Sons, Inc" id="8201_341" theme="8201_329" party2_string="Arthur Lessard &amp; Sons, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="260 A. 2d 111, 112-113 (1969)" id="8201_344" at_date_string="1969" theme="8201_328" at_date="8201_334" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_363" party1_string="Thibault" theme_string="Thibault v. Sears" id="8201_389" theme="8201_358" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_364" theme_string="Thibault v. Sears" id="8201_390" theme="8201_358" party2_string="Sears" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="395 A. 2d 843, 847 (1978)" id="8201_391" at_date_string="1978" theme="8201_349" at_date="8201_373" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_365" party1_string="Reid" theme_string="Reid v. Spadone Mach" id="8201_392" theme="8201_359" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_366" theme_string="Reid v. Spadone Mach" id="8201_393" theme="8201_359" party2_string="Spadone Mach" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="404 A. 2d 1094, 1099 (1979)" id="8201_394" at_date_string="1979" theme="8201_351" at_date="8201_374" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_353" id="8201_398" standard_case_string="637 A. 2d 148, 150" X_vs_Y_string="Chellman v. Saab-Scania AB" X_vs_Y="8201_360" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_352" id="8201_397" standard_case_string="138 N. H. 73, 78" X_vs_Y_string="Chellman v. Saab-Scania AB" X_vs_Y="8201_360" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_367" party1_string="Chellman" theme_string="Chellman v. Saab-Scania AB" id="8201_395" theme="8201_360" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_368" theme_string="Chellman v. Saab-Scania AB" id="8201_396" theme="8201_360" party2_string="Saab-Scania AB" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="138 N. H. 73, 78" id="8201_400" at_date_string="1993" theme="8201_352" at_date="8201_375" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="637 A. 2d 148, 150" id="8201_399" at_date_string="1993" theme="8201_353" at_date="8201_375" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_369" party1_string="Simoneau" theme_string="Simoneau v. South Bend Lathe" id="8201_401" theme="8201_361" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_370" theme_string="Simoneau v. South Bend Lathe" id="8201_402" theme="8201_361" party2_string="South Bend Lathe" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="130 N. H. 466, 469" id="8201_404" at_date_string="1988" theme="8201_354" at_date="8201_376" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="543 A. 2d 407, 409" id="8201_403" at_date_string="1988" theme="8201_355" at_date="8201_376" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_357" id="8201_408" standard_case_string="702 A. 2d 330, 333" X_vs_Y_string="Price v. BIC Corp" X_vs_Y="8201_362" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_356" id="8201_407" standard_case_string="142 N. H. 386, 390" X_vs_Y_string="Price v. BIC Corp" X_vs_Y="8201_362" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_371" party1_string="Price" theme_string="Price v. BIC Corp" id="8201_405" theme="8201_362" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_372" theme_string="Price v. BIC Corp" id="8201_406" theme="8201_362" party2_string="BIC Corp" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="142 N. H. 386, 390" id="8201_410" at_date_string="1997" theme="8201_356" at_date="8201_377" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="702 A. 2d 330, 333" id="8201_409" at_date_string="1997" theme="8201_357" at_date="8201_377" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_416" id="8201_435" standard_case_string="784 A. 2d 1178, 1181 (2001)" X_vs_Y_string="Vautour v. Body Masters Sports Industries, Inc" X_vs_Y="8201_420" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_415" id="8201_434" standard_case_string="147 N. H. 150, 153" X_vs_Y_string="Vautour v. Body Masters Sports Industries, Inc" X_vs_Y="8201_420" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_421" party1_string="Vautour" theme_string="Vautour v. Body Masters Sports Industries, Inc" id="8201_432" theme="8201_420" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_422" theme_string="Vautour v. Body Masters Sports Industries, Inc" id="8201_433" theme="8201_420" party2_string="Body Masters Sports Industries, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="784 A. 2d 1178, 1181 (2001)" id="8201_436" at_date_string="2001" theme="8201_416" at_date="8201_423" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="760 F. Supp. 2d 220, 231" id="8201_470" at_date_string="2011" theme="8201_456" at_date="8201_459" ></RELATION>

<RELATION gram_type="parentheses" relation_type="comment" theme_string="564 U. S., at ___" id="8201_485" comment="8201_478" theme="8201_481" comment_string="slip op., at 14" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_490" id="8201_509" standard_case_string="588 F. 3d 603, 611" X_vs_Y_string="Mensing v. Wyeth, Inc" X_vs_Y="8201_493" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_494" party1_string="Mensing" theme_string="Mensing v. Wyeth, Inc" id="8201_507" theme="8201_493" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_495" theme_string="Mensing v. Wyeth, Inc" id="8201_508" theme="8201_493" party2_string="Wyeth, Inc" ></RELATION>

<RELATION gram_type="parentheses" relation_type="comment" theme_string="564 U. S., at ___" id="8201_510" comment="8201_489" theme="8201_491" comment_string="slip op., at 12" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Sotomayor" id="8201_518" theme="8201_516" profession="8201_515" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_520" id="8201_536" standard_case_string="514 U. S. 280, 287" X_vs_Y_string="Freightliner Corp. v. Myrick" X_vs_Y="8201_523" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_525" party1_string="Freightliner Corp." theme_string="Freightliner Corp. v. Myrick" id="8201_534" theme="8201_523" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_526" theme_string="Freightliner Corp. v. Myrick" id="8201_535" theme="8201_523" party2_string="Myrick" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="514 U. S. 280, 287" id="8201_537" at_date_string="1995" theme="8201_520" at_date="8201_529" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_522" id="8201_540" standard_case_string="487 U. S. 131, 138 (1988)" X_vs_Y_string="Felder v. Casey" X_vs_Y="8201_524" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_527" party1_string="Felder" theme_string="Felder v. Casey" id="8201_538" theme="8201_524" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_528" theme_string="Felder v. Casey" id="8201_539" theme="8201_524" party2_string="Casey" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="487 U. S. 131, 138 (1988)" id="8201_541" at_date_string="1988" theme="8201_522" at_date="8201_530" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_551" id="8201_571" standard_case_string="544 U. S. 431 (2005)" X_vs_Y_string="Bates v. Dow Agrosciences LLC" X_vs_Y="8201_556" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_557" party1_string="Bates" theme_string="Bates v. Dow Agrosciences LLC" id="8201_569" theme="8201_556" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_558" theme_string="Bates v. Dow Agrosciences LLC" id="8201_570" theme="8201_556" party2_string="Dow Agrosciences LLC" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="544 U. S. 431 (2005)" id="8201_572" at_date_string="2005" theme="8201_551" at_date="8201_559" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_573" id="8201_586" standard_case_string="555 U. S. 555 (2009)" X_vs_Y_string="Wyeth v. Levine" X_vs_Y="8201_575" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_576" party1_string="Wyeth" theme_string="Wyeth v. Levine" id="8201_584" theme="8201_575" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_577" theme_string="Wyeth v. Levine" id="8201_585" theme="8201_575" party2_string="Levine" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="555 U. S. 555 (2009)" id="8201_587" at_date_string="2009" theme="8201_573" at_date="8201_578" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="570 U. S. ____ (2013)" id="8201_595" at_date_string="2013" theme="8201_593" at_date="8201_594" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_598" party1_string="MUTUAL PHARMACEUTICAL COMPANY, INC.," theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" id="8201_602" theme="8201_597" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_599" theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" id="8201_603" theme="8201_597" party2_string="KAREN L. BARTLETT" ></RELATION>

<RELATION gram_type="multi_line" relation_type="equivalence" standard_case="8201_593" id="8201_604" standard_case_string="570 U. S. ____ (2013)" X_vs_Y_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" X_vs_Y="8201_597" ></RELATION>

<RELATION gram_type="multi_line" relation_type="asymmetric" includes_docket="8201_596" theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" id="8201_605" includes_docket_string="12-142" theme="8201_597" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Breyer" id="8201_611" theme="8201_608" profession="8201_607" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Kagan" id="8201_612" theme="8201_610" profession="8201_609" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_613" id="8201_624" standard_case_string="530 U. S. 363, 373 (2000)" X_vs_Y_string="Crosby v. National Foreign Trade Coun-cil" X_vs_Y="8201_614" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_615" party1_string="Crosby" theme_string="Crosby v. National Foreign Trade Coun-cil" id="8201_622" theme="8201_614" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_616" theme_string="Crosby v. National Foreign Trade Coun-cil" id="8201_623" theme="8201_614" party2_string="National Foreign Trade Coun-cil" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="530 U. S. 363, 373 (2000)" id="8201_625" at_date_string="2000" theme="8201_613" at_date="8201_617" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_627" id="8201_669" standard_case_string="518 U. S. 470, 503" X_vs_Y_string="Medtronic, Inc. v. Lohr" X_vs_Y="8201_635" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_642" party1_string="Medtronic, Inc." theme_string="Medtronic, Inc. v. Lohr" id="8201_667" theme="8201_635" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_643" theme_string="Medtronic, Inc. v. Lohr" id="8201_668" theme="8201_635" party2_string="Lohr" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="518 U. S. 470, 503" id="8201_670" at_date_string="1996" theme="8201_627" at_date="8201_656" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_628" id="8201_673" standard_case_string="517 U. S. 735, 739-741 (1996)" X_vs_Y_string="Smiley v. Citibank (South Dakota), N. A" X_vs_Y="8201_636" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_644" party1_string="Smiley" theme_string="Smiley v. Citibank (South Dakota), N. A" id="8201_671" theme="8201_636" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_645" theme_string="Smiley v. Citibank (South Dakota), N. A" id="8201_672" theme="8201_636" party2_string="Citibank (South Dakota), N. A" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="517 U. S. 735, 739-741 (1996)" id="8201_674" at_date_string="1996" theme="8201_628" at_date="8201_657" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_629" id="8201_677" standard_case_string="471 U. S. 707, 721 (1985)" X_vs_Y_string="Hillsborough County v. Automated Medical Laboratories, Inc" X_vs_Y="8201_637" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_646" party1_string="Hillsborough County" theme_string="Hillsborough County v. Automated Medical Laboratories, Inc" id="8201_675" theme="8201_637" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_647" theme_string="Hillsborough County v. Automated Medical Laboratories, Inc" id="8201_676" theme="8201_637" party2_string="Automated Medical Laboratories, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="471 U. S. 707, 721 (1985)" id="8201_678" at_date_string="1985" theme="8201_629" at_date="8201_658" ></RELATION>

<RELATION gram_type="apposition" relation_type="asymmetric" includes_docket="8201_634" theme_string="Lawrence County v. Lead-Deadwood School Dist" id="8201_681" includes_docket_string="40-1" theme="8201_638" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_648" party1_string="Lawrence County" theme_string="Lawrence County v. Lead-Deadwood School Dist" id="8201_679" theme="8201_638" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_649" theme_string="Lawrence County v. Lead-Deadwood School Dist" id="8201_680" theme="8201_638" party2_string="Lead-Deadwood School Dist" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="469 U. S. 256, 261-262 (1985)" id="8201_682" at_date_string="1985" theme="8201_630" at_date="8201_659" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_631" id="8201_685" standard_case_string="467 U. S. 837, 842-845 (1984)" X_vs_Y_string="Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc" X_vs_Y="8201_639" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_650" party1_string="Chevron U. S. A. Inc." theme_string="Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc" id="8201_683" theme="8201_639" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_651" theme_string="Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc" id="8201_684" theme="8201_639" party2_string="Natural Resources Defense Council, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="467 U. S. 837, 842-845 (1984)" id="8201_686" at_date_string="1984" theme="8201_631" at_date="8201_660" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_632" id="8201_689" standard_case_string="555 U. S. 555, 576-577 (2009)" X_vs_Y_string="Wyeth v. Levine" X_vs_Y="8201_640" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_652" party1_string="Wyeth" theme_string="Wyeth v. Levine" id="8201_687" theme="8201_640" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_653" theme_string="Wyeth v. Levine" id="8201_688" theme="8201_640" party2_string="Levine" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="555 U. S. 555, 576-577 (2009)" id="8201_690" at_date_string="2009" theme="8201_632" at_date="8201_661" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_633" id="8201_693" standard_case_string="323 U. S. 134, 140 (1944)" X_vs_Y_string="Skidmore v. Swift &amp; Co" X_vs_Y="8201_641" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_654" party1_string="Skidmore" theme_string="Skidmore v. Swift &amp; Co" id="8201_691" theme="8201_641" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_655" theme_string="Skidmore v. Swift &amp; Co" id="8201_692" theme="8201_641" party2_string="Swift &amp; Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="323 U. S. 134, 140 (1944)" id="8201_694" at_date_string="1944" theme="8201_633" at_date="8201_662" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_697" id="8201_711" standard_case_string="488 U. S. 204, 212-213" X_vs_Y_string="Bowen v. Georgetown Univ. Hospital" X_vs_Y="8201_699" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_701" party1_string="Bowen" theme_string="Bowen v. Georgetown Univ. Hospital" id="8201_709" theme="8201_699" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_702" theme_string="Bowen v. Georgetown Univ. Hospital" id="8201_710" theme="8201_699" party2_string="Georgetown Univ. Hospital" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="488 U. S. 204, 212-213" id="8201_712" at_date_string="1988" theme="8201_697" at_date="8201_705" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_698" id="8201_715" standard_case_string="529 U. S. 576, 587 (2000)" X_vs_Y_string="Christensen v. Harris County" X_vs_Y="8201_700" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_703" party1_string="Christensen" theme_string="Christensen v. Harris County" id="8201_713" theme="8201_700" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_704" theme_string="Christensen v. Harris County" id="8201_714" theme="8201_700" party2_string="Harris County" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="529 U. S. 576, 587 (2000)" id="8201_716" at_date_string="2000" theme="8201_698" at_date="8201_706" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_719" id="8201_749" standard_case_string="564 U. S. ___" X_vs_Y_string="PLIVA, Inc. v. Mensing" X_vs_Y="8201_723" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_727" party1_string="PLIVA, Inc." theme_string="PLIVA, Inc. v. Mensing" id="8201_747" theme="8201_723" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_728" theme_string="PLIVA, Inc. v. Mensing" id="8201_748" theme="8201_723" party2_string="Mensing" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_720" id="8201_752" standard_case_string="545 U. S. 967, 981" X_vs_Y_string="National Cable &amp; Telecommunications Assn. v. Brand X Internet Services" X_vs_Y="8201_724" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_729" party1_string="National Cable &amp; Telecommunications Assn." theme_string="National Cable &amp; Telecommunications Assn. v. Brand X Internet Services" id="8201_750" theme="8201_724" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_730" theme_string="National Cable &amp; Telecommunications Assn. v. Brand X Internet Services" id="8201_751" theme="8201_724" party2_string="Brand X Internet Services" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="545 U. S. 967, 981" id="8201_753" at_date_string="2005" theme="8201_720" at_date="8201_736" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_721" id="8201_756" standard_case_string="463 U. S. 29, 41-42" X_vs_Y_string="Motor Vehicle Mfrs. Assn. of United States, Inc. v. State Farm Mut. Automobile Ins. Co" X_vs_Y="8201_725" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_731" party1_string="Motor Vehicle Mfrs. Assn. of United States, Inc." theme_string="Motor Vehicle Mfrs. Assn. of United States, Inc. v. State Farm Mut. Automobile Ins. Co" id="8201_754" theme="8201_725" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_732" theme_string="Motor Vehicle Mfrs. Assn. of United States, Inc. v. State Farm Mut. Automobile Ins. Co" id="8201_755" theme="8201_725" party2_string="State Farm Mut. Automobile Ins. Co" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="463 U. S. 29, 41-42" id="8201_757" at_date_string="1983" theme="8201_721" at_date="8201_737" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_722" id="8201_760" standard_case_string="535 U. S. 467, 502" X_vs_Y_string="Verizon Communications Inc. v. FCC" X_vs_Y="8201_726" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_733" party1_string="Verizon Communications Inc." theme_string="Verizon Communications Inc. v. FCC" id="8201_758" theme="8201_726" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_734" theme_string="Verizon Communications Inc. v. FCC" id="8201_759" theme="8201_726" party2_string="FCC" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="570 U. S. ____ (2013)" id="8201_775" at_date_string="2013" theme="8201_773" at_date="8201_774" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_778" party1_string="MUTUAL PHARMACEUTICAL COMPANY, INC.," theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" id="8201_782" theme="8201_777" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_779" theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" id="8201_783" theme="8201_777" party2_string="KAREN L. BARTLETT" ></RELATION>

<RELATION gram_type="multi_line" relation_type="equivalence" standard_case="8201_773" id="8201_784" standard_case_string="570 U. S. ____ (2013)" X_vs_Y_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" X_vs_Y="8201_777" ></RELATION>

<RELATION gram_type="multi_line" relation_type="asymmetric" includes_docket="8201_776" theme_string="MUTUAL PHARMACEUTICAL COMPANY, INC., PETITIONER v. KAREN L. BARTLETT" id="8201_785" includes_docket_string="12-142" theme="8201_777" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Sotomayor" id="8201_791" theme="8201_788" profession="8201_787" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Ginsburg" id="8201_792" theme="8201_790" profession="8201_789" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_793" id="8201_805" standard_case_string="564 U. S. ___ (2011)" X_vs_Y_string="PLIVA, Inc. v. Mensing" X_vs_Y="8201_794" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_795" party1_string="PLIVA, Inc." theme_string="PLIVA, Inc. v. Mensing" id="8201_803" theme="8201_794" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_796" theme_string="PLIVA, Inc. v. Mensing" id="8201_804" theme="8201_794" party2_string="Mensing" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="564 U. S. ___ (2011)" id="8201_806" at_date_string="2011" theme="8201_793" at_date="8201_797" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Mutual Pharmaceutical" legal_role="8201_808" id="8201_815" legal_role_string="petitioner" theme="8201_809" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Karen Bartlett" legal_role="8201_812" id="8201_816" legal_role_string="respondent" theme="8201_813" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_827" id="8201_857" standard_case_string="555 U. S. 555, 565 (2009)" X_vs_Y_string="Wyeth v. Levine" X_vs_Y="8201_831" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_835" party1_string="Wyeth" theme_string="Wyeth v. Levine" id="8201_855" theme="8201_831" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_836" theme_string="Wyeth v. Levine" id="8201_856" theme="8201_831" party2_string="Levine" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="555 U. S. 555, 565 (2009)" id="8201_858" at_date_string="2009" theme="8201_827" at_date="8201_843" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_828" id="8201_861" standard_case_string="518 U. S. 470, 485 (1996)" X_vs_Y_string="Medtronic, Inc. v. Lohr" X_vs_Y="8201_832" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_837" party1_string="Medtronic, Inc." theme_string="Medtronic, Inc. v. Lohr" id="8201_859" theme="8201_832" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_838" theme_string="Medtronic, Inc. v. Lohr" id="8201_860" theme="8201_832" party2_string="Lohr" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="518 U. S. 470, 485 (1996)" id="8201_862" at_date_string="1996" theme="8201_828" at_date="8201_844" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_829" id="8201_865" standard_case_string="331 U. S. 218, 230 (1947)" X_vs_Y_string="Rice v. Santa Fe Elevator Corp" X_vs_Y="8201_833" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_839" party1_string="Rice" theme_string="Rice v. Santa Fe Elevator Corp" id="8201_863" theme="8201_833" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_840" theme_string="Rice v. Santa Fe Elevator Corp" id="8201_864" theme="8201_833" party2_string="Santa Fe Elevator Corp" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="331 U. S. 218, 230 (1947)" id="8201_866" at_date_string="1947" theme="8201_829" at_date="8201_845" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_830" id="8201_869" standard_case_string="555 U. S. 70, 77 (2008)" X_vs_Y_string="Altria Group, Inc. v. Good" X_vs_Y="8201_834" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_841" party1_string="Altria Group, Inc." theme_string="Altria Group, Inc. v. Good" id="8201_867" theme="8201_834" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_842" theme_string="Altria Group, Inc. v. Good" id="8201_868" theme="8201_834" party2_string="Good" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="555 U. S. 70, 77 (2008)" id="8201_870" at_date_string="2008" theme="8201_830" at_date="8201_846" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_894" id="8201_909" standard_case_string="552 U. S. 312, 340" X_vs_Y_string="Riegel v. Medtronic, Inc" X_vs_Y="8201_895" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_896" party1_string="Riegel" theme_string="Riegel v. Medtronic, Inc" id="8201_907" theme="8201_895" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_897" theme_string="Riegel v. Medtronic, Inc" id="8201_908" theme="8201_895" party2_string="Medtronic, Inc" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="552 U. S. 312, 340" id="8201_910" at_date_string="2008" theme="8201_894" at_date="8201_899" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_912" id="8201_932" standard_case_string="544 U. S. 431, 451 (2005)" X_vs_Y_string="Bates v. Dow Agrosciences LLC" X_vs_Y="8201_913" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_914" party1_string="Bates" theme_string="Bates v. Dow Agrosciences LLC" id="8201_930" theme="8201_913" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_915" theme_string="Bates v. Dow Agrosciences LLC" id="8201_931" theme="8201_913" party2_string="Dow Agrosciences LLC" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="544 U. S. 431, 451 (2005)" id="8201_933" at_date_string="2005" theme="8201_912" at_date="8201_918" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_934" id="8201_956" standard_case_string="537 U. S. 51, 64 (2002)" X_vs_Y_string="Sprietsma v. Mercury Marine" X_vs_Y="8201_939" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_941" party1_string="Sprietsma" theme_string="Sprietsma v. Mercury Marine" id="8201_954" theme="8201_939" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_942" theme_string="Sprietsma v. Mercury Marine" id="8201_955" theme="8201_939" party2_string="Mercury Marine" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="537 U. S. 51, 64 (2002)" id="8201_957" at_date_string="2002" theme="8201_934" at_date="8201_945" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_935" id="8201_960" standard_case_string="464 U. S. 238, 251 (1984)" X_vs_Y_string="Silkwood v. Kerr-McGee Corp" X_vs_Y="8201_940" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_943" party1_string="Silkwood" theme_string="Silkwood v. Kerr-McGee Corp" id="8201_958" theme="8201_940" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_944" theme_string="Silkwood v. Kerr-McGee Corp" id="8201_959" theme="8201_940" party2_string="Kerr-McGee Corp" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="464 U. S. 238, 251 (1984)" id="8201_961" at_date_string="1984" theme="8201_935" at_date="8201_946" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_962" id="8201_972" standard_case_string="373 U. S. 132, 142-143 (1963)" X_vs_Y_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" X_vs_Y="8201_963" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_964" party1_string="Florida Lime &amp; Avocado Growers, Inc." theme_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" id="8201_970" theme="8201_963" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_965" theme_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" id="8201_971" theme="8201_963" party2_string="Paul" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="373 U. S. 132, 142-143 (1963)" id="8201_973" at_date_string="1963" theme="8201_962" at_date="8201_966" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_977" id="8201_988" standard_case_string="487 U. S. 131, 138 (1988)" X_vs_Y_string="Felder v. Casey" X_vs_Y="8201_978" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_979" party1_string="Felder" theme_string="Felder v. Casey" id="8201_986" theme="8201_978" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_980" theme_string="Felder v. Casey" id="8201_987" theme="8201_978" party2_string="Casey" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="487 U. S. 131, 138 (1988)" id="8201_989" at_date_string="1988" theme="8201_977" at_date="8201_981" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_990" id="8201_1011" standard_case_string="479 U. S. 272, 292 (1987)" X_vs_Y_string="Loan Assn. v. Guerra" X_vs_Y="8201_993" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_996" party1_string="Loan Assn." theme_string="Loan Assn. v. Guerra" id="8201_1009" theme="8201_993" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_997" theme_string="Loan Assn. v. Guerra" id="8201_1010" theme="8201_993" party2_string="Guerra" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="479 U. S. 272, 292 (1987)" id="8201_1012" at_date_string="1987" theme="8201_990" at_date="8201_1004" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_991" id="8201_1015" standard_case_string="517 U. S. 25, 31 (1996)" X_vs_Y_string="Barnett Bank of Marion Cty., N. A. v. Nelson" X_vs_Y="8201_994" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_998" party1_string="Barnett Bank of Marion Cty., N. A." theme_string="Barnett Bank of Marion Cty., N. A. v. Nelson" id="8201_1013" theme="8201_994" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_999" theme_string="Barnett Bank of Marion Cty., N. A. v. Nelson" id="8201_1014" theme="8201_994" party2_string="Nelson" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="517 U. S. 25, 31 (1996)" id="8201_1016" at_date_string="1996" theme="8201_991" at_date="8201_1005" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_992" id="8201_1019" standard_case_string="467 U. S. 461, 478" X_vs_Y_string="Michigan Canners &amp; Freezers Assn., Inc. v. Agricultural Marketing and Bargaining Bd" X_vs_Y="8201_995" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1000" party1_string="Michigan Canners &amp; Freezers Assn., Inc." theme_string="Michigan Canners &amp; Freezers Assn., Inc. v. Agricultural Marketing and Bargaining Bd" id="8201_1017" theme="8201_995" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1003" theme_string="Michigan Canners &amp; Freezers Assn., Inc. v. Agricultural Marketing and Bargaining Bd" id="8201_1018" theme="8201_995" party2_string="Agricultural Marketing and Bargaining Bd" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1020" id="8201_1030" standard_case_string="530 U. S. 363, 372-373 (2000)" X_vs_Y_string="Crosby v. National Foreign Trade Council" X_vs_Y="8201_1021" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1022" party1_string="Crosby" theme_string="Crosby v. National Foreign Trade Council" id="8201_1028" theme="8201_1021" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1023" theme_string="Crosby v. National Foreign Trade Council" id="8201_1029" theme="8201_1021" party2_string="National Foreign Trade Council" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="530 U. S. 363, 372-373 (2000)" id="8201_1031" at_date_string="2000" theme="8201_1020" at_date="8201_1024" ></RELATION>

<RELATION gram_type="parentheses" relation_type="comment" theme_string="564 U. S., at ___" id="8201_1047" comment="8201_1040" theme="8201_1041" comment_string="slip op., at 10" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1050" id="8201_1065" standard_case_string="49 F. 3d 26, 29" X_vs_Y_string="Cheshire Medical Center v. W. R. Grace &amp; Co" X_vs_Y="8201_1051" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1052" party1_string="Cheshire Medical Center" theme_string="Cheshire Medical Center v. W. R. Grace &amp; Co" id="8201_1063" theme="8201_1051" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1053" theme_string="Cheshire Medical Center v. W. R. Grace &amp; Co" id="8201_1064" theme="8201_1051" party2_string="W. R. Grace &amp; Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1072" party1_string="Thibault" theme_string="Thibault v. Sears" id="8201_1085" theme="8201_1070" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1073" theme_string="Thibault v. Sears" id="8201_1086" theme="8201_1070" party2_string="Sears" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="395 A. 2d 843, 846 (1978)" id="8201_1087" at_date_string="1978" theme="8201_1067" at_date="8201_1076" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1069" id="8201_1091" standard_case_string="784 A. 2d 1178, 1183 (2001)" X_vs_Y_string="Vautour v. Body Masters Sports Industries, Inc" X_vs_Y="8201_1071" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1068" id="8201_1090" standard_case_string="147 N. H. 150, 156" X_vs_Y_string="Vautour v. Body Masters Sports Industries, Inc" X_vs_Y="8201_1071" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1074" party1_string="Vautour" theme_string="Vautour v. Body Masters Sports Industries, Inc" id="8201_1088" theme="8201_1071" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1075" theme_string="Vautour v. Body Masters Sports Industries, Inc" id="8201_1089" theme="8201_1071" party2_string="Body Masters Sports Industries, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="784 A. 2d 1178, 1183 (2001)" id="8201_1092" at_date_string="2001" theme="8201_1069" at_date="8201_1078" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1094" id="8201_1117" standard_case_string="642 F. 2d 652, 655" X_vs_Y_string="Brochu v. Ortho Pharmaceutical Corp" X_vs_Y="8201_1098" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1099" party1_string="Brochu" theme_string="Brochu v. Ortho Pharmaceutical Corp" id="8201_1115" theme="8201_1098" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1100" theme_string="Brochu v. Ortho Pharmaceutical Corp" id="8201_1116" theme="8201_1098" party2_string="Ortho Pharmaceutical Corp" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1121" id="8201_1133" standard_case_string="891 A. 2d 477, 492 (2006)" X_vs_Y_string="Kelleher v. Marvin Lumber &amp; Cedar Co" X_vs_Y="8201_1122" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1120" id="8201_1132" standard_case_string="152 N. H. 813, 831" X_vs_Y_string="Kelleher v. Marvin Lumber &amp; Cedar Co" X_vs_Y="8201_1122" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1123" party1_string="Kelleher" theme_string="Kelleher v. Marvin Lumber &amp; Cedar Co" id="8201_1130" theme="8201_1122" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1124" theme_string="Kelleher v. Marvin Lumber &amp; Cedar Co" id="8201_1131" theme="8201_1122" party2_string="Marvin Lumber &amp; Cedar Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="891 A. 2d 477, 492 (2006)" id="8201_1134" at_date_string="2006" theme="8201_1121" at_date="8201_1125" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1140" party1_string="Heath" theme_string="Heath v. Sears" id="8201_1154" theme="8201_1138" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1141" theme_string="Heath v. Sears" id="8201_1155" theme="8201_1138" party2_string="Sears" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="464 A. 2d 288, 293 (1983)" id="8201_1156" at_date_string="1983" theme="8201_1136" at_date="8201_1144" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1137" id="8201_1159" standard_case_string="486 U. S. 174, 185-186 (1988)" X_vs_Y_string="Goodyear Atomic Corp. v. Miller" X_vs_Y="8201_1139" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1142" party1_string="Goodyear Atomic Corp." theme_string="Goodyear Atomic Corp. v. Miller" id="8201_1157" theme="8201_1139" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1143" theme_string="Goodyear Atomic Corp. v. Miller" id="8201_1158" theme="8201_1139" party2_string="Miller" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="486 U. S. 174, 185-186 (1988)" id="8201_1160" at_date_string="1988" theme="8201_1137" at_date="8201_1145" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1168" id="8201_1184" standard_case_string="688 A. 2d 556, 562 (1997)" X_vs_Y_string="LeBlanc v. American Honda Motor Co" X_vs_Y="8201_1170" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1167" id="8201_1183" standard_case_string="141 N. H. 579, 586" X_vs_Y_string="LeBlanc v. American Honda Motor Co" X_vs_Y="8201_1170" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1171" party1_string="LeBlanc" theme_string="LeBlanc v. American Honda Motor Co" id="8201_1181" theme="8201_1170" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1172" theme_string="LeBlanc v. American Honda Motor Co" id="8201_1182" theme="8201_1170" party2_string="American Honda Motor Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="688 A. 2d 556, 562 (1997)" id="8201_1185" at_date_string="1997" theme="8201_1168" at_date="8201_1174" ></RELATION>

<RELATION gram_type="parentheses" relation_type="comment" theme_string="564 U. S., at ___" id="8201_1221" comment="8201_1216" theme="8201_1217" comment_string="slip op., at 14" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1229" id="8201_1239" standard_case_string="562 U. S. ___" X_vs_Y_string="Williamson v. Mazda Motor of America, Inc" X_vs_Y="8201_1230" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1231" party1_string="Williamson" theme_string="Williamson v. Mazda Motor of America, Inc" id="8201_1237" theme="8201_1230" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1232" theme_string="Williamson v. Mazda Motor of America, Inc" id="8201_1238" theme="8201_1230" party2_string="Mazda Motor of America, Inc" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1270" id="8201_1288" standard_case_string="529 U. S. 861, 883 (2000)" X_vs_Y_string="Geier v. American Honda Motor Co" X_vs_Y="8201_1274" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1276" party1_string="Geier" theme_string="Geier v. American Honda Motor Co" id="8201_1286" theme="8201_1274" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1277" theme_string="Geier v. American Honda Motor Co" id="8201_1287" theme="8201_1274" party2_string="American Honda Motor Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="529 U. S. 861, 883 (2000)" id="8201_1289" at_date_string="2000" theme="8201_1270" at_date="8201_1280" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1272" id="8201_1292" standard_case_string="563 U. S. ___" X_vs_Y_string="Act,&quot; Chamber of Commerce of United States of America, v. Whiting" X_vs_Y="8201_1275" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1278" party1_string="Act,&quot; Chamber of Commerce of United States of America," theme_string="Act,&quot; Chamber of Commerce of United States of America, v. Whiting" id="8201_1290" theme="8201_1275" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1279" theme_string="Act,&quot; Chamber of Commerce of United States of America, v. Whiting" id="8201_1291" theme="8201_1275" party2_string="Whiting" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1293" id="8201_1311" standard_case_string="332 U. S. 689, 696 (1948)" X_vs_Y_string="United States v. Sullivan" X_vs_Y="8201_1296" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1297" party1_string="United States" theme_string="United States v. Sullivan" id="8201_1309" theme="8201_1296" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1298" theme_string="United States v. Sullivan" id="8201_1310" theme="8201_1296" party2_string="Sullivan" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="332 U. S. 689, 696 (1948)" id="8201_1312" at_date_string="1948" theme="8201_1293" at_date="8201_1301" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1325" id="8201_1342" standard_case_string="562 U. S. ___" X_vs_Y_string="Bruesewitz v. Wyeth LLC" X_vs_Y="8201_1327" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1328" party1_string="Bruesewitz" theme_string="Bruesewitz v. Wyeth LLC" id="8201_1340" theme="8201_1327" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1329" theme_string="Bruesewitz v. Wyeth LLC" id="8201_1341" theme="8201_1327" party2_string="Wyeth LLC" ></RELATION>

<RELATION gram_type="parentheses" relation_type="comment" theme_string="562 U. S., at ___" id="8201_1343" comment="8201_1324" theme="8201_1326" comment_string="slip op., at 4" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1369" party1_string="Riegel" theme_string="Riegel v. Medtronic" id="8201_1382" theme="8201_1367" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1370" theme_string="Riegel v. Medtronic" id="8201_1383" theme="8201_1367" party2_string="Medtronic" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="552 U. S. 312, 323-324 (2008)" id="8201_1384" at_date_string="2008" theme="8201_1364" at_date="8201_1373" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1365" id="8201_1387" standard_case_string="518 U. S. 470 (1996)" X_vs_Y_string="[Medtronic, Inc. v. Lohr" X_vs_Y="8201_1368" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1371" party1_string="[Medtronic, Inc." theme_string="[Medtronic, Inc. v. Lohr" id="8201_1385" theme="8201_1368" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1372" theme_string="[Medtronic, Inc. v. Lohr" id="8201_1386" theme="8201_1368" party2_string="Lohr" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="518 U. S. 470 (1996)" id="8201_1388" at_date_string="1996" theme="8201_1365" at_date="8201_1374" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="505 U. S. 504, 522 (1992)" id="8201_1389" at_date_string="1992" theme="8201_1366" at_date="8201_1375" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1391" id="8201_1409" standard_case_string="352 A. 2d 723, 725 (1976)" X_vs_Y_string="Bellotte v. Zayre Corp" X_vs_Y="8201_1393" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1390" id="8201_1408" standard_case_string="116 N. H. 52, 54-55" X_vs_Y_string="Bellotte v. Zayre Corp" X_vs_Y="8201_1393" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1395" party1_string="Bellotte" theme_string="Bellotte v. Zayre Corp" id="8201_1406" theme="8201_1393" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1396" theme_string="Bellotte v. Zayre Corp" id="8201_1407" theme="8201_1393" party2_string="Zayre Corp" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="352 A. 2d 723, 725 (1976)" id="8201_1410" at_date_string="1976" theme="8201_1391" at_date="8201_1399" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1392" id="8201_1413" standard_case_string="562 U. S. ___" X_vs_Y_string="Bruesewitz v. Wyeth" X_vs_Y="8201_1394" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1397" party1_string="Bruesewitz" theme_string="Bruesewitz v. Wyeth" id="8201_1411" theme="8201_1394" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1398" theme_string="Bruesewitz v. Wyeth" id="8201_1412" theme="8201_1394" party2_string="Wyeth" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1420" id="8201_1438" standard_case_string="373 U. S. 132, 143" X_vs_Y_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" X_vs_Y="8201_1422" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1424" party1_string="Florida Lime &amp; Avocado Growers, Inc." theme_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" id="8201_1436" theme="8201_1422" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1425" theme_string="Florida Lime &amp; Avocado Growers, Inc. v. Paul" id="8201_1437" theme="8201_1422" party2_string="Paul" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="373 U. S. 132, 143" id="8201_1439" at_date_string="1963" theme="8201_1420" at_date="8201_1428" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1421" id="8201_1442" standard_case_string="564 U. S. ___ (2011)" X_vs_Y_string="PLIVA, Inc. v. Mensing" X_vs_Y="8201_1423" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1426" party1_string="PLIVA, Inc." theme_string="PLIVA, Inc. v. Mensing" id="8201_1440" theme="8201_1423" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1427" theme_string="PLIVA, Inc. v. Mensing" id="8201_1441" theme="8201_1423" party2_string="Mensing" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="564 U. S. ___ (2011)" id="8201_1443" at_date_string="2011" theme="8201_1421" at_date="8201_1429" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1446" id="8201_1459" standard_case_string="544 U. S. 431, 447" X_vs_Y_string="Bates v. Dow Agrosciences LLC" X_vs_Y="8201_1448" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1449" party1_string="Bates" theme_string="Bates v. Dow Agrosciences LLC" id="8201_1457" theme="8201_1448" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1450" theme_string="Bates v. Dow Agrosciences LLC" id="8201_1458" theme="8201_1448" party2_string="Dow Agrosciences LLC" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="544 U. S. 431, 447" id="8201_1460" at_date_string="2005" theme="8201_1446" at_date="8201_1451" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1465" id="8201_1475" standard_case_string="331 U. S. 218, 230 (1947)" X_vs_Y_string="Rice v. Santa Fe Elevator Corp" X_vs_Y="8201_1466" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1467" party1_string="Rice" theme_string="Rice v. Santa Fe Elevator Corp" id="8201_1473" theme="8201_1466" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1468" theme_string="Rice v. Santa Fe Elevator Corp" id="8201_1474" theme="8201_1466" party2_string="Santa Fe Elevator Corp" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="331 U. S. 218, 230 (1947)" id="8201_1476" at_date_string="1947" theme="8201_1465" at_date="8201_1469" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1479" id="8201_1494" standard_case_string="562 U. S. ___" X_vs_Y_string="Bruesewitz v. Wyeth LLC" X_vs_Y="8201_1480" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1481" party1_string="Bruesewitz" theme_string="Bruesewitz v. Wyeth LLC" id="8201_1492" theme="8201_1480" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1482" theme_string="Bruesewitz v. Wyeth LLC" id="8201_1493" theme="8201_1480" party2_string="Wyeth LLC" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1502" party1_string="Riegel" theme_string="Riegel v. Medtronic" id="8201_1518" theme="8201_1500" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1503" theme_string="Riegel v. Medtronic" id="8201_1519" theme="8201_1500" party2_string="Medtronic" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="552 U. S. 312, 323-324 (2008)" id="8201_1520" at_date_string="2008" theme="8201_1497" at_date="8201_1506" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1498" id="8201_1523" standard_case_string="332 F. 3d 323, 332-333" X_vs_Y_string="Dow Agrosciences LLC v. Bates" X_vs_Y="8201_1501" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1504" party1_string="Dow Agrosciences LLC" theme_string="Dow Agrosciences LLC v. Bates" id="8201_1521" theme="8201_1501" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1505" theme_string="Dow Agrosciences LLC v. Bates" id="8201_1522" theme="8201_1501" party2_string="Bates" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1543" id="8201_1552" standard_case_string="567 U. S. __" X_vs_Y_string="National Federation of Independent Business v. Sebelius" X_vs_Y="8201_1544" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1545" party1_string="National Federation of Independent Business" theme_string="National Federation of Independent Business v. Sebelius" id="8201_1550" theme="8201_1544" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1546" theme_string="National Federation of Independent Business v. Sebelius" id="8201_1551" theme="8201_1544" party2_string="Sebelius" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8201_1571" id="8201_1582" standard_case_string="555 U. S. 555, 578-579" X_vs_Y_string="Wyeth v. Levine" X_vs_Y="8201_1572" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8201_1573" party1_string="Wyeth" theme_string="Wyeth v. Levine" id="8201_1580" theme="8201_1572" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8201_1574" theme_string="Wyeth v. Levine" id="8201_1581" theme="8201_1572" party2_string="Levine" ></RELATION>

<NAME local_name_id="5" name="MUTUALPHARMACEUTICAL" from="from_legal_role" >MUTUALPHARMACEUTICAL</NAME>

<NAME local_name_id="16" name="KARENBARTLETT" from="from_legal_role" >KARENBARTLETT</NAME>

<NAME local_name_id="37" name="KARENLBARTLETT" from="from_legal_role" >KARENLBARTLETT</NAME>

<NAME local_name_id="39" name="MUTUALPHARMACEUTICAL" from="from_legal_role" >MUTUALPHARMACEUTICAL</NAME>

<NAME local_name_id="70" name="KARENBARTLETT" from="from_legal_role" >KARENBARTLETT</NAME>

